{
    "Iboga": {
        "sections": {
            "Overview": "Iboga is a shrub that grows wild in Gabon, Republic of Congo, Cameroon, Guinea, and other countries in Africa (89188, 105386). Its root bark is used in some ceremonial practices for its hallucinogenic and stimulant properties (812, 27122, 105382). Iboga root bark contains the constituent ibogaine which the U.S. Drug Enforcement Administration (DEA) lists as a schedule I substance, meaning this substance has a high potential for abuse (89201).",
            "Safety": "POSSIBLY UNSAFE when ibogaine, a constituent of iboga, is used orally. Ibogaine has been associated with cases of arrhythmia, cardiac arrest, psychological disturbance, and death (89182, 89183, 89184, 89185, 89186, 89187, 89188, 89192, 89194, 89198)(92951, 105381, 105383, 105384, 105386, 111735).\nThere is insufficient reliable information available about the safety of whole iboga products or extracts.\nPREGNANCY AND LACTATION: There is insufficient reliable information available about the safety of iboga in pregnancy and lactation. Avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nThere is currently a limited amount of information available about the adverse effects of whole iboga products or extracts. Orally, ibogaine, a constituent of iboga, can cause serious adverse effects.\nMost Common Adverse Effects\nOrally: Arrhythmia, ataxia, diarrhea, hallucinations, headache, nausea, and vomiting.\nCardiovascular\nIbogaine is a constituent of iboga. There are numerous case reports of ventricular tachyarrhythmias, cardiac arrest, and QT interval prolongation, some of which resulted in torsade de pointes, in patients who took ibogaine orally. Some of these patients did not have any prior cardiovascular disease (89183, 89184, 89185, 89186, 89192, 89198, 94529, 94531, 105381, 105383)(105386, 111735). In some cases, cardiac complications resulted in death (89187, 89194, 105382, 105384, 111735). One case series suggests that most deaths associated with ibogaine occur in patients with pre-existing co-morbidities, specifically cardiovascular disease, or those taking benzodiazepines, cocaine, methadone, or opiates (111735). Noribogaine, a metabolite of ibogaine, is also associated with cardiotoxic effects, including dose-dependent prolongation of the QT interval (94529, 94531, 111735).\nless\nGastrointestinal\nIbogaine, a constituent of iboga, taken orally may cause nausea and vomiting in some individuals (89199, 92951, 92952, 105383, 105386, 105389, 111735). Doses up to 25 mg/kg have been associated with diarrhea (92952). In one case report, a 61-year-old male developed hypokalemia following heavy vomiting and diarrhea within 6-12 hours of ingesting a single dose of 5.6 grams of ibogaine (105386). However, a meta-analysis of 2 small clinical trials shows no greater risk of nausea between ibogaine/noribogaine and placebo among adults being treated for substance use disorder (111735).\nless\nMusculoskeletal\nIbogaine is a constituent of iboga. When taken orally in doses ranging from 12-29 mg/kg, ibogaine may cause ataxia, tremors, and muscular pain (89199, 92951, 92952, 111735). Noribogaine, the metabolite of ibogaine, is thought to be less likely to cause tremors (94529).\nless\nNeurologic/CNS\nIbogaine, a constituent of iboga, taken orally in doses ranging from 10-32 mg/kg may cause confusion, dizziness, dream-like states, hallucinations, and headaches (89199, 105389, 111735). Ibogaine in doses up to 25 mg/kg has been associated with cases of extreme sensitivity to color and sound, sweating, cold sensations, increased energy and appetite, insomnia, and a strong aphrodisiac effect (92952, 111735). Severe transient ataxia was reported in all patients in an observational study with full remission within 24 hours (105383).\n\nIn one case report, 3.8 grams of ibogaine taken over a few hours resulted in dissociation and motor agitation in a 33-year-old heroin addict (89183). There have also been three case reports of mania in patients taking unspecified doses of ibogaine, often in combination with various other medications (89182). A 43-year old female who was using ibogaine for heroin and benzodiazepine addiction was admitted to the emergency room unconscious with idiopathic encephalopathy; it was unclear if the encephalopathy was due to ibogaine or concurrent hypoxia (89192). In another case report, a 61-year-old male developed an alteration in consciousness level within 12 hours of ingesting a single dose of 5.6 grams of ibogaine (105386). In another case report, a 34-year-old female developed hallucinations, seizure activity, and CNS depression shortly after taking ibogaine 2 grams. Confusion persisted after four days in hospital requiring transport to a psychiatric unit (105381).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAlcohol use disorder. It is unclear if oral iboga is beneficial for improving abstinence in patients with alcohol use disorder.\nAn observational study in patients with a history of substance use disorder, primarily with cocaine but also other substances such as alcohol, tobacco, and cannabis, suggest that taking a single dose of ibogaine is associated with 5.5 months of self-reported abstinence and taking multiple doses of ibogaine is associated with 8.4 months of abstinence. These patients were required to be abstinent for 30-60 days prior to receiving ibogaine, which likely helped to improve the total duration of abstinence (89199).\nless\nCocaine dependence. It is unclear if oral iboga is beneficial for improving abstinence in patients with cocaine dependence.\nAn observational study in patients with a history of substance use disorder, primarily with cocaine but also other substances such as alcohol, tobacco, and cannabis, suggests that taking a single dose of ibogaine is associated with 5.5 months of self-reported abstinence and taking multiple doses of ibogaine is associated with 8.4 months of abstinence. These patients were required to be abstinent for 30-60 days prior to receiving ibogaine, which likely helped to improve the total duration of abstinence (89199). Additionally, a small clinical trial in adult males with cocaine use disorder shows that taking dried iboga extract 1800 mg decreases cocaine use and cravings acutely and over six months of follow-up when compared with placebo (111735).\nless\nDepression. Although there is interest in using oral iboga for depression, there is insufficient reliable information about the clinical effects of iboga for this condition.\nFatigue. Although there is interest in using oral iboga for fatigue, there is insufficient reliable information about the clinical effects of iboga for this purpose.\nHIV/AIDS. Although there is interest in using oral iboga for HIV/AIDS, there is insufficient reliable information about the clinical effects of iboga for this condition.\nHypertension. Although there is interest in using oral iboga for hypertension, there is insufficient reliable information about the clinical effects of iboga for this condition.\nInfluenza. Although there is interest in using oral iboga for influenza, there is insufficient reliable information about the clinical effects of iboga for this condition.\nOpioid withdrawal. It is unclear if oral iboga is beneficial for opioid withdrawal. Some low-quality clinical research suggests that ibogaine, a constituent of iboga, may reduce withdrawal symptoms and risk of relapse in patients with opioid dependence.\nMultiple case reports, case series, and observational studies suggest that taking ibogaine as a single 10-25 mg/kg dose, with or without an 18-20 mg/kg dose within 2 hours, or as 25-55 mg/kg over multiple doses within a 24-96 hour period, can alleviate acute opioid withdrawal symptoms for 24-72 hours in up to 79% of patients addicted to opioids, including heroin, prescription opioids, and codeine, often in combination with other substances (92951, 92952, 105383, 105387, 105388, 111735). An observational study in individuals receiving ibogaine as part of a 1-week detoxification treatment protocol for heroin or prescription opioid use suggests that withdrawal symptoms are eliminated or drastically reduced in 80% of patients. Craving also seems to improve for at least one week in about 50% of patients, with abstinence rates of approximately 16% and 9% at one and two years, respectively. Also, about 48% of patients decreased use when compared with pre-treatment usage rates. However, consumption increased in 6% of individuals (105389). Additionally, a small observational study in adults with opioid use disorder suggests that taking ibogaine 10-32 mg/kg, administered in a treatment facility, is associated with an attenuation of opioid withdrawal symptoms. Also, a small clinical study in males with heroin use disorder shows that taking noribogaine 120 mg might improve opioid withdrawal symptoms when compared with placebo (111735).\nless\nSexual arousal. Although there is interest in using oral iboga to increase sexual arousal, there is insufficient reliable information about the clinical effects of iboga for this use.\nMore evidence is needed to rate iboga for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of iboga.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICHOLINERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, iboga might decrease the effectiveness of anticholinergic drugs.\nIn vitro research shows that iboga can inhibit acetylcholinesterase and might increase acetylcholine levels. However, the constituent ibogaine does not appear to have this effect (92940).\nless\nCHOLINERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, iboga might have additive effects with cholinergic drugs.\nIn vitro research shows that iboga can inhibit acetylcholinesterase and might increase acetylcholine levels. However, the constituent ibogaine does not appear to have this effect (92940).\nless\nCYTOCHROME P450 2D6 (CYP2D6) INHIBITORS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, taking iboga with CYP2D6 inhibitors might increase the levels and clinical effects of ibogaine.\nIbogaine, the active constituent of iboga, is a substrate of CYP2D6 (94529, 105380). One pharmacokinetic study shows that taking the CYP2D6 inhibitor paroxetine prior to taking ibogaine 20 mg increases the exposure to ibogaine and its metabolite noribogaine by 2-fold when compared with ibogaine alone (94530).\nless\nPAROXETINE (PAXIL)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, taking paroxetine with iboga might increase the levels and clinical effects of ibogaine.\nOne pharmacokinetic study shows that taking paroxetine prior to taking ibogaine, a constituent of iboga, 20 mg increases the exposure to ibogaine and its metabolite noribogaine by 2-fold when compared with taking ibogaine alone (94530). This is thought to be due to inhibition of cytochrome P450 2D6 by paroxetine. Additionally, ibogaine has serotonergic effects and may increase the risk for serotonergic adverse effects when taken with paroxetine (813, 94531).\nless\nQT INTERVAL-PROLONGING DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, iboga may have an additive effect with drugs that prolong the QT interval.\nNumerous case reports suggest that ibogaine, a constituent in iboga, can cause QT interval prolongation (89183, 89184, 89185, 89186, 89192, 89198, 94531, 105381, 105383, 105386).\nless\nSEROTONERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking iboga with serotonergic drugs might increase levels of serotonin, resulting in additive effects with serotonergic drugs.\nIbogaine, a constituent in iboga, has serotonergic effects (813, 94531). Theoretically, combining serotonergic drugs with iboga might increase the risk of serotonergic side effects, including serotonin syndrome and cerebral vasoconstrictive disorders (8056). Monitor patients for signs of serotonin syndrome and other serotonergic side effects if using iboga with serotonergic drugs.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nHERBS AND SUPPLEMENTS WITH SEROTONERGIC PROPERTIES\nTheoretically, iboga might increase the effects and adverse effects of products that increase serotonin levels.\nIbogaine, a constituent in iboga, has serotonergic effects (813, 94531). Theoretically, taking iboga with herbs and supplements that have serotonergic properties might increase therapeutic and adverse effects. See other products with serotonergic activity here.\nless\nQT INTERVAL-PROLONGING HERBS AND SUPPLEMENTS\nIboga may increase the QT interval when used short-term.\nNumerous case reports suggest that ibogaine, a constituent in iboga, can cause QT interval prolongation (89183, 89184, 89185, 89186, 89192, 89198, 94531, 105381, 105383, 105386). Theoretically, ibogaine or iboga might have an additive effect when used with herbs and supplements that prolong the QT interval. This might increase the risk of arrhythmias. See other products with this activity here.\nless",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "General\n\nThere is currently a limited amount of information available about the presentation of overdose with iboga. However, overdose with ibogaine, a constituent in iboga, has been reported to cause acute overdose symptoms, including arrhythmia, seizures, respiratory arrest, and death.\n\nThere are numerous case reports of ventricular tachyarrhythmias, bradycardia, cardiac arrest, and QT interval prolongation, some of which resulted in torsade de pointes, in patients who took ibogaine orally. Some of these patients did not have any prior cardiovascular disease. Doses ranged from 600 mg or 10 mg/kg to 7 grams. In some cases, QT prolongation lasted for up to 7-9 days (89183, 89184, 89185, 89186, 89192, 89198, 94529, 94531, 105381, 105383, 105386). Ibogaine has also resulted in ataxia and seizures (89199, 92952, 105381, 105383).\n\nIbogaine has been associated with death, primarily due to cardiovascular complications. In one case report, a 52-year-old male with liver and coronary disease died from cardiac complications after ingesting ibogaine resulting in a serum concentration of 2 mg/L (89194). There is also a report of a 25-year-old male with chronic heroin addiction and a history of supraventricular tachycardia that consumed 2.5 grams of ibogaine over 3 hours and subsequently experienced hallucinations, ataxia, muscle spasms, weakness, fever, and urinary retention. Over two days, these symptoms progressed to breathing difficulty, cardiopulmonary arrest, and death from multi-organ failure (89187).In a third case report, a 40-year-old male died of acute cardiac arrest following use of ibogaine 4 grams in combination with 2 grams of an additional unknown substance for symptoms of heroin withdrawal (105384). In one case report, a female given ibogaine 29 mg/kg experienced respiratory arrest and death (92951). Finally, one death was reported in an observational study related to the use of ibogaine during opioid treatment (105387).\n\nCases of death related to the use of iboga have also been reported. In one case report, a 27-year-old male took a \"teaspoon\" of iboga root in addition to methadone and diazepam and died 12 hours after ingestion. The patient's post-mortem serum concentration of ibogaine was 0.65 mcg/mL. Death was attributed to poisoning from iboga (89188). In another case report of a 27-year-old male, death was thought to be related to the use of a powder purchased online, labelled as iboga, 5-12 hours previously. Conclusions were based on histological analysis as well as findings of ibogaine, noribogaine, and other metabolites in blood and urine samples. Ibogaine concentrations were 3.26 and 28.87 mg/L, in blood and urine, respectively (105382).\nTreatment\nObservational research found that magnesium infusions were required in the treatment of ibogaine-induced QT-interval prolongation with bradycardia (105383). Defibrillation for ventricular flutter was required after ingestion of ibogaine by a 61-year-old male with no history of cardiovascular disease (105386).",
            "Pharmacokinetics": "Absorption\nIbogaine, a lipophilic molecule, is absorbed after oral, mucosal and intraperitoneal administration (27122).\nDistribution\nIbogaine distributes through the body following a two-compartment model. Ibogaine and its metabolite noribogaine are highly lipophilic leading to accumulation in the brain and fat tissue (94531). In addition to distributing to the brain, ibogaine distributes to the lungs, the spleen, and the liver (27122, 94531).\nMetabolism\nIbogaine undergoes first-pass metabolism and is also metabolized by cytochrome P450 2D6 (CYP2D6) to noribogaine (27122).\nExcretion\nNoribogaine is cleared from the body more slowly than ibogaine (94531). The elimination half-life of ibogaine is estimated to be 3.3 hours (27122). The half-life of noribogaine is reported to be 28-49 hours in healthy patients. However, in one case report, the half-life of noribogaine was 2540 hours (94529). It is possible that this patient was a slow CYP2D6 metabolizer. Since CYP2D6 is one of the main metabolism pathways of ibogaine, patients that are slow CYP2D6 metabolizers will experience a slower clearance (94531).",
            "Mechanism of Action": "General\nThe applicable part of iboga is the root. Iboga is known to cause hallucinations. The hallucinogenic properties of iboga are due to the indole alkaloids, ibogaine, ibogaline, ibogamine, and tabernanthine (271, 105380, 105381).\nAntimicrobial effects\nPreliminary evidence suggests that iboga has leishmanicidal activity in vitro and also inhibits HIV-1 replication in vitro (15013).\nCentral nervous system effects\nIbogaine, a constituent of iboga, is most commonly used for managing addiction and cravings to opioids and other substances (27122). Ibogaine has kappa agonist effects; it is serotonergic; and it exhibits nicotinic and N-methyl-D-aspartate (NMDA) antagonism (813, 94531, 105388). Animal experiments suggest these effects may have value in treating human addictions to alcohol, nicotine, opioids, cocaine, and other stimulants (812, 813). NMDA antagonism seems to modulate opioid withdrawal symptoms. Kappa agonism seems to increase concentrations of the substance dynorphin in the brain. Dynorphin is thought to increase dysphoric effects of cocaine, which can increase aversion to cocaine (94531). Noribogaine, a metabolite of ibogaine, seems to have overlapping, and possibly stronger, receptor affinities compared with ibogaine. Noribogaine also has high affinity with the mu opioid receptor (105388). Evidence also suggests ibogaine and noribogaine may competitively block dopamine active transporter (111735).\n\nResearchers are also interested in the indole alkaloid coronaridine as a potential anti-addiction treatment. But this constituent causes tremor, neurotoxicity, and bradycardia. A coronaridine analog, 18-methoxycoronaridine, which is produced in the lab, has some similar activity, but does not cause as much neurotoxicity (15013).\n\nIbogaine has also been used recreationally, possibly because it induces dose-dependent CNS stimulation ranging from mild excitation and euphoria to visual and auditory hallucinations (271).\n\nAdditional in vitro research shows that iboga can inhibit acetylcholinesterase and might increase synaptic acetylcholine levels. However the constituent ibogaine does not appear to have this effect (92940).\nDysrhythmic effects\nDysrhythmic effects of ibogaine have been shown in multiple case reports and observational studies (89183, 89184, 89185, 89186, 89192, 89198, 94529, 94531, 105381, 105383)(105386). The mechanism of action may be related to modulation of various myocardial ion channels and muscarinic activity (105381).\nNeurologic effects\nIn animal research, both ibogaine and its metabolite noribogaine have demonstrated antidepressant-like effects, possibly related to increases in brain-derived neurotrophic factor (BDNF) levels in some brain regions (105380). There is also interest in the stimulant properties of ibogaine. In animal research, ibogaine 20 mg/kg and 40 mg/kg increased time awake and reduced time in slow wave or rapid-eye movement (REM) sleep. Motor function was also altered, with increased locomotion with 20 mg/kg and decreased locomotion with 40 mg/kg (105385). However, in human research, a single dose of ibogaine 20 mg failed to produce stimulant effects or alter mood ratings (105390)."
        }
    },
    "Iceland Moss": {
        "sections": {
            "Overview": "Iceland moss is a lichen, or an algae and a fungus growing together in a symbiotic relationship (3). Iceland is one of the least polluted countries in the world, which is important for lichens. Lichens derive their nutrients from the environment and are easily contaminated with radioactive or heavy metals. Most of the lichens in Europe were contaminated by the fallout from the Chernobyl accident, but Iceland only received negligible radioactivity (6002).",
            "Safety": "POSSIBLY SAFE when the dried plant is used orally, short-term for medicinal use (3, 12). The dried plant can be contaminated with lead (3).\nPOSSIBLY UNSAFE when consumed as a food source, long-term. Lead contamination can occur in amounts of up to 30 mg/kg of dry weight (3). Iceland moss is regulated in the US and allowable only as a flavoring agent in alcoholic beverages (12).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally; avoid Iceland moss due to the potential for lead contamination (3).",
            "Adverse Effects": "General\nOrally, Iceland moss can cause GI irritation (12). Sensitization to Iceland moss is rare (18). Iceland moss can be contaminated with lead up to 30 mg/kg of its dry weight, which may result in lead toxicity when consumed as a primary food source for an extended period of time (3).\nGastrointestinal\nOrally, Iceland moss can cause GI irritation (12).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of Iceland moss.",
            "Dosing & Administration": "Adult\nORAL: The typical dose of Iceland moss is one cup of tea several times daily. The tea is prepared by steeping or simmering 1.5-3 grams of the dried plant in 150 mL boiling water for 5-10 minutes and then straining (3, 7). The maximum dose of the moss is 4-6 grams per day of the dried plant or equivalent preparations (2).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Iceland moss.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "GASTRODUODENAL ULCERS\nThe alcohol extract and powder of Iceland moss is contraindicated due to the potential for mucosal irritation (12).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of Iceland moss.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Iceland moss.",
            "Mechanism of Action": "General\nThe applicable part of Iceland moss is the dried plant body (2).\nAntimicrobial effects\nIceland moss has mild antimicrobial action (2). Iceland moss extract has demonstrated in vitro activity against Staphylococcus aureus (112197).The bitter organic acid constituents can be responsible for an antibiotic effect (18).\nAntioxidant effects\nIn vitro, Iceland moss extract acts as an antioxidant and scavenges free radicals (112197).\nDemulcent effects\nThe mucilage constituents, lichenin and isolichenin, as well as the bitter principles of Iceland moss, are thought to be responsible for its soothing effects (2, 3)."
        }
    },
    "Idebenone": {
        "sections": {
            "Overview": "Idebenone is a synthetic, smaller analogue of coenzyme Q10. It belongs to the family of benzoquinones (96036, 96037).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately. Idebenone has been safely used in clinical research at doses up to 2250 mg daily for up to 2 years or 900 mg daily for up to 5 years (11410, 11413, 11421, 11424, 11427, 15703, 105705, 105706, 105707, 105708). Doses as high as 75 mg/kg daily have been safely used for up to a month (15703). ...when used topically, short-term. Lotions containing idebenone in concentrations up to 1% have been safely used for up to 6 weeks (96036).\nCHILDREN: POSSIBLY SAFE when used orally and appropriately. Idebenone has been safely used at doses of 300 mg three times daily for up to 12 months in children at least 7 years-old (96028, 96031, 96032, 96034) and for up to 6 years in children at least 10 years-old (105706). Higher doses of 450 mg three times daily in children â‰¥45 kg and 750 mg three times daily in children >45 kg has been safely used for up to 6 months (96031, 96034).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, idebenone seems to be well-tolerated (11410, 11413, 11421, 11424, 11427, 15703, 105705, 105707, 105708). In clinical studies, there have been no reports of serious adverse effects occurring more frequently than with placebo. Some people who take idebenone have experienced nausea and vomiting, abdominal pain, elevated alkaline phosphatase, and loose stools (96028, 96034, 105705, 105708); however, these side effects are not common. High doses up to 2250 mg or 75 mg/kg per day have also been well-tolerated without a clinically significant increase in side effects (15703, 105707).\n\nTopically, contact allergic dermatitis has been reported, but this adverse effect is uncommon (96035).\nCardiovascular\nIn a clinical trial, tachycardia was reported by a single person taking idebenone orally. Treatment was not required (11410).\nless\nGastrointestinal\nOrally, adverse effects related to idebenone have included nausea and vomiting, abdominal pain, elevated alkaline phosphatase, and loose stools (96028, 96034, 105705, 105708). Increased appetite leading to weight gain has also been reported (11413).\nless\nHematologic\nNeutropenia in a single person in a clinical trial was considered to be possibly related to the oral intake of idebenone. Levels resolved within one week of discontinuation (96031).\nless\nImmunologic\nThere is a case report of allergic contact dermatitis related to topical use of a cream containing idebenone. The 38-year old woman applied a facial cream (Prevage MD, Elizabeth Arden, Inc.) with reactions appearing with the second dose. Symptoms included a red, itchy, burning, swollen face. She was treated with topical hydrocortisone. She reacted to idebenone with patch testing. This was the fourth known topical allergic reaction to idebenone (96035).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nAlzheimer disease. There is some evidence that taking idebenone 90-120 mg three times daily orally for 6 months slows cognitive function decline in patients with Alzheimer disease when compared with placebo. Idebenone appears most effective in patients with moderately severe Alzheimer disease, based on standard Alzheimer disease rating scales (11421, 11427).\nLeber hereditary optic neuropathy. Small and low-quality research shows that taking oral idebenone 900 mg orally daily moderately improves or stabilizes visual acuity in patients with early Leber hereditary optic neuropathy (LHON). The efficacy of initiating treatment in patients with a long history of LHON is unknown.\nClinical research shows that idebenone 300 mg orally three times daily for 24 weeks improves visual acuity when compared with placebo in patients with LHON with discordant visual acuity, which is most common during early disease (96032). The benefits of idebenone may persist for up to 30 months after treatment discontinuation (95693). Other preliminary clinical research in patients with LHON shows that taking a specific idebenone product (Raxone/Catena, Santhera Pharmaceuticals) starting at 360 mg orally daily and titrating weekly up to 900 mg daily, for a total of 24 weeks improves measures of visual acuity, but not visual field, when compared to baseline, but not when compared with placebo. The study may have been inadequately powered to detect a difference between groups, and its validity is also limited by non-randomized treatment allocation (105708).\n\nObservational research in patients diagnosed with LHON within the previous 6 months to 1 year suggests that taking idebenone 900 mg orally daily for an average of 2 years is associated with clinically relevant recovery of vision in 46% to 53% of patients, and stabilization of vision above the limit for legal blindness in 11% to 50% of patients, when compared to baseline. However, the thinning of the retinal ganglion cell layer that occurs in LHON is not reversed (105705, 112058).\n\nAn international consensus statement published in 2017 recommends that patients with early stage (<1 year) LHON begin idebenone treatment as soon as possible, since it seems to have the most benefit when started during early stages of the disease (96029). There is not enough evidence to recommend initiating idebenone in patients with the disease for 1 year or more (96029, 96032). It is recommended that patients be followed-up every 3 months during the first year, and that treatment continue for at least one year after the disease has plateaued (96029). A specific idebenone product (Raxone, Santhera Pharmaceuticals) is approved for the treatment of visual impairment in patients with LHON by the European Medicine Agency under exceptional circumstances (96029). This product is not approved for use in the US.\nless\nMuscular dystrophy. Idebenone is associated with a small improvement in respiratory function in adolescents and teens with Duchenne muscular dystrophy (DMD) who are not taking glucocorticoids.\nClinical research in patients aged 10-18 years with DMD suggests that taking idebenone (Raxone, Santhera Pharmaceuticals) 300 mg three times daily orally for one year attenuates loss of respiratory function., as measured by the decline in peak expiratory flow (PEF). It is reduced by about 3% with idebenone, compared with about 9% with placebo (96028, 112057). Idebenone also attenuates reductions in forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1), but has little effect on quality of life (112057). One year of treatment with the same dose of idebenone also reduces the risk of respiratory complications (96037). A follow-up study over a mean of 2-4 years shows that taking idebenone continues to attenuate, but does not entirely prevent, the loss of respiratory function. An exploratory analysis also suggests that taking idebenone reduces hospitalization rates and use of systemic antibiotics. The validity of these results is limited by a very small number of events (105706).\n\nTaking idebenone does not seem to improve respiratory function in patients with Duchenne muscular dystrophy who are already receiving glucocorticoids (95692).\nless\nPOSSIBLY INEFFECTIVE\nFriedreich ataxia. While some preliminary research shows conflicting results (11410, 11413, 11416, 11418, 96039), higher quality clinical research shows that idebenone does not help control cardiac hypertrophy associated with Friedreich ataxia (11415, 96033). Most clinical research also shows that taking idebenone does not treat or slow the progression of ataxia in children and young adults with this condition (11410, 11411, 96030, 96031, 96034, 96038, 96039). Although some preliminary clinical research suggests that idebenone might improve neurological symptoms when taken in higher doses or for longer durations (96031, 96038, 96039), current clinical management guidelines for Friedreich ataxia state that idebenone does not improve cardiac or neurological status in patients with Friedreich ataxia when used over an extended time period (96030).\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nDepression. Preliminary clinical research in adults aged 55-75 years with post-stroke depression suggests that adding idebenone 30 mg three times daily to paroxetine treatment for 12 weeks increases the effectiveness (cured or improved) rate, as measured by the Hamilton Rating Scale for Depression, from 62% with paroxetine alone to 82% with the combination (112059).\nMitochondrial myopathies. There is preliminary clinical research that suggests idebenone given orally might reduce symptoms in patients with mitochondrial dysfunction associated with the syndrome of mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (11422, 11424, 11426).\nMultiple sclerosis (MS). Preliminary clinical research in adults with primary progressive MS shows that taking a specific idebenone product (Santhera Pharmaceuticals) 750 mg three times daily for 2 years does not slow the progression of disability or attenuate central nervous system tissue destruction when compared with placebo (105707).\nWrinkled skin. Preliminary clinical research shows that topical application of a lotion containing 0.5% or 1% idebenone twice daily for 6 weeks reduces signs of photoaging when compared to baseline. Skin roughness and drying is reduced by up to 26%, and fine lines and wrinkles by up to 29%, while skin hydration is increased by 37%. Skin pigmentation is also improved (96036).\nMore evidence is needed to rate idebenone for these uses.",
            "Dosing & Administration": "Adult\nOral:\nAlzheimer disease: Idebenone 90-120 mg three times daily for 6 months has been used (11421, 11427).\n\nLeber hereditary optic neuropathy: Idebenone, including a specific idebenone product (Raxone, Santhera Pharmaceuticals), 300 mg three times daily with meals has been used for up to 5 years (96029, 96032, 105705, 105708). In one clinical trial, idebenone was initiated at 360 mg daily and titrated weekly to 900 mg daily (105708).\n\nMitochondrial myopathies: Idebenone 90-270 mg divided and given three times daily has been used (11422, 11424, 11426).\nTopical:\nWrinkled skin: A lotion containing 0.5% or 1% idebenone applied twice daily for 6 weeks has been used (96036).\nChildren\nOral:\nLeber hereditary optic neuropathy: Idebenone (Raxone, Santhera Pharmaceuticals) 300 mg three times daily with meals has been used (96029, 96032).\n\nMitochondrial encephalomyopathies: Idebenone 90-270 mg divided and given three times daily has been used (11422, 11424, 11426).\n\nMuscular dystrophy: Idebenone 900 mg daily (Raxone, Santhera Pharmaceuticals) for 1-6 years has been used in patients aged 10 years and older with Duchenne muscular dystrophy (96028, 96037, 105706).\nStandardization & Formulation\nMost clinical trials have used a specific oral idebenone product (Raxone, Santhera Pharmaceuticals) (96028, 96029, 96032, 96037, 105707, 105708). Idebenone has also been incorporated into a lotion for topical use (96036).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with idebenone.",
            "Pharmacokinetics": "Absorption\nIn adults, doses of 5 mg/kg idebenone reach a maximum plasma concentration of about 1640 ng/mL in 3 hours. Doses of 75 mg/kg reach a maximum plasma concentration of about 9530 ng/mL in 2.7 hours. In children, doses of 5 mg/kg reach a maximum plasma concentration of about 800 ng/mL in 3 hours. Doses of 75 mg/kg reach a maximum plasma concentration of about 5360 ng/mL in 2 hours (15703).\nDistribution\nIdebenone diffuses across cell membranes more readily than coenzyme Q10 and reaches concentrations in the brain similar to the plasma. Idebenone also distributes into tissues, with highest concentrations found in the kidney, gut, and liver (11414, 11417, 15703).\nExcretion\nAfter oral administration, the half-life of idebenone is approximately 9-21 hours across a range of doses in adults and children (11414, 11417, 15703). The half-life in children is 3-4 hours shorter compared to adults (15703).",
            "Mechanism of Action": "General\nIdebenone is a synthetic quinone that is similar to, but less lipophilic than, coenzyme Q10 (96036, 96037, 105707).\nAnti-inflammatory effects\nIn older adults, aged 55-75 years, taking idebenone 30 mg three times daily for 12 weeks is associated with decreases in levels of inflammatory mediators, including tumor necrosis factor-alpha, C-reactive protein, and interleukin-6 (112059).\nAntioxidant effects\nMany of the therapeutic benefits of idebenone are attributed to its antioxidant effects. As an antioxidant, idebenone appears to protect a wide variety of cell membranes and mitochondria from oxidative stress by inhibiting lipid peroxidation. This protects the central nervous system from nerve damage and ischemia (11412, 11417, 11419, 11420, 11425, 96032). Antioxidant activity may also contribute to protective effects of idebenone on muscle fibers in muscular dystrophy. By preventing mitochondrial damage and apoptosis, it can reduce muscle inflammation and fibrosis (112057). In older adults, aged 55-75 years, taking idebenone 30 mg three times daily for 12 weeks is associated with increased levels of antioxidant factors including superoxide dismutase and catalase, and an increase in total antioxidant capacity (112059).\nDermatologic effects\nWhen applied topically, idebenone reduces the production of inflammatory cytokines in the epidermis, possibly allowing for increased production of collagen in the dermis and improving quality of the skin (96036). The antioxidant effects of idebenone in the skin might improve quality of the skin similar to melanin (96036).\nNeuroprotective effects\nThere is interest in using idebenone for many neurologic disorders, such as Alzheimer disease and Leber hereditary optic neuropathy (LHON). Idebenone seems to maintain ATP formation in ischemic sites, possibly by functioning as a carrier within the electron transport chain (11412, 11417, 11419, 11423, 11425, 105707). The lower lipophilicity of idebenone may improve mitochondrial membrane transport and may make it a more effective agent than coenzyme Q10 in treating dysfunctional electron transport, protecting the central nervous system from nerve damage and ischemia (11412, 11417, 11419, 11423, 11425, 105707). Idebenone may also slow cognitive function decline in patients with Alzheimer disease, possibly by stimulating nerve growth factor (11417).\n\nPreliminary clinical research in patients with LHON shows that taking idebenone 900 mg daily for 24 weeks improves some measures of visual evoked potential, but not retinal nerve fiber layer thickness, when compared with baseline. However, the study may have been inadequately powered to detect a difference between groups (105708)."
        }
    },
    "Ignatius Bean": {
        "sections": {
            "Overview": "Ignatius bean is the seed of a tree found in the Philippines and other parts of Southeast Asia. Due to its toxic constituents, Ignatius bean is considered poisonous (18).",
            "Safety": "UNSAFE when used orally due to its toxic strychnine constituent. The US Food and Drug Administration (FDA) banned strychnine from nonprescription drug products in 1989 (18).\nPREGNANCY AND LACTATION: UNSAFE when used orally due to toxic effects (18).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, Ignatius bean is generally regarded as unsafe for use. Any benefits of therapy may not outweigh the risk of toxicity. Ignatius bean 30-50 mg, which contains approximately 5 mg of strychnine, can cause restlessness, anxiety, heightened sense perception, enhanced reflexes, equilibrium disorders, painful back and neck stiffness, twitching, spasms of jaw and neck muscles, myoglobinuric renal failure, rhabdomyolysis, extreme muscle tension, and agitation and difficulty breathing after respiratory spasms (55854). Seizures have been reported to occur within 15 minutes of Ignatius bean ingestion (17). Taking Ignatius bean at a dose of 1-2 grams can be fatal (18). Most deaths occur within 3-6 hours of ingestion and are due to respiratory and subsequent cardiac arrest, anoxic brain damage, or multiple organ failure secondary to hyperthermia (18, 505).\n\nLong-term consumption of Ignatius bean can cause strychnine accumulation, particularly in individuals with liver damage. Chronic use can cause death after a period of weeks (18).\n\nBy inhalation, Ignatius bean has been reported to cause seizures (17).\nCardiovascular\nOrally, Ignatius bean 1-2 grams has been reported to cause fatal cardiac arrest within 3-6 hours of ingestion (55853, 55855).\nless\nEndocrine\nOrally, Ignatius bean 1-2 grams has been reported to cause hyperthermia resulting in multiple organ failure within 3-6 hours of ingestion (18, 505).\nless\nMusculoskeletal\nOrally, Ignatius bean 30-50 mg, which contains approximately 5 mg of strychnine, has been reported to cause rhabdomyolysis, painful back and neck stiffness, spasms of jaw and neck muscles, and extreme muscle tension (55854).\nless\nNeurologic/CNS\nOrally, Ignatius bean 30-50 mg, which contains approximately 5 mg of strychnine, has been reported to cause restlessness, anxiety, heightened sense perception, enhanced reflexes, and twitching. It has also been reported to cause seizures within 15 minutes of ingestion (55854). Taking 1-2 grams of Ignatius bean has been reported to cause death due to anoxic brain damage (18, 505).\n\nBy inhalation, Ignatius bean has been reported to cause seizures within 5 minutes (17).\nless\nPulmonary/Respiratory\nOrally, Ignatius bean 30-50 mg, which contains approximately 5 mg of strychnine, has been reported to cause respiratory acidosis and difficulty breathing due to respiratory spasms (55854).\nless\nRenal\nOrally, Ignatius bean has been associated with myoglobinuric renal failure (55854).\nless\nOther\nOrally, Ignatius bean 1-2 grams can be fatal. Most deaths occur 3-6 hours after exposure and occur from respiratory and cardiac arrest, anoxic brain damage, or multiple organ failure due to hyperthermia (55853). Chronic use of lower doses of Ignatius bean has been reported to cause death after a period of weeks (55853).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of Ignatius bean.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Ignatius bean.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "LIVER DISEASE\nStrychnine, a constituent of Ignatius bean, accumulates in individuals with liver damage. Strychnine accumulation resulting from chronic use of Ignatius bean can lead to serious adverse effects, including death (18).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of Ignatius bean.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Ignatius bean.",
            "Mechanism of Action": "General\nThe applicable part of Ignatius bean is the seed. Ignatius bean contains the centrally-acting neurotoxins strychnine and brucine (18, 55852).\nNeurologic effects\nStrychnine antagonizes the post-synaptic binding of glycine, which allows for a heightened reflex excitability in muscles and can lead to convulsions (505). Strychnine can also selectively inhibit the spinal cord when consumed in sub-convulsive quantities (2)."
        }
    },
    "Ilex guayusa": {
        "sections": {
            "Overview": "Ilex guayusa is a type of tree native to the Northern Andean region of South America, such as Ecuador, Bolivia, Peru, and Colombia. The leaves are consumed as a tea-like beverage, also known as guayusa (115140, 115141, 115142, 115147). Ilex guayusa is traditionally used as an emetic, stimulant, and diuretic, to increase fertility and sexual drive, and for diabetes and pain.",
            "Safety": "LIKELY SAFE when Ilex guayusa is used orally in the amounts found in foods. Ilex guayusa has Generally Recognized as Safe (GRAS) status in the US (4912).\nThere is insufficient reliable information available about the safety of using Ilex guayusa orally for medicinal purposes. Ilex guayusa contains caffeine. Although the exact caffeine content of Ilex guayusa tea may vary, it is likely lower than that of coffee. However, the caffeine content in extracts of Ilex guayusa may be higher than that of coffee (113625, 115143, 115145, 115148). According to a review by Health Canada, and a subsequent large meta-analysis conducted in the US, doses of caffeine up to 400 mg daily are not associated with significant adverse cardiovascular, bone, behavioral, or reproductive effects in healthy adults (11733, 98806). The US Dietary Guidelines Advisory Committee states that there is strong and consistent evidence that consumption of caffeine 400 mg daily is not associated with increased risk of major chronic diseases, such as cardiovascular disease or cancer, in healthy adults (98806). Keep in mind that only the amount of ADDED caffeine must be stated on product labels. The amount of caffeine found in ingredients such as Ilex guayusa, which naturally contains caffeine, does not need to be provided. This can make it difficult to determine the total amount of caffeine in a given product.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, Ilex guayusa is generally well tolerated when consumed as a beverage in moderation. However, Ilex guayusa contains caffeine, which may cause adverse effects when taken in large amounts.\nCardiovascular\nOrally, a single dose of guayasa extract 600 mg or 1200 mg has been reported to increase systolic blood pressure by 4-6 mmHg and diastolic blood pressure by 2-5 mmHg on average in small clinical studies (113625, 115148).\n\nAlthough acute administration of caffeine, a constituent of Ilex guayusa, can cause increased blood pressure, regular consumption does not seem to increase either blood pressure or pulse, even in mildly hypertensive patients (1451, 1452, 2722, 13739). Drinking one or more cups daily of caffeinated coffee also doesn't seem to increase the risk of developing hypertension in habitual coffee drinkers (8033, 13739).\nless\nEndocrine\nSome evidence shows that caffeine, a constituent of Ilex guayusa, is associated with fibrocystic breast disease, breast cancer, and endometriosis in females; however, this is controversial since findings are conflicting (8043). Restricting caffeine in females with fibrocystic breast conditions doesn't seem to affect breast nodularity, swelling, or pain (8996). A population analysis of the Women's Health Initiative observational study has found no association between consumption of caffeine-containing beverages and the incidence of invasive breast cancer in models adjusted for demographic, lifestyle, and reproductive factors (108806). Also, a dose-response analysis of 2 low-quality observational studies has found that high consumption of caffeine is not associated with an increased risk of breast cancer (108807).\n\nClinical research in healthy adults shows that increased consumption of caffeine results in increased insulin resistance (91023).\nless\nGastrointestinal\nOrally, dry mouth was reported by one study participant taking a single dose of guayusa extract (113625).\nless\nMusculoskeletal\nEpidemiological evidence regarding the relationship between caffeine, which is found in Ilex guayusa, and the risk of osteoporosis is contradictory. Caffeine can increase urinary excretion of calcium (2669, 10202, 11317). Females identified with a genetic variant of the vitamin D receptor appear to be at an increased risk of the detrimental effect of caffeine on bone mass (2669). However, moderate caffeine intake, less than 300 mg per day, does not seem to significantly increase osteoporosis risk in most postmenopausal adults with normal calcium intake (2669, 6025, 10202, 11317).\nless\nNeurologic/CNS\nOrally, jitteriness increased in females, but not males, taking a single dose of guayusa extract in a clinical trial. The level of jitteriness reported was greater in those taking 1200 mg than those taking 600 mg (115148). In one clinical trial, a study participant reported tremors after taking a single 650 mg dose of guayusa extract (113625).\nless\nPsychiatric\nChronic use of caffeine, especially in large amounts, may produce tolerance, habituation, and psychological dependence (3719). There is some concern that stopping regular use of caffeine may cause withdrawal symptoms such as headache, tiredness and fatigue, decreased energy, alertness, and attentiveness, drowsiness, decreased contentedness, depressed mood, difficulty concentrating, irritability, and lack of clear-headedness (13738). Other symptoms such as delirium, nervousness, restlessness, and anxiety have been described. However, these symptoms may be from nonpharmacological factors related to knowledge and expectation of effects (2723, 11839). Certain populations such as children and the elderly may be more susceptible to the adverse effects of caffeine (13736).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nCognitive function. It is unclear if oral Ilex guayusa is beneficial for improving cognitive performance in adults.\nA small clinical trial in healthy adults shows that taking a single dose of Ilex guayusa extract (AmaTea Max, Applied Food Sciences, Texas) 650 mg modestly improves some, but not all, measures of cognitive performance for 1-2 hours when compared with placebo (113625). Another small clinical trial in healthy, physically active adults shows that taking a single dose of Ilex guayusa extract (AmaTea Max, Applied Food Sciences) 600 mg modestly improves motor and psychomotor speeds when compared with placebo. Taking 1200 mg modestly improves psychomotor speed and motor-cognitive reaction time. However, there was no effect on other measures of cognitive function (115148). The extract used in these studies is standardized to contain 20% caffeine, or 120 mg caffeine for each 600 mg dose.\nless\nDiabetes. Although there has been interest in using oral Ilex guayusa for diabetes, there is insufficient reliable information about the clinical effects of Ilex guayusa for this condition.\nMore evidence is needed to rate Ilex guayusa for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nOne specific extract of Ilex guayusa (AmaTea Max) is standardized to contain 20% caffeine and 30% chlorogenic acids. This extract also contains 8-12% freuloylquinic acids, 2-5% quercetin glucosides, 1-3% kaempferols, and other polyphenols (113625, 115148).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nADENOSINE (Adenocard)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Ilex guayusa might decrease the vasodilatory effects of adenosine and interfere with its use prior to stress testing.\nIlex guayusa contains caffeine. Caffeine is a competitive inhibitor of adenosine at the cellular level. However, caffeine does not seem to affect supplemental adenosine because high interstitial levels of adenosine overcome the antagonistic effects of caffeine (11771). It is recommended that methylxanthines such as caffeine, as well as methylxanthine-containing products, be stopped 24 hours prior to pharmacological stress tests (11770). However, methylxanthines appear more likely to interfere with dipyridamole (Persantine) than adenosine-induced stress testing (11771).\nless\nALCOHOL (Ethanol)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, alcohol might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. Concomitant use of alcohol can increase caffeine serum concentrations and the risk of caffeine adverse effects. Alcohol reduces caffeine metabolism (6370, 24693).\nless\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nUNLIKELY\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Ilex guayusa may increase the risk of bleeding if used with anticoagulant or antiplatelet drugs.\nIlex guayusa contains caffeine. Caffeine is reported to have antiplatelet activity (8028, 8029). Theoretically, caffeine in Ilex guayusa might increase the risk of bleeding when used concomitantly with these agents. However, this interaction has not been reported in humans. There is some evidence that caffeinated coffee might increase the fibrinolytic activity in blood (8030).\nless\nANTIDIABETES DRUGS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMODERATE\nOccurrence\nUNLIKELY\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking Ilex guayusa with antidiabetes drugs might increase the risk of hypoglycemia.\nAnimal research in a model of hyperglycemia suggests that Ilex guayusa may have antihyperglycemic effects, although it does not appear to lower glucose levels when compared with baseline (115139, 116609). This effect has not been evaluated in humans.\nless\nBETA-ADRENERGIC AGONISTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMILD\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use of large amounts of Ilex guayusa might increase cardiac inotropic effects of beta-agonists.\nIlex guayusa contains caffeine. Caffeine can increase cardiac inotropic effects of beta-agonists (15).\nless\nCIMETIDINE (Tagamet)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMILD\nOccurrence\nLIKELY\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, cimetidine might increase the effects and adverse effects of caffeine in Ilex guayusa.\nIlex guayusa contains caffeine. Cimetidine can reduce caffeine clearance by 31% to 42% (11736, 24700).\nless\nCLOZAPINE (Clozaril)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, Ilex guayusa might increase the levels and adverse effects of clozapine and acutely exacerbate psychotic symptoms.\nIlex guayusa contains caffeine. Caffeine can increase the effects and toxicity of clozapine. Caffeine doses of 400-1000 mg daily inhibit clozapine metabolism (5051). Clozapine is metabolized by cytochrome P450 1A2 (CYP1A2). Researchers speculate that caffeine might inhibit CYP1A2. However, there is no reliable evidence that caffeine affects CYP1A2. There is also speculation that genetic factors might make some patients more sensitive to an interaction between clozapine and caffeine (13741).\nless\nCONTRACEPTIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMILD\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, concomitant use might increase the effects and adverse effects of caffeine found in Ilex guayusa.\nIlex guayusa contains caffeine. Oral contraceptives decrease the rate of caffeine clearance by 40% to 65% (2714, 11737).\nless\nDIPYRIDAMOLE (Persantine)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, Ilex guayusa might decrease the vasodilatory effects of dipyridamole and interfere with its use prior to stress testing.\nIlex guayusa contains caffeine. Caffeine is a methylxanthine that may inhibit dipyridamole-induced vasodilation (11770, 11772, 24974, 37985, 53795). It is recommended that methylxanthines such as caffeine, as well as methylxanthine-containing products such as Ilex guayusa, be stopped 24 hours prior to pharmacological stress tests (11770). Methylxanthines appear more likely to interfere with dipyridamole (Persantine) than adenosine-induced stress testing (11771).\nless\nDISULFIRAM (Antabuse)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMILD\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, disulfiram might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. In human research, disulfiram decreases the clearance and increases the half-life of caffeine (11840).\nless\nDIURETIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use might increase the risk of hypokalemia.\nIlex guayusa contains caffeine. Caffeine, especially in excessive amounts, can reduce potassium levels due to stimulation of the sodium-potassium pump (23579, 37905, 37953, 38003, 38034). Diuretics can also cause lower potassium levels.\nless\nEPHEDRINE\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use might increase the risk of stimulant adverse effects.\nIlex guayusa contains caffeine. There is evidence that using ephedrine with caffeine might increase the risk of serious life-threatening or debilitating adverse effects such as hypertension, myocardial infarction, stroke, seizures, and death (1275, 6486, 9740, 10307). Tell patients to avoid taking caffeine with ephedrine and other stimulants.\nless\nESTROGENS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMILD\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, estrogens might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. Estrogen inhibits caffeine metabolism (2714).\nless\nFLUCONAZOLE (Diflucan)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, fluconazole might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. Fluconazole decreases caffeine clearance by approximately 25% (11022, 24978).\nless\nFLUTAMIDE (Eulexin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, Ilex guayusa might increase the levels and adverse effects of flutamide.\nIlex guayusa contains caffeine. In vitro evidence suggests that caffeine can inhibit the metabolism of flutamide (23553). Theoretically, concomitant use of caffeine and flutamide might increase serum concentrations of flutamide and increase the risk adverse effects.\nless\nFLUVOXAMINE (Luvox)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMILD\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, fluvoxamine might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. Fluvoxamine reduces caffeine metabolism (6370, 38287).\nless\nLITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, abrupt Ilex guayusa withdrawal might increase the levels and adverse effects of lithium.\nIlex guayusa contains caffeine. Abrupt caffeine withdrawal can increase serum lithium levels (609). Two cases of lithium tremor that worsened with abrupt coffee withdrawal have been reported (609, 610).\nless\nMETFORMIN (Glucophage)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, metformin might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. Animal research suggests that metformin can reduce caffeine metabolism (23571). Theoretically, concomitant use can increase caffeine serum concentrations and the risk of caffeine adverse effects.\nless\nMETHOXSALEN (Oxsoralen)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, methoxsalen might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. Methoxsalen can reduce caffeine metabolism (23572). Concomitant use can increase caffeine serum concentrations and the risk of caffeine adverse effects.\nless\nMEXILETINE (Mexitil)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, mexiletine might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. Mexiletine can decrease caffeine elimination by 50% (1260, 11741, 24981).\nless\nMONOAMINE OXIDASE INHIBITORS (MAOIs)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use might increase the risk of a hypertensive crisis.\nIlex guayusa can contain caffeine. Caffeine has been shown to inhibit monoamine oxidase (MAO) A and B in laboratory studies (37724, 37877, 37912, 38108). Concomitant intake of large amounts of caffeine with MAOIs might precipitate a hypertensive crisis (15).\nless\nNICOTINE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, concomitant use might increase the risk of hypertension.\nIlex guayusa contains caffeine. Concomitant use of caffeine and nicotine has been shown to have additive cardiovascular effects, including increased heart rate and blood pressure. Blood pressure was increased by 10.8/12.4 mmHg when the agents were used concomitantly (36549).\nless\nPENTOBARBITAL (Nembutal)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, Ilex guayusa might reduce the effects of pentobarbital.\nIlex guayusa contains caffeine. Theoretically, caffeine might negate the hypnotic effects of pentobarbital (13742).\nless\nPHENOBARBITAL (Luminal)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, Ilex guayusa might reduce the effects of phenobarbital and increase the risk for convulsions.\nIlex guayusa contains caffeine. Animal research suggests that caffeine can decrease the anticonvulsant activity of phenobarbital (23558, 23559, 23561). The exact mechanism of this interaction is unclear.\nless\nPHENOTHIAZINES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, phenothiazines might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. Phenothiazines can reduce the metabolism of caffeine by inhibiting cytochrome P450 1A2 (CYP1A2) (23573, 23574).\nless\nPHENYLPROPANOLAMINE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, phenylpropanolamine might increase the risk of hypertension, as well as the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. Concomitant use of phenylpropanolamine and caffeine might cause an additive increase in blood pressure (11738). Phenylpropanolamine also seems to increase caffeine serum levels (13743).\nless\nPHENYTOIN (Dilantin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, Ilex guayusa might reduce the effects of phenytoin and increase the risk for convulsions.\nIlex guayusa contains caffeine. Animal research suggests that caffeine can decrease the anticonvulsant activity of phenytoin (23559, 23561). The effect does not seem to be related to the seizure threshold-lowering effects of caffeine. However, the exact mechanism of this interaction is unclear.\nless\nPIOGLITAZONE (Actos)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, caffeine might increase the levels and clinical effects of pioglitazone.\nIlex guayusa contains caffeine. Animal research suggests that caffeine can modestly increase the maximum concentration, area under the curve, and half-life of pioglitazone, and also reduce its clearance. This increased the antidiabetic effects of pioglitazone (108812). However, the exact mechanism of this interaction is unclear.\nless\nQUINOLONE ANTIBIOTICS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, quinolone antibiotics might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. Concomitant use of quinolones can decrease caffeine clearance and increase effects and risk of adverse effects (606, 607, 608, 23554, 23555, 23556, 24695, 24696, 24697).\nless\nRILUZOLE (Rilutek)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use might increase the levels and adverse effects of both caffeine and riluzole.\nIlex guayusa contains caffeine. Caffeine and riluzole are both metabolized by cytochrome P450 1A2 (CYP1A2), and concomitant use might reduce metabolism of one or both agents (11739).\nless\nSTIMULANT DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nC (Expert opinion)\nTheoretically, concomitant use might increase stimulant adverse effects.\nIlex guayusa contains caffeine. Due to the central nervous system (CNS) stimulant effects of caffeine, concomitant use with stimulant drugs can increase the risk of adverse effects (11832).\nless\nTERBINAFINE (Lamisil)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, terbinafine might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. Terbinafine decreases the clearance of intravenous caffeine by 19% (11740).\nless\nTHEOPHYLLINE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMILD\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, Ilex guayusa might increase the levels and adverse effects of theophylline.\nIlex guayusa contains caffeine. Large amounts of caffeine might inhibit theophylline metabolism (11741).\nless\nTIAGABINE (Gabitril)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, Ilex guayusa might increase the levels and adverse effects of tiagabine.\nIlex guayusa contains caffeine. Animal research suggests that chronic caffeine administration can increase the serum concentrations of tiagabine. However, concomitant use does not seem to reduce the antiepileptic effects of tiagabine (23561).\nless\nTICLOPIDINE (Ticlid)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, ticlopidine might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. In vitro evidence suggests that ticlopidine can inhibit caffeine metabolism (23557). However, this effect has not been reported in humans.\nless\nVALPROATE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, Ilex guayusa might reduce the effects of valproate and increase the risk for convulsions.\nIlex guayusa contains caffeine. Animal research suggests that caffeine can decrease the anticonvulsant activity of valproate (23558, 23559, 23561, 37882). However, the exact mechanism of this interaction is unclear.\nless\nVERAPAMIL (Calan, others)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. Verapamil increases plasma caffeine concentrations by 25% (11741).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, Ilex guayusa may have antiplatelet effects in some people.\nIlex guayusa contains caffeine. Caffeine is reported to have antiplatelet activity (8028, 8029). Concomitant use of herbs and supplements that affect platelet aggregation could theoretically increase the risk of bleeding in some people. See other products with antiplatelet activity here. See products with anticoagulant activity here.\nless\nBITTER ORANGE\nTheoretically, concomitant use may increase the risk for adverse stimulant effects.\nIlex guayusa contains caffeine. Ilex guayusa in combination with caffeine or caffeine-containing herbs can increase blood pressure and heart rate in otherwise healthy normotensive adults, potentially increasing the risk of serious cardiovascular adverse effects (13657). However, in young mildly overweight individuals a combination product containing bitter orange, caffeine, and green tea does not seem to affect heart rate or blood pressure (20897).\nless\nCAFFEINE-CONTAINING HERBS AND SUPPLEMENTS\nConcomitant use may increase the risk for adverse effects.\nUsing Ilex guayusa, which contains caffeine, with other products that contain caffeine can increase the risk for caffeine-related adverse effects. See caffeine-containing natural ingredients here.\nless\nCALCIUM\nTheoretically, Ilex guayusa may increase calcium loss.\nIlex guayusa contains caffeine. High caffeine intake from foods and beverages, including Ilex guayusa, increases urinary calcium excretion (2570, 21534).\nless\nCORDYCEPS\nTheoretically, Ilex guayusa may increase the clearance of caffeine from the body.\nIlex guayusa contains caffeine. Cordyceps can speed up the clearance of caffeine from the body by inducing cytochrome P450 1A2 (CYP1A2) (24986).\nless\nDANSHEN\nTheoretically, concomitant use might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. Animal research shows that danshen slows the clearance of caffeine from the body by inhibiting cytochrome P450 1A2 (CYP1A2) (23580).\nless\nECHINACEA\nTheoretically, Ilex guayusa might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. In healthy individuals, taking echinacea 400 mg daily for 8 days seems to inhibit the oral clearance of caffeine (23581). This effect seems to be due to the inhibition of cytochrome P450 1A2 (CYP1A2) enzyme, which is involved in caffeine metabolism.\nless\nEPHEDRA (Ma Huang)\nConcomitant use increases the risk for adverse stimulant effects.\nIlex guayusa contains caffeine. There is evidence that using ephedra with caffeine might increase the risk of serious life-threatening or debilitating adverse effects such as hypertension, myocardial infarction, stroke, seizures, and death (6486, 10307). Tell patients to avoid taking Ilex guayusa with ephedra and other stimulants.\nless\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, Ilex guayusa might have hypoglycemic effects.\nAnimal research suggests that Ilex guayusa may have antihyperglycemic effects (115139, 116609). Theoretically, Ilex guayusa might have additive effects with herbs that decrease blood glucose levels. See other products with hypoglycemic activity here.\nless\nKUDZU\nTheoretically, kudzu might increase the levels and adverse effects of caffeine.\nIlex guayusa contains caffeine. Kudzu inhibits caffeine clearance and metabolism in healthy male individuals (23583). This effect has been attributed to inhibition of cytochrome P450 1A2 (CYP1A2) enzyme, which is involved in caffeine metabolism.\nless\nMAGNESIUM\nTheoretically, Ilex guayusa may increase magnesium loss.\nIlex guayusa contains caffeine. Consuming large amounts of caffeine can increase urinary excretion of magnesium (21534).\nless\nMELATONIN\nCaffeine seems to increase levels of melatonin. Theoretically, concomitant use with Ilex guayusa may increase the risk for melatonin-related adverse effects.\nIlex guayusa contains caffeine. Co-administration of caffeine and melatonin can increase melatonin levels by about 142%; this effect is more pronounced in non-smoking individuals (23584). Also, when taken in the evening, caffeine can increase endogenous melatonin levels in healthy individuals (23585).\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nANXIETY DISORDERS\nIlex guayusa contains caffeine. Taking more than 400 mg caffeine daily has been shown to aggravate anxiety disorders (11743, 98806). Use with caution.\nless\nBLEEDING DISORDERS\nIlex guayusa contains caffeine. Caffeine is reported to have antiplatelet activity (8028, 8029), although this interaction has not been reported in humans (1701). Caffeine can prolong bleeding time and increase the results of a bleeding time test (1701). Ilex guayusa might aggravate bleeding disorders. Use with caution.\nless\nCARDIAC CONDITIONS\nIlex guayusa contains caffeine. Caffeine has been reported to both increase and decrease heart rate, although this is not thought to be clinically significant at doses below 400 mg daily (98806). Ilex guayusa might induce cardiac arrhythmias in sensitive individuals. Use with caution (11845).\nless\nDIABETES\nIlex guayusa contains caffeine, which might interfere with glucose control in patients with diabetes. Some research suggests that caffeine may impair postprandial glucose metabolism in people with diabetes and contribute to insulin resistance. The effect of caffeinated beverages and herbs has not been studied (12374, 12375). Caffeine in Ilex guayusa may enhance the frequency and intensity of hypoglycemic warning symptoms in people with type 1 diabetes. Theoretically, this may increase the ability of diabetic patients to detect and treat hypoglycemia early. However, it might also increase the frequency of hypoglycemic events (6024). Some clinical research suggests symptoms of hypoglycemia are more intense at onset in the absence of caffeine, but with increasing duration of hypoglycemia, symptoms are greater with caffeine (13740). Caffeine has been reported to cause increases and decreases in blood glucose (8646).\nless\nDIARRHEA\nIlex guayusa contains caffeine, which can exacerbate diarrhea, especially when taken in large amounts. Use with caution in patients with diarrhea.\nless\nEPILEPSY\nIlex guayusa contains caffeine. Some animal research indicates that high doses of caffeine can significantly reduce seizure threshold or induce seizures (23559, 23560, 23561). Furthermore, caffeine seems to decrease the activity of various anticonvulsant drugs, including carbamazepine, ethosuximide, felbamate, phenobarbital, phenytoin, and valproate (23558, 23559, 23560, 23561, 23562, 23563). However, caffeine does not seem to affect the anticonvulsant effects of lamotrigine, tiagabine, or oxcarbazepine (23561). Patients with epilepsy should avoid high doses of caffeine; low doses of caffeine should be used with caution.\nless\nGLAUCOMA\nIlex guayusa contains caffeine, which increases intraocular pressure within 30 minutes and persists for at least 90 minutes (8540). Use with caution in patients with glaucoma.\nless\nHYPERTENSION\nIlex guayusa contains caffeine, which can temporarily increase blood pressure. However, increases are generally small and not clinically significant, being less than the normal diurnal variation in blood pressure (98806). Use with caution in patients with hypertension.\nless\nINCONTINENCE\nIlex guayusa can contain caffeine, which acts as a diuretic. Caffeine intake of more than 400 mg daily worsened detrusor instability (urge incontinency) in older females (36346). Increasing caffeine intake worsens symptoms of urinary incontinence, such as urinary frequency and urgency (36382). Use with caution in patients with urinary incontinence.\nless\nIRRITABLE BOWEL SYNDROME (IBS)\nIlex guayusa contains caffeine, which might worsen symptoms of diarrhea-predominant IBS, especially when taken in large amounts. Use with caution in patients with IBS.\nless\nOSTEOPOROSIS\nIlex guayusa contains caffeine, which can increase urinary excretion of calcium, although it usually remains within the normal range (98806). Some sources suggest that caffeine consumption should be limited to less than 300 mg daily, unless there is adequate calcium supplementation to compensate for calcium losses (2669, 10202, 11317). However, according to a review by Health Canada, and a subsequent large meta-analysis conducted in the US, doses of caffeine up to 400 mg daily are not associated with significant adverse cardiovascular, bone, behavioral, or reproductive effects in healthy adults (11733, 98806). Postmenopausal adults with a genetic variant of the vitamin D receptor appear to have an 8% higher risk for bone loss from caffeine (2669).\nless",
            "Interactions with Lab Tests": "EXPAND ALL\n|\nCOLLAPSE ALL\nDIPYRIDAMOLE THALLIUM IMAGING\nIlex guayusa contains caffeine. Taking Ilex guayusa might interfere with dipyridamole thallium imaging studies. Caffeine attenuates the characteristic cardiovascular responses to dipyridamole and has altered test results (11742).\nless\nFUNCTIONAL MAGNETIC RESONANCE IMAGING (fMRI)\nIlex guayusa contains caffeine, which might interfere with functional magnetic resonance imaging (fMRI) tests. Caffeine can increase the linearity of the blood oxygenation level dependent (BOLD) signal that is used in most fMRI studies (23587).\nless\nNEUROBLASTOMA TESTS\nDue to its caffeine content, Ilex guayusa might cause false-positive diagnosis of neuroblastoma when diagnosis is based on tests of urine vanillylmandelic acid (VMA) or catecholamine concentrations. Caffeine can increase urine catecholamine and VMA concentrations (15).\nless\nPHARMACOLOGICAL STRESS TESTS\nIlex guayusa contains caffeine which might interfere with pharmacological stress tests. Caffeine is a competitive antagonist for adenosine receptors and therefore may inhibit coronary vasodilation and compromise detection of ischemia (11771, 37784, 114659). It is recommended that caffeine and caffeine-containing products be stopped 24 hours prior to pharmacological stress tests (11770). However, caffeine appears more likely to interfere with dipyridamole (Persantine) than adenosine (Adenocard) stress testing (11771). The interaction between caffeine and dipyridamole is unlikely to be significant in stress testing if the heart rate increase is greater than 5% after dipyridamole infusion (11772). Additionally, clinical research shows that caffeine 200 mg and 400 mg given 90 minutes before stress testing significantly impairs the ability of regadenoson, an adenosine receptor agonist, to detect existing ischemia (91083), while other research reported no effect with caffeine doses 80 mg or less consumed 1 hour prior to testing. Additionally, some clinical research suggests that any effect of caffeine on tests of left ventricular ejection fraction may be minimal (114659).\nless\nPHEOCHROMOCYTOMA TESTS\nTaking Ilex guayusa might cause false-positive diagnosis of pheochromocytoma, when diagnosis is based on tests of urine vanillylmandelic acid (VMA) or catecholamine concentrations. Ilex guayusa contains caffeine. Caffeine can increase urine catecholamine and VMA concentrations (15).\nless\nPULMONARY FUNCTION TESTS\nIlex guayusa contains caffeine. People may need to avoid caffeine and caffeinated beverages for at least four hours prior to lung function testing. Forced expiratory volume in one minute (FEV1) seems to show a small improvement up to two hours after caffeine use. Mid-expiratory flow rates may also improve with caffeine for up to four hours (9607).\nless\nURATE\nIlex guayusa contains caffeine. Caffeine causes false elevations in serum urate test results determined by the Bittner method (11844).\nless",
            "Overdose": "Presentation\nThere is insufficient reliable information available about the presentation of overdose with Ilex guayusa. However, Ilex guayusa contains caffeine. Large doses of caffeine can cause massive catecholamine release and subsequent sinus tachycardia, metabolic acidosis, hyperglycemia, ketosis, and death (11838, 13734, 13735). The fatal acute oral dose of caffeine in adults is estimated to be 10-14 grams (150-200 mg per kilogram), although fatality has occurred at lower doses (11832, 37908, 37925, 38228, 38229, 91025, 91052, 91070, 97454). In fatal caffeine overdose, the cause of death is usually ventricular fibrillation (11838, 97454). Additional findings on autopsy after fatal overdose have identified acute cardiopulmonary failure and extensive congestion of the internal organs (95956).\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with Ilex guayusa.",
            "Pharmacokinetics": "Absorption\nIn healthy, physically active males, serum caffeine levels were increased for at least 4 hours following intake of a single dose of Ilex guayusa leaf extract. Maximum levels occurred about 47 minutes after intake (115138).\nExcretion\nIn young adults, the estimated half-life of caffeine was approximately 284 minutes following intake of a single dose of Ilex guayusa leaf extract (115138).",
            "Mechanism of Action": "General\nThe applicable part of Ilex guayusa is the leaf. Constituents include caffeine, chlorogenic acid, secondary chlorogenic acid esters, triterpenoid derivatives, quercetin glucosides, kaempferols, and carotenoids (115140, 115141, 115143, 115144, 115145, 115146, 115147, 115148). Analyses of the leaves have yielded variable findings related to caffeine content, ranging between 1.86% to 2.27% (115145).\nAnti-inflammatory effects\nAlthough the mechanism of action is unclear, the hydroalcoholic and aqueous extracts of Ilex guayusa have shown anti-inflammatory effects in vitro (115146).\nAntibacterial effects\nIn vitro, Ilex guayusa demonstrates antimicrobial activity against bacteria implicated in periodontal disease, including Porphyromonas gingivalis and Prevotella intermedia (115144). In a separate in vitro study, Ilex guayusa did not demonstrate antibacterial activity against Escherichia coli or Staphylococcus aureus (115146).\nAntidiabetic effects\nIlex guayusa is traditionally used for diabetes. In vitro, Ilex guayusa extract activated the G-protein coupled receptor TGR5 (GP-BAR1), a receptor involved in the regulation of glucose homeostasis. Ursolic acid, a triterpenoid constituent of Ilex guayusa, also activated GP-BAR1 (115142). In female streptozotocin-induced diabetic rats, ad libitum consumption of Ilex guayusa tea for 21 days modestly attenuated the increase in blood glucose levels when compared with those not consuming Ilex guayusa; however, it did not alter any hemodynamic or cardiovascular outcomes (116609).\nAntioxidant effects\nAlthough the mechanism of action is unclear, constituents of Ilex guayusa have shown antioxidant effects in vitro (115141, 115143, 115146)."
        }
    },
    "Immortelle": {
        "sections": {
            "Overview": "Immortelle is a protected species. It can easily be confused with sandy everlasting (Helichrysum angustifolium, synonym Helichrysum italicum), or Helichrysum stoechas (18). Avoid confusion with immortal (Asclepias asperula) (11).",
            "Safety": "There is insufficient reliable information available about the safety of immortelle.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nThere is currently a limited amount of information on the adverse effects of immortelle. Orally, immortelle can cause biliary colic when used by people with gallstones (18).\nGastrointestinal\nOrally, immortelle can cause biliary colic and sudden pain in people with gallstones (18).\nless\nImmunologic\nTheoretically, immortelle can cause an allergic reaction in individuals sensitive to the Asteraceae/Compositae family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many other herbs.\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of immortelle.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: One cup of tea daily. The tea is prepared by steeping 3-4 grams of dried flower in 150 mL of boiling water for 10 minutes and straining. The average daily dose is 3 grams of immortelle (18).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of immortelle.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "CROSS-ALLERGENICITY\nTheoretically, immortelle can cause allergic reactions in individuals sensitive to the Asteraceae/Compositae family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many other herbs.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of immortelle.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of immortelle.",
            "Mechanism of Action": "General\nThe applicable part of immortelle is the dried flower. Immortelle flower extract contains phenolic compounds and phytosterols, including quercitrin, isoquercitrin, chlorogenic acid, dicaffeoylquinic acids, kaempferol, luteolin, beta-sitosterol, stigmasterol, and campesterol, as well as apigenin and naringenin and their glycosides (99053, 105511).\nAntibacterial effects\nAn extract of immortelle flowers has demonstrated in vitro antibacterial activity against Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, and Moraxella catarrhalis, including some antibiotic-resistant strains (99053, 105511).\nAntifungal effects\nAn extract of immortelle flowers has demonstrated in vitro antifungal activity against Candida albicans, Aspergillus niger, and Aspergillus flavus (105511).\nAntioxidant effects\nAn extract of immortelle flowers has demonstrated in vitro free radical scavenging activity (105511)."
        }
    },
    "Indian Cassia": {
        "sections": {
            "Overview": "Indian cassia is a medium-sized evergreen tree that grows to a height of about 8 meters (94315). It is found in tropical and sub-tropical regions of the Himalayas, northeast India, Asia, and Australia (94273, 94274, 94296, 94297, 94314, 94315, 103166). The leaves and bark have been used in cooking and medicine, and as a fragrance, for many centuries (94272, 94273).",
            "Safety": "There is insufficient reliable information available about the safety of Indian cassia.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nDiabetes. Preliminary clinical research shows that taking Indian cassia dried leaf, 10 grams three times daily for up to 3 months, lowers fasting blood glucose levels to 100 mg/dL or less in about 50% of patients with diabetes (94272). However, the patients in this study also followed a reduced carbohydrate diet. Therefore it is unclear if the improvement was due to Indian cassia, the diet, or the combination.\nMuscle strength. One small clinical trial in young, resistance-trained males shows that taking a combination product (CinDura, Laila Nutraceuticals) containing Indian cassia and mangosteen extracts, 400 mg twice daily for 42 days, increases muscle strength and endurance when compared with placebo. Single bench and leg presses improved by approximately 23.5 and 29.3 kg, respectively, compared with 3.4 and 5.2 kg, respectively, in those taking placebo. Also, the number of leg extension repetitions increased by 6.5 compared to an increase of 2 with placebo (101079). It is unclear if these benefits are due to Indian cassia, mangosteen, or the combination.\nMore evidence is needed to rate Indian cassia for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information about the standardization of Indian cassia.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, Indian cassia might have additive effects with antidiabetes drugs. Clinical research shows that taking Indian cassia 10 grams three times daily for 3 months while following a reduced carbohydrate diet can decrease fasting blood glucose levels by up to 41% in patients with diabetes (94272). Monitor blood glucose levels closely; dose adjustments of antidiabetes drugs might be necessary.\nDIURETIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, Indian cassia might increase the risk of potassium depletion in patients taking diuretic drugs. However, this has not been shown in humans. Indian cassia leaf extract 200-400 mg/kg body weight has shown mild diuretic activity in animal research. The effect of Indian cassia on urine volume and electrolyte loss was similar to that of furosemide (94296). Until more is known, use with caution.",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nIndian cassia might lower blood glucose levels (94272). Theoretically, concomitant use with other herbs and supplements with hypoglycemic potential might increase the risk of hypoglycemia. Some herbs and supplements with hypoglycemic effects include alpha-lipoic acid, ba ji tian, bitter melon, chromium, devil's claw, fenugreek, garlic, guar gum, horse chestnut, Panax ginseng, psyllium, Siberian ginseng, and others.\nHORSETAIL\nTheoretically, use of large quantities of horsetail and Indian cassia concurrently may increase the risk of potassium depletion (94296).\nLICORICE\nTheoretically, use of large quantities of licorice and Indian cassia concurrently may increase the risk of potassium depletion (94296).",
            "Interactions with Conditions": "PERIOPERATIVE\nIndian cassia might decrease blood glucose levels (94272). Theoretically, Indian cassia might interfere with blood glucose control during and after surgical procedures. Tell patients to discontinue Indian cassia at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with Indian cassia.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Indian cassia.",
            "Mechanism of Action": "General\nThe applicable parts of Indian cassia are the leaf and bark (94273, 94314). Indian cassia leaf extract contains terpenoids, polyphenols, alkaloids, tannins, and flavonoids (94275). Phenolic compounds present include alpha-pinene, camphene, myrcene, limonene, and p-cymene (101079). The bark contains procyanidins, such as parameritannin A1 and cinnamtannins B1 and D1 (94279, 94280). Major constituents of the essential oil of Indian cassia leaves include cinnamaldehyde, cinnamyl acetate, ascabin, beta-caryophyllene, caryophyllene oxide, linalool, and eugenol (94274, 94293, 94314). The major constituents of Indian cassia depend on geographical region of growth and chemotype. Chemotypes differ in the main compound found in the essential oil, which can be eugenol, cinnamaldehyde, linalool, or trans sabinene hydrate-beta-ocimene (94273).\nAnti-inflammatory effects\nPreliminary evidence suggests that Indian cassia leaf extracts might reduce inflammation by inhibiting the production of pro-inflammatory prostaglandins (94273, 94309). In an animal model of colitis, cinnamtannin D1, a polyphenol constituent of Indian cassia, reduces inflammation and colon damage. It decreases levels of the proinflammatory cytokines, tumor necrosis factor-alpha, interleukin (IL)-1-beta, and IL-6 (112761).\nAntidiabetic effects\nHuman research shows that taking dried leaf of Indian cassia reduces fasting blood glucose levels in patients with diabetes (94272). Preliminary evidence suggests that oil from Indian cassia leaf may reduce blood glucose by promoting insulin secretion and peripheral utilization of glucose (94293, 94308). There is also preliminary evidence that Indian cassia bark extract may protect beta cells against oxidative stress and apoptosis, and promote glucose-stimulated insulin release (94276, 94279, 94310). The bark extract also appears to inhibit the enzyme alpha-amylase (94273, 94314).\nAntimicrobial effects\nEssential oils, volatile oils, and extracts of Indian cassia leaf have antimicrobial effects in laboratory research. Various oils and extracts of Indian cassia leaf have antifungal effects against various species of fungi, including ringworm, Aspergillus species, and Candida albicans (94273, 94294). The leaf extract and volatile oils have anti-bacterial effects against Shigella, Salmonella typhi, and others (94273, 94296). The bark extract also appears to have antibacterial effects (94273). The mechanism of action is not clear and it is not known if Indian cassia has antimicrobial benefits in humans.\nAntioxidant effects\nExtracts of Indian cassia leaves and essential oil have antioxidant activity in vitro and in animal models, possibly due to phenolic and flavonoid constituents (101079, 103166). Gastroprotective and hepatoprotective activity of Indian cassia have also been attributed to antioxidant and free radical scavenging activity (94273, 94295).\nDermatologic effects\nPreliminary clinical evidence shows that applying a gel emulsion formulation containing 4% Indian cassia leaf extract to facial skin twice daily for 90 days reduces melanin production, skin erythema, pore size, and sebum production when compared with placebo in healthy females. These effects may help reduce the damaging effects of sun exposure, and could be due to antioxidant and anti-inflammatory activity of Indian cassia. Flavonoids present may also inhibit tyrosinase which is involved in melanin biosynthesis (103166).\nGastrointestinal effects\nGastroprotective effects of Indian cassia leaf have been shown in animal models. Indian cassia leaf extract decreases stomach acid output and protects against ulcers. It also reduces diarrhea. The gastroprotective activity is attributed to antioxidant and free radical scavenging capabilities of its constituents (94273).\nHepatoprotective effects\nIndian cassia leaf powder in suspension has hepatoprotective effects in animal models of liver toxicity (94273, 94295). The antioxidant effects of the leaf are thought to play a role in the mechanism of action. Other potential mechanisms of action include modification of liver metabolic processes (94295).\nHypolipidemic effects\nIn animal hyperlipidemic models, Indian cassia reduces levels of cholesterol. This may be due to its flavonoid content (94277, 94315).\nImmune effects\nIn laboratory research, Indian cassia extract and its polyphenol constituent cinnamtannin D1 have immunosuppressive effects, reducing levels of cytokines and activity of T-lymphocytes (94280, 112761). In animal models, Indian cassia extracts reduce delayed-type hypersensitivity responses, antibody production, white blood cell counts, and the activity of macrophages (94273).\n\nIn an animal model, cinnamtannin D1 corrects the imbalance between T-helper 17 (Th17) cells and regulatory T-cells (T-reg) seen in colitis. In mesenteric lymph nodes, it reduces levels of T-helper cells and increases levels of T-reg cells by affecting levels of regulatory transcription factor proteins, including decreasing STAT3 and ROR-gamma-t levels, and increasing STAT5 and FOXP3. These effects of cinnamtannin D1 on Th17/T-reg balance are mediated via the AMPK/mTOR pathway which controls cellular survival and metabolism (112761)."
        }
    },
    "Indian Gooseberry": {
        "sections": {
            "Overview": "Indian gooseberry is a medium-sized deciduous tree that is native to India and the Middle East, but also grown in other countries such as Pakistan, Uzbekistan, Sri Lanka, China, and Malaysia (31016). Indian gooseberry has been used in Ayurvedic, Unani, and other traditional Asian medicinal practices (2079, 3563, 31030, 31040, 111569). Traditionally, Indian gooseberry has been used for ophthalmic, cardiovascular, gastrointestinal, liver, and joint problems, as well as for gonorrhea and menstrual irregularities.",
            "Safety": "LIKELY SAFE when consumed in amounts commonly found in foods (6, 2076).\nPOSSIBLY SAFE when used orally and appropriately in medicinal amounts. Indian gooseberry fruit extract has been used safely in doses of up to 1000 mg daily for up to 6 months, 1500 mg daily for up to 8 weeks, or 2000 mg daily for up to 4 weeks (92515, 99238, 99240, 99241, 102855, 102857, 105352, 105354, 105356). Indian gooseberry leaf extract has been used with apparent safety at a dose of 750 mg daily for 10 days (99846). ...when used topically and appropriately. An emulsion containing Indian gooseberry extract 3% and other ingredients has been applied safely to the skin twice daily for up to 60 days (111571).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, Indian gooseberry seems to be well tolerated.\nDermatologic\nOrally, itching has been reported by one individual in a clinical trial (105354).\nless\nGastrointestinal\nOrally, epigastric discomfort or dyspepsia have been reported by up to four individuals in clinical trials (105354, 105356).\nless\nHepatic\nIn clinical research, increased serum glutamic pyruvic transaminase (SGPT) levels, with otherwise normal liver function, occurred in patients taking Ayurvedic formulations containing ginger, Tinospora cordifolia, and Indian gooseberry, with or without Boswellia serrata. The SGPT levels normalized after discontinuing the treatments (89557). It is unclear if these hepatic effects were due to Indian gooseberry or other ingredients contained in the formulations.\nless\nMusculoskeletal\nOrally, musculoskeletal pain has been reported by three individuals in a clinical trial (105354).\nless\nNeurologic/CNS\nOrally, fatigue has been reported by one individual in a clinical trial (105354).\nless\nPulmonary/Respiratory\nOrally, breathlessness has been reported by one individual in a clinical trial (105354).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nDyslipidemia. Oral Indian gooseberry seems to be beneficial for dyslipidemia.\nMeta-analyses of 12 small clinical studies in healthy adults or patients with dyslipidemia, diabetes, hypertension, or metabolic syndrome show that taking Indian gooseberry fruit extract or powder 0.5-3 grams daily or Indian gooseberry fruit 12 grams daily for 2-12 weeks reduces total cholesterol by around 39 mg/dL, low-density lipoprotein (LDL) cholesterol by around 15-34 mg/dL, and triglycerides by around 22-52 mg/dL when compared with control groups. Results are conflicting whether Indian gooseberry increases high-density lipoprotein (HDL) cholesterol (111567, 111568). Subgroup analysis suggests that Indian gooseberry is more effective at doses greater than 1 gram daily and in adults with triglycerides above 150 mg/dL (111568). Clinical research in patients with dyslipidemia shows that taking Indian gooseberry whole fruit extract (Tri-low, Arjuna Natural Ltd.) 500 mg twice daily for 12 weeks reduces triglyceride and low-density lipoprotein (LDL) cholesterol levels by 34% and 20%, respectively, compared with 15% and 5%, respectively, in patients taking placebo (99238).\nless\nGastroesophageal reflux disease (GERD). Oral Indian gooseberry seems to be beneficial for reducing symptoms of GERD.\nClinical research in adults who have had non-erosive symptoms of GERD for at least 3 months shows that taking Indian gooseberry fruit extract 1000 mg twice daily for 4 weeks reduces the frequency and severity of heartburn and regurgitation by about 63% and 50%, respectively, compared with reductions of 24% and 5%, respectively, in patients taking placebo (99240).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAging skin. Oral Indian gooseberry has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in healthy, middle-aged females shows that drinking 50 mL of a juice containing Indian gooseberry extract 30-60 mg and lingonberry extract 25-50 mg daily for 12 weeks improves skin elasticity, thickness, wrinkles, and hydration when compared with placebo (102856). It is unclear if these effects are due to Indian gooseberry, lingonberry, or the combination. Another small clinical study in healthy, middle-aged females shows that applying a topical emulsion containing extracts of Indian gooseberry 3% and gotu kola 3% twice daily for 60 days improves skin hydration, some measures of skin wrinkles, and elasticity of the cheek but not the eye when compared with placebo (111571). It is unclear if these effects are due to Indian gooseberry, gotu kola, or the combination.\nless\nAndrogenic alopecia. Topical Indian gooseberry has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nIn individuals with self-perceived hair loss, preliminary clinical research shows that applying a hair product containing Indian gooseberry modestly improves hair growth rate and density, as well as hair thinning, when compared with baseline. Patients used a leave-in product containing Indian gooseberry (Saberry), coconut water solids (Cococin), gamma-L-glutamyl-selenomethionine (Peptiselect), and other ingredients as 3.5 mL in females and 2 mL in males, once daily for 3 months (105353).\nless\nCancer. Although there is interest in using oral Indian gooseberry for cancer, there is insufficient reliable information about the clinical effects of Indian gooseberry for this purpose.\nCardiovascular disease (CVD). It is unclear if oral Indian gooseberry is beneficial for the prevention of CVD.\nA meta-analysis of 9 small clinical studies in adults who are healthy or have CVD risk factors shows that taking Indian gooseberry fruit extract or powder 500-1500 mg daily for 2-12 weeks reduces low-density lipoprotein (LDL) cholesterol by around 15 mg/dL, very low-density lipoprotein (VLDL) cholesterol by around 5 mg/dL, triglycerides by around 22 mg/dL, and high-sensitivity C-reactive protein when compared with control groups. However, the meta-analysis suggests that Indian gooseberry does not improve high-density lipoprotein (HDL) cholesterol, systolic blood pressure, or diastolic blood pressure (111567). The validity of these findings is limited by small sample sizes and considerable heterogeneity among the included studies.\nless\nCoronavirus disease 2019 (COVID-19). It is unclear if oral Indian gooseberry is beneficial for the treatment of COVID-19 in hospitalized adults.\nA small clinical trial in adults hospitalized with COVID-19 shows that receiving Indian gooseberry powder 2 grams twice daily for 10 days does not impact RT-PCR positivity rate at day 10 when compared with placebo. Additionally, there were no clear trends in clinical improvement in patients receiving Indian gooseberry when compared with placebo. All patients in this study also received oral hydroxychloroquine and lopinavir/ritonavir (110012).\nless\nDiabetes. Several small or limited-quality clinical studies suggest that oral Indian gooseberry may modestly improve glycemic control and blood lipid levels in patients with type 2 diabetes.\nA moderate-sized, open-label study in adults with newly-diagnosed type 2 diabetes and dyslipidemia shows that taking Indian gooseberry extract, standardized to 10% beta-glucogallin, 2 grams daily for 90 days reduces glycated hemoglobin (HbA1c), fasting blood glucose, and postprandial blood glucose when compared to baseline, with superior effects on fasting blood glucose and postprandial blood glucose when compared with metformin 500 mg (111569). A smaller clinical study in patients with type 2 diabetes on stable doses of metformin shows that taking Indian gooseberry fruit extract (Capros, Natreon Inc) 500 mg twice daily for 12 weeks reduces HbA1c by around 0.5% and improves low-density lipoprotein (LDL) cholesterol, triglyceride, and high-density lipoprotein (HDL) levels when compared with placebo. Taking a lower dose, 250 mg twice daily, does not seem to improve HbA1c but has a modest effect on lipid levels (105356). Another small clinical study in patients with type 2 diabetes using various antidiabetes drugs shows that taking powdered Indian gooseberry fruit 1 gram, 2 grams, or 3 grams daily for 3 weeks modestly reduces fasting and 2-hour postprandial blood glucose levels and improves lipid levels when compared to baseline (105355). The validity of these findings is limited by the lack of a comparator group.\nless\nHangover. It is unclear if oral Indian gooseberry is beneficial for hangover prevention.\nA small clinical trial shows that taking Indian gooseberry leaf extract (Phyllpro) 750 mg daily for 10 days prior to alcohol intoxication modestly reduces some hangover symptoms 10 hours later, including nausea, headache, lack of appetite, and dizziness, when compared with placebo. Blood alcohol levels after 12 hours were also reduced. However, the overall hangover score was not significantly different between groups (99846).\nless\nHepatitis B. Although there is interest in using oral Indian gooseberry for hepatitis B, there is insufficient reliable information about the clinical effects of Indian gooseberry for this condition.\nHypercholesterolemia. Small studies suggest that oral Indian gooseberry might help to reduce low-density lipoprotein (LDL) cholesterol levels.\nPreliminary clinical research shows that taking Indian gooseberry might reduce levels of LDL cholesterol in patients with hypercholesterolemia. One preliminary clinical study shows that taking Indian gooseberry 50 grams for 4 weeks decreases LDL cholesterol by 15% when compared to baseline (2077). Other preliminary clinical research shows that taking Indian gooseberry fruit extract (Amlamax, Arjuna Natural Ltd.) 500 mg or 1000 mg daily for 6 months reduces levels of LDL cholesterol by about 13% when compared with baseline (99241). Also, one small study shows that taking an Indian gooseberry fruit juice powder 500 mg daily for 6 weeks modestly decreases LDL cholesterol and triglyceride levels when compared with baseline (99242). Some preliminary clinical research also shows that Indian gooseberry reduces LDL cholesterol in obese individuals. One small study shows that taking Indian gooseberry fruit extract (Capros, Natreon Inc.) 500 mg twice daily for 12 weeks reduces LDL cholesterol by 16 mg/dL in this population when compared to baseline (92515). However, the validity of these studies is limited by the lack of comparator groups.\nless\nHypertension. It is unclear if oral Indian gooseberry is beneficial for hypertension.\nIn patients with uncontrolled hypertension using standard therapies, clinical research shows that taking Indian gooseberry dried fruit powder 500 mg three times daily for 8 weeks reduces systolic blood pressure (SBP) and diastolic blood pressure (DBP) by 16% and 12%, respectively, from baseline, which is significantly greater than reductions seen with placebo. The frequency of response to treatment, based on a reduction in SBP or DBP of at least 10 mmHg or 5 mmHg, respectively, was also increased from up to 50% to at least 83% of patients (105352). However, other clinical research in adults with cardiovascular risk factors shows that taking Indian gooseberry 500-1500 mg twice daily for 2-12 weeks does not reduce SBP or DBP more than placebo (105354, 111567).\nless\nIrritable bowel syndrome (IBS). Indian gooseberry has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small, open-label study of adults with IBS shows that taking 7 grams of an Unani medicinal product called Jawarish Shahi, containing Indian gooseberry, terminalia, coriander, cardamom, and willow bark, twice daily for 45 days reduces the severity of IBS, as measured by improvements in abdominal pain and distension, bowel habits, and quality of life, when compared to baseline (111570). The validity of these findings is limited by insufficient blinding and the lack of a comparator group. It is unclear if these effects are due to Indian gooseberry, other ingredients, or the combination.\nless\nMetabolic syndrome. It is unclear if oral Indian gooseberry is beneficial for metabolic syndrome.\nPreliminary clinical research in adults with metabolic syndrome shows that taking a specific Indian gooseberry extract (Capros, Natreon Inc.) 250 mg twice daily for 12 weeks reduces total cholesterol by nearly 10%, low-density lipoprotein (LDL) cholesterol by 15%, and triglycerides by 10%, and increases high-density lipoprotein (HDL) cholesterol by about 7% when compared with placebo. Additionally, taking this product as 500 mg twice daily reduces total cholesterol by 14%, LDL cholesterol by 26%, and triglycerides by 19%, and increases HDL cholesterol by 22% when compared with placebo. Both doses also seem to improve markers of endothelial function, oxidative stress, and systemic inflammation (102857).\nless\nObesity. It is unclear if oral Indian gooseberry is beneficial for improving weight loss or metabolic parameters in adults with obesity.\nPreliminary clinical research in overweight or obese individuals shows that taking Indian gooseberry fruit extract (Capros, Natreon Inc.) 500 mg twice daily for 12 weeks reduces low-density lipoprotein (LDL) cholesterol by 16 mg/dL when compared to baseline. However, there was no effect on other lipids or on blood pressure, body weight, or body mass index (92515). The validity of these findings is limited by the lack of a comparator group.\nless\nOral mucositis. It is unclear if oral Indian gooseberry is beneficial in patients with radiation-induced mucositis.\nA retrospective observational study in patients with head and neck cancer receiving radiotherapy suggests that rinsing the mouth with Indian gooseberry 1% and povidone-iodine twice daily is associated with delayed development of mucositis and intolerable mucositis and a decreased incidence of intolerable mucositis when compared with povidone-iodine alone (111566). The validity of these findings is limited by the retrospective study design.\nless\nOsteoarthritis. Oral Indian gooseberry has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in adults with knee osteoarthritis suggests that specific Ayurvedic formulas containing Indian gooseberry may be equivalent to glucosamine sulfate 2 grams daily or celecoxib 200 mg daily for reducing pain. Two capsules containing Indian gooseberry 166.66 mg/capsule, ginger 33.33 mg/capsule, and Tinospora cordifolia 73.33 mg/capsule, with or without Boswellia serrata 100 mg/capsule, taken three times daily for 24 weeks, were used. All four treatments reduced active pain by about 28% to 38%, functional pain by 19% to 29%, and functional difficulty by 18% to 25%, with no significant between-group differences in the observed improvements (89557). It is not clear if these effects are due to Indian gooseberry, the other ingredients, or the combination.\nless\nPeriodontitis. It is unclear if subgingival Indian gooseberry is beneficial for periodontitis.\nClinical research in patients with chronic periodontitis shows that the subgingival application of a sustained-release Indian gooseberry fruit 10% gel following scaling and root planing does not affect plaque or gingivitis development over 2-3 months when compared with placebo. However, there was a modest benefit on periodontal destruction based on probing pocket depth (105358).\nless\nVitiligo. Oral Indian gooseberry has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with vitiligo shows that taking 1 tablet containing Indian gooseberry 100 mg, vitamin E 10 mg, and carotenoids 4.7 mg orally 3 times daily for 6 months, in combination with conventional topical therapy and/or phototherapy, increases re-pigmentation in the head, neck, and trunk and decreases signs of inflammation when compared with conventional treatment alone (92513).\nless\nMore evidence is needed to rate Indian gooseberry for these uses.",
            "Dosing & Administration": "Adult\nOral:\nIndian gooseberry has most often been used as a fruit extract in doses of 500-1000 mg daily for 4-12 weeks. See Effectiveness section for condition-specific information.\nTopical:\nIndian gooseberry has been applied as a subgingival gel or a hair product. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nIn one clinical trial, a specific formulation (Tri-low, Arjuna Natural Ltd.) of Indian gooseberry was prepared as the extract of the whole fruit, including the seeds. The extract was standardized to contain at least 35% polyphenols, 8% triterpenoids, and 10% oil (99238). Other extracts used in clinical trials have been prepared from the de-seeded fruit (92515, 99240, 99241). One such product (Capros) was standardized to contain about 60% low-molecular-weight hydrolysable tannins such as emblicanin-A, emblicanin-B, punigluconin, and pedunculagin (92515, 105356). In one clinical trial, a topical product contained Indian gooseberry extract (Saberry) standardized to 10% beta-glucogallin (105353). In one trial, a leaf extract (Phyllpro) was standardized to contain not less than 0.1% hypophyllanthin and 0.4% phyllanthin by weight (99846).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, Indian gooseberry may increase the risk of bleeding if used with anticoagulant or antiplatelet drugs; however, research is conflicting.\nClinical research shows that taking Indian gooseberry 500 mg as a single dose or twice daily for 10 days reduces platelet aggregation by about 24% to 36%, increases bleeding time by about 3.8-5.9 seconds, and increases clotting time by about 9.8-12.7 seconds when compared to baseline. However, taking Indian gooseberry 500 mg along with clopidogrel 75 mg or ecosprin 75 mg, as a single dose or for 10 days, does not significantly reduce platelet aggregation or increase bleeding time or clotting time when compared with clopidogrel 75 mg or ecosprin 75 mg alone (92514). Until more is known, use caution when taking Indian gooseberry in combination with anticoagulant/antiplatelet drugs.\nless\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTaking Indian gooseberry with antidiabetes drugs might increase the risk of hypoglycemia.\nClinical research shows that taking Indian gooseberry fruit or fruit extract alone or in conjunction with antidiabetes medications can lower blood glucose levels (31025, 105355, 105356, 111569). Dose adjustments to diabetes medications might be necessary.\nless\nASPIRIN\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, Indian gooseberry may increase the risk of bleeding if used with aspirin; however, research is conflicting.\nClinical research shows that taking Indian gooseberry 500 mg as a single dose or twice daily for 10 days reduces platelet aggregation by about 24% to 36%, increases bleeding time by about 3.8-5.9 seconds, and increases clotting time by about 9.8-12.7 seconds when compared to baseline. However, taking a single dose of Indian gooseberry 500 mg along with ecosprin 75 mg, or taking a combination of Indian gooseberry 500 mg twice daily plus ecosprin 75 mg once daily for 10 days, does not significantly reduce platelet aggregation or increase bleeding time or clotting time when compared with ecosprin 75 mg alone (92514).\nless\nCLOPIDOGREL (Plavix)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, Indian gooseberry may increase the risk of bleeding if used with clopidogrel; however, research is conflicting.\nClinical research shows that taking Indian gooseberry 500 mg as a single dose or twice daily for 10 days reduces platelet aggregation by about 24% to 36%, increases bleeding time by about 3.8-5.9 seconds, and increases clotting time by about 9.8-12.7 seconds when compared to baseline. However, taking a single dose of Indian gooseberry 500 mg along with clopidogrel 75 mg, or taking a combination of Indian gooseberry 500 mg twice daily plus clopidogrel 75 mg once daily for 10 days, does not significantly reduce platelet aggregation or increase bleeding time or clotting time when compared with clopidogrel 75 mg alone (92514).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nIndian gooseberry may have antiplatelet effects.\nIndian gooseberry can inhibit platelet aggregation (2079, 92514). Theoretically, Indian gooseberry might increase the risk of bleeding when used concomitantly with other anticoagulant/antiplatelet herbs and supplements. See other products with antiplatelet activity here. See other products with anticoagulant activity here.\nless\nCOPPER\nTheoretically, Indian gooseberry may decrease the absorption of copper.\nIn vitro research suggests that Indian gooseberry chelates with copper (25177). The clinical significance of this effect is unclear.\nless\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nIndian gooseberry has hypoglycemic effects.\nClinical research shows that Indian gooseberry lowers blood glucose levels (31025, 105355, 105356, 111569). Theoretically, Indian gooseberry may have additive effects when used with other herbs and supplements that also lower glucose levels. See other products with hypoglycemic activity here.\nless\nIRON\nTheoretically, Indian gooseberry may decrease the absorption of iron.\nIn vitro research suggests that Indian gooseberry chelates with iron (25177). The clinical significance of this effect is unclear.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLEEDING DISORDERS\nTheoretically, taking Indian gooseberry may exacerbate bleeding disorders. Indian gooseberry can inhibit platelet aggregation (2079, 92514).\nless\nPERIOPERATIVE\nIndian gooseberry can inhibit platelet aggregation and might increase the risk of excessive bleeding during surgery (2079, 92514). Tell patients to discontinue Indian gooseberry at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with Indian gooseberry.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Indian gooseberry.",
            "Mechanism of Action": "Anti-inflammatory effects\nIndian gooseberry leaf extract might have anti-inflammatory activity (2078, 2079). In humans, Indian gooseberry extract reduces levels of C-reactive protein (CRP) (92515, 99241, 102857, 105356) and increases levels of interleukin (IL)-8 and IL-10 (99846).\nAnticancer effects\nIndian gooseberry decreased tumor size and increased survival in tumor-bearing mice (31021). The juice of Indian gooseberry inhibits the formation of the genotoxic compounds N-nitrosomorpholine (NMOR) and N-nitrosoproline (NPRO) in humans and animals (2080).\nAntioxidant effects\nIn rats, the tannins emblicanin A, emblicanin B, punigluconin, and pedunculagin found in Indian gooseberry increased concentrations of superoxide dismutase, catalase, and glutathione peroxidase within the brain (2081).\nCardiovascular effects\nClinical research shows that taking Indian gooseberry extract 250-500 mg twice daily orally for 12 weeks reduces levels of high-sensitivity C-reactive protein (hs-CRP), which is a marker of coronary heart disease (92515, 102857, 105356). Preliminary evidence also shows that Indian gooseberry fruit, juice, or extract may lower total serum cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and phospholipids, improve high-density lipoprotein (HDL) cholesterol levels, and have positive effects on atherosclerosis and endothelial function (2077, 8180, 102855, 102857, 105356). Animal studies suggest that Indian gooseberry may prevent age-related hyperlipidemia by reducing nitric oxide synthase and cyclooxygenase-2 (COX-2) protein levels via inhibiting NF-kappaB activation (31046).\nCoagulation effects\nClinical research shows that Indian gooseberry extract can inhibit adenosine diphosphate (ADP)- and collagen-induced platelet aggregation (92514, 92515). Indian gooseberry extract also inhibited platelet aggregation and thromboxane B2 production in animals (2079).\nConstituents\nThe applicable part of Indian gooseberry is primarily the fruit (2075), but extracts from the leaves and bark have also been used (2078, 2079, 99242). The vitamin C content of Indian gooseberry fruit has been assayed at approximately 1 gram per 100 mL of fresh fruit juice (31016). The fruit also contains gallic acid, flavonoids, and tannins such as emblicanin-A, emblicanin-B, punigluconin, and pedunculagin (92515, 99240).\nDental effects\nIn humans, chewing gum containing Indian gooseberry fruit extract increased saliva flow and reduced levels of pathogenic bacteria such as Streptococcus mutans and Porphyromonas gingivalis (99239).\nEndocrine effects\nIn animal studies and in vitro, Indian gooseberry reduces the release of inflammatory cytokines that cause insulin resistance (31025).\nGastroprotective effects\nAlcoholic and aqueous extracts of Indian gooseberry show protective and healing effects in alcohol-induced gastric ulcers in animal experiments (31026, 31036).\nImmunomodulatory effects\nIndian gooseberry extract inhibits leukotriene B4-induced migration, leukotriene B4 release, and degranulation of human polymorphonuclear lymphocytes in vitro (2078, 2079)."
        }
    },
    "Indian Long Pepper": {
        "sections": {
            "Overview": "Indian long pepper is commonly found in parts of Southern Asia, including Indonesia, Sri Lanka, Vietnam, the Philippines, and China. It is used as a spice in cooking. It is also traditionally used in Ayurvedic medicine for pain and various cardiovascular, gastrointestinal, metabolic, reproductive, and respiratory disorders (101151, 101156).",
            "Safety": "LIKELY SAFE when used orally in food amounts. The fruit is commonly used in foods (101151).\nThere is insufficient reliable information available about the safety of Indian long pepper when used in medicinal amounts.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using in medicinal amounts.",
            "Adverse Effects": "General\nOrally, Indian long pepper is well tolerated when used in food (101151). No adverse effects have been reported when Indian long pepper is used as medicine. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAsthma. Although there has been interest in using oral Indian long pepper for asthma, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nBronchitis. Although there has been interest in using oral Indian long pepper for bronchitis, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nCancer. Although there has been interest in using oral Indian long pepper for cancer, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nCardiovascular disease (CVD). Although there has been interest in using oral Indian long pepper for CVD, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nCognitive function. Although there has been interest in using oral Indian long pepper for cognitive function, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nCommon cold. Although there has been interest in using oral Indian long pepper for the common cold, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nCough. Although there has been interest in using oral Indian long pepper for cough, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nDepression. Although there has been interest in using oral Indian long pepper for depression, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nDyspepsia. Although there has been interest in using oral Indian long pepper for dyspepsia, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nEpilepsy. Although there has been interest in using oral Indian long pepper for epilepsy, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nGastroesophageal reflux disease (GERD). Although there has been interest in using oral Indian long pepper for GERD, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nHypothyroidism. It is unclear if oral Indian long pepper is beneficial in patients with hypothyroidism.\nA small, uncontrolled clinical study in adults with subclinical or overt hypothyroidism shows that taking Indian long pepper powder 0.69 grams daily for 19 days or following a dose escalating and deescalating regimen for 19 days improves some symptoms of hypothyroidism, as measured by Zulewski scores, but has little to no effect on thyroid hormone levels when compared to baseline. The dose escalating and deescalating regimen included 0.69 grams of Indian long pepper powder on day 1 which was titrated up to 6.9 grams by day 10 and then deescalated down to 0.69 grams by day 19 (111111). The validity of these findings is limited by the lack of a placebo control group.\nless\nLiver disease. Although there has been interest in using oral Indian long pepper for liver disease, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nMuscle soreness. Although there has been interest in using oral Indian long pepper for muscle soreness, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nOsteoarthritis. Although there has been interest in using oral Indian long pepper for osteoarthritis, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nPsoriasis. Although there has been interest in using oral Indian long pepper for psoriasis, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nRheumatoid arthritis (RA). Although there has been interest in using oral Indian long pepper for RA, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nStress. Although there has been interest in using oral Indian long pepper for stress, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nTuberculosis. Although there has been interest in using oral Indian long pepper for tuberculosis, there is insufficient reliable information about the clinical effects of Indian long pepper for this purpose.\nMore evidence is needed to rate Indian long pepper for these uses.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Indian long pepper.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nAMOXICILLIN (Amoxil, Trimox)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Indian long pepper might increase the effects and adverse effects of amoxicillin.\nEvidence from animal research shows that piperine, a constituent of Indian long pepper, increases the plasma levels of amoxicillin when taken concomitantly (29269).\nless\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, Indian long pepper might increase the risk of bleeding when taken with anticoagulant/antiplatelet drugs.\nIn vitro research shows that Indian long pepper extract inhibits platelet aggregation (101151).\nless\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Indian long pepper might increase the risk of hypoglycemia when taken with antidiabetes drugs.\nAnimal research shows that piperine, a constituent of Indian long pepper, can reduce blood glucose levels (29225). Monitor blood glucose levels closely. Dose adjustments might be necessary.\nless\nCARBAMAZEPINE (Tegretol)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, Indian long pepper might increase blood levels of carbamazepine.\nA small pharmacokinetic study in patients taking carbamazepine 300 mg or 500 mg twice daily shows that a single 20 mg dose of purified piperine, which is a constituent of Indian long pepper, increases carbamazepine levels. Piperine may increase absorption by increasing blood flow to the GI tract, increasing the surface area of the small intestine, or by cytochrome P450 3A4 (CYP3A4) inhibition in the gut wall. Absorption was significantly increased by 7-10 mcg/mL/hour. The time to eliminate carbamazepine was also increased by 4-8 hours. Although carbamazepine levels were increased, this did not appear to increase side effects (16833).\nless\nCEFOTAXIME (Claforan)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Indian long pepper might increase the effects and adverse effects of cefotaxime.\nAnimal research shows that piperine, a constituent of Indian long pepper, increases the plasma levels of cefotaxime when taken concomitantly (29269).\nless\nCYCLOSPORINE (Neoral, Sandimmune)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Indian long pepper might increase the effects and adverse effects of cyclosporine.\nIn vitro research shows that piperine, a constituent of Indian long pepper, increases the bioavailability of cyclosporine (29282).\nless\nCYTOCHROME P450 1A1 (CYP1A1) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Indian long pepper might increase the effects and adverse effects of CYP1A1 substrates.\nIn vitro research shows that piperine, a constituent of Indian long pepper, inhibits CYP1A1 (29213).\nless\nCYTOCHROME P450 2B1 (CYP2B1) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Indian long pepper might increase the effects and adverse effects of CYP2B1 substrates.\nIn vitro research shows that piperine, a constituent of Indian long pepper, inhibits CYP2B1 (29332).\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Indian long pepper might increase the effects and adverse effects of CYP3A4 substrates.\nIn vitro research shows that piperine, a constituent of Indian long pepper, inhibits CYP3A4 (14375).\nless\nNEVIRAPINE (Viramune)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMILD\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, Indian long pepper might increase blood levels of nevirapine.\nA small pharmacokinetic study shows that piperine, a constituent of Indian long pepper, increases the plasma concentration and systemic exposure of nevirapine. However, no adverse effects were associated with the elevated plasma levels of nevirapine (29209).\nless\nP-GLYCOPROTEIN SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Indian long pepper might increase levels of P-glycoprotein substrates.\nIn vitro research shows that piperine, a constituent of Indian long pepper, can inhibit P-glycoprotein (14375, 29281).\nless\nPENTOBARBITAL (Nembutal)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Indian long pepper might increase the sedative effects of pentobarbital.\nAnimal research shows that piperine, a constituent of Indian long pepper, can increase pentobarbitone-induced sleeping time (29214).\nless\nPHENYTOIN (Dilantin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, Indian long pepper might increase blood levels of phenytoin.\nA small pharmacokinetic study shows that piperine, a constituent of Indian long pepper, increases phenytoin serum levels and slows its elimination (537).\nless\nPROPRANOLOL (Inderal)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, Indian long pepper might increase blood levels of propranolol.\nA small pharmacokinetic study shows that piperine, a constituent of Indian long pepper, accelerates absorption and increases serum concentrations of propranolol (538).\nless\nRIFAMPIN (Rifadin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Indian long pepper might increase blood levels of rifampin.\nPiperine, a constituent of Indian long pepper, seems to increase absorption and serum levels of rifampin (14375, 29284).\nless\nTHEOPHYLLINE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nIndian long pepper might increase blood levels of theophylline.\nA small pharmacokinetic study shows that piperine, a constituent of Indian long pepper, increases serum concentrations and slows elimination of theophylline (538).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, Indian long pepper might have antiplatelet effects.\nTaking Indian long pepper with other products that increase the risk of bleeding might have additive effects. In vitro research shows that Indian long pepper extract inhibits platelet aggregation (101151). See products with anticoagulant activity here. See products with antiplatelet activity here.\nless\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, Indian long pepper might have hypoglycemic effects.\nTaking Indian long pepper with other products with hypoglycemic potential might increase the risk of hypoglycemia. Animal research shows that piperine, a constituent of Indian long pepper, can reduce blood glucose levels (29225). See other products with hypoglycemic potential here.\nless\nRHODIOLA\nTheoretically, Indian long pepper might decrease the effects of rhodiola.\nIndian long pepper contains piperine. Animal research shows that concomitant use of piperine with rhodiola extract reduces the activity of rhodiola extract (71176).\nless\nSCOTCH BROOM\nTheoretically, Indian long pepper might increase the effects of scotch broom.\nPiperine, a constituent of Indian long pepper, increases the bioavailability of sparteine, a constituent of scotch broom (19).\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLEEDING CONDITIONS\nTheoretically, Indian long pepper might have antiplatelet effects, which might increase the risk of bleeding in individuals with bleeding disorders. Until more is known, medicinal amounts of Indian long pepper should be avoided or used with caution in these individuals. In vitro research shows that Indian long pepper extract inhibits platelet aggregation (101151).\nless\nPERIOPERATIVE\nIndian long pepper might have antiplatelet effects (101151). Theoretically, Indian long pepper might cause excessive bleeding if used perioperatively. Tell patients to discontinue Indian long pepper at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with Indian long pepper.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Indian long pepper.",
            "Mechanism of Action": "General\nThe applicable parts of Indian long pepper are the fruit and the root (101151). Indian long pepper fruit contains alkaloids such as piperine, piperanine, pipereicosalidine, guineensine, pipercide, dihydropiperlonguminine, piperlonguminine, piperchabamide B, and other components, including terpenes and flavonoids. The root contains alkaloids, including piperine and piperlongumine (3757, 101138, 101151, 101156).\nAnthelmintic effects\nIndian long pepper is traditionally used as an anthelmintic. In vitro, Indian long pepper has shown anthelmintic effects against various organisms (101151).\nAnti-asthmatic effects\nIndian long pepper is traditionally used for asthma. In an animal asthma model, the constituent piperlongumine reduced airway inflammation and inflammatory pathways (101138).\nAnti-inflammatory effects\nIndian long pepper is used as an anti-inflammatory agent, for conditions such as asthma, arthritis, and muscle pain. In vitro, the fruit extract and various constituents had anti-inflammatory effects and inhibited anti-inflammatory cellular pathways. Antioxidant effects of constituents of Indian long pepper are possibly partially responsible (101151, 101156).\nAnticancer effects\nIndian long pepper is traditionally used for cancer. In vitro, Indian long pepper extracts and some constituents have cytotoxic effects against various cancer cell lines, possibly by inducing apoptosis and immune responses, and inhibiting angiogenesis (1011151, 101156).\nAntimicrobial effects\nIndian long pepper has been used traditionally for infections including dysentery, leprosy, and tuberculosis. Some evidence in vitro, suggests that Indian long pepper has antibacterial effects (101151). Some laboratory evidence also suggests an ethanolic extract and isolated piperine might have amoebicidal activity (3758). An Ayurvedic herbal preparation containing Piper longum and Butea monosperma (Pippali rasayana) shows evidence that it is useful for managing giardiasis (3754, 3755).\nBioavailability enhancing effects\nPiperine, a constituent of black pepper, seems to increase oral absorption of drugs and other substances by forming a complex with them (3757).\nCognitive effects\nIndian long pepper is traditionally used to improve cognitive function. In an aging animal model, the constituent piperlongumine improves cognitive function and social behavior. Piperlongumine alters cellular signalling in the hippocampus and induces neurogenesis (101139). In animal models, the fruit extract of Indian long pepper had nootropic effects (101151)."
        }
    },
    "Indian Snakeroot": {
        "sections": {
            "Overview": "Indian snakeroot is an evergreen shrub found in the forests of Southeast Asia. It grows to a height of 60-90 cm. The root has been traditionally used as an antipyretic and uterine stimulant as part of folk medicine in India (94328). Indian snakeroot is considered endangered by the International Union for Conservation of Nature (94355).",
            "Safety": "POSSIBLY UNSAFE when used orally. Indian snakeroot contains small amounts of the drugs reserpine and yohimbine. Although most adverse effects to Indian snakeroot appear to be mild, higher doses can cause cardiovascular side effects including bradycardia and hypotension. Prolonged use can cause depression in some people (94330, 94331, 94332, 94438, 94440).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using. The reserpine alkaloid constituents appear to cross the placenta and are excreted in breast milk (4260).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, Indian snakeroot may be unsafe, particularly at high doses. Most adverse effects are thought to be from the constituents reserpine and yohimbine.\nMost Common Adverse Effects\nOrally: Abdominal pain, bradycardia, congestion, diarrhea, hypotension, increased appetite, nightmares, sedation, weight gain.\nSerious Adverse Effects (Rare)\nOrally: Atrial fibrillation, convulsions, depression, myocardial infarction.\nCardiovascular\nOrally, Indian snakeroot has been associated with reports of bradycardia and mild hypotension. These adverse effects are thought to be related to the constituent reserpine (94331, 94440). Adverse reactions to reserpine also include angina-like symptoms (94328). At high doses, adverse effects related to yohimbine, another constituent of Indian snakeroot, include hypertension, tachycardia, palpitations, myocardial infarction, and atrial fibrillation (3312, 17465, 86801, 91521). A supplement containing Indian snakeroot and several other ingredients (Carditone, Ayush Herbs) has been associated with reduction in blood pressure and increase in serum potassium levels (102838).\nless\nDermatologic\nIndian snakeroot contains small amounts of reserpine and yohimbine and may theoretically cause some of the adverse effects associated with these constituents. Orally, reserpine can cause facial flushing, skin rash, and itching (94328). Yohimbine may cause rash, erythrodermic skin eruption, and exanthema (3312, 3971, 86878, 86896).\nless\nEndocrine\nIndian snakeroot contains small amounts of reserpine and may theoretically cause some of the adverse effects associated with this constituent. Orally, reserpine can cause galactorrhea and breast enlargement (275, 94328).\nless\nGastrointestinal\nOrally, Indian snakeroot has been associated with increased or decreased appetite, diarrhea, nausea, vomiting, and abdominal pain (94332, 94438, 94440). Yohimbine, a constituent of Indian snakeroot, has been associated with nausea, vomiting, increased salivation, diarrhea, and gastrointestinal distress (3970, 17465, 86780, 86786, 86804, 86827, 86896). Reserpine, another constituent of Indian snakeroot, may cause gastrointestinal irritation and activation of peptic ulcers (15, 19).\nless\nGenitourinary\nIndian snakeroot contains small amounts of yohimbine and may theoretically cause some of the adverse effects associated with this constituent. Yohimbine may cause dartos contraction or decreased libido in some patients (86786, 86882).\nless\nHematologic\nIndian snakeroot contains small amounts of reserpine and yohimbine and may theoretically cause some of the adverse effects associated with these constituents. A case of drug-induced agranulocytosis has been reported following prolonged use of oral yohimbine (86877). Reserpine may cause thrombocytopenia (275).\nless\nImmunologic\nThere is one report of a hypersensitivity reaction to yohimbine, a constituent of Indian snakeroot. Symptoms included fever, chills, malaise, itchy, scaly skin, progressive kidney failure, and a lupus-like syndrome (6169).\nless\nMusculoskeletal\nOrally, Indian snakeroot has been associated with muscle aches and cramps (94438).\nless\nNeurologic/CNS\nOrally, Indian snakeroot may cause headaches, feeling cold, dizziness, drowsiness, nightmares, and mild sedation (94331, 94332, 94438, 94440). Indian snakeroot contains small amounts of reserpine and yohimbine and may theoretically cause some of the adverse effects associated with these constituents. Doses of reserpine of greater than 0.5 mg daily can increase the risk of side effects. In extremely large amounts, Parkinson-like symptoms, extrapyramidal reactions, and convulsions may occur (15, 94328, 94332). Orally, yohimbine has been associated with reports of tremulousness, head twitching, seizures, loss of consciousness, decreased energy, dizziness, vertigo, headache, feeling cold, flushing, diaphoresis, and paralysis (11, 18, 3312, 3971, 17465, 86786, 86801, 86804, 86827, 86896).\nless\nOncologic\nIndian snakeroot contains small amounts of reserpine and may theoretically cause some of the adverse effects associated with this constituent. Some preliminary research suggests a link between reserpine and an increased risk of breast cancer; but this has not been confirmed in further research (94328).\nless\nPsychiatric\nOrally, Indian snakeroot can cause emotional upset or depression, especially in people with prior episodes. This appears to be related to the constituent reserpine (94332, 94438). One study shows the rate of depressive episodes is similar for patients taking Indian snakeroot and those taking reserpine (94438). Some research suggests that the risk of depression might increase with dose or the length of use. When taken for less than 40 days, depression did not occur in patients taking Indian snakeroot or reserpine (94330).\n\nIndian snakeroot contains small amounts of yohimbine and may theoretically cause some of the adverse effects associated with this constituent. Orally, yohimbine may increase anxiety and impulsivity (17465, 86784, 86810).\nless\nPulmonary/Respiratory\nOrally, Indian snakeroot can cause nasal stuffiness or congestion and shortness of breath (94330, 94332, 94438, 94440). One study shows that Indian snakeroot may increase the risk for nasal congestion more than the constituent reserpine. (94438). Reserpine is also associated with rare reports of allergic reactions that can precipitate asthma (15, 94328). Another constituent of Indian snakeroot, yohimbine, may cause bronchospasm, tachypnea, cough, sinusitis, and rhinorrhea (17465, 86825, 86850, 94112). Excessive doses of yohimbine can cause respiratory depression (1118).\nless\nRenal\nOrally, Indian snakeroot may cause increased urination (94332).\n\nIndian snakeroot contains small amounts of yohimbine and may theoretically cause some of the adverse effects associated with this constituent. A case of acute kidney failure related to yohimbine-induced systemic lupus erythematosus has been reported (6169).\nless\nOther\nOrally, Indian snakeroot has been associated with reports of weight gain (94438).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAbdominal pain. Although there has been interest in using oral Indian snakeroot for abdominal pain, there is insufficient reliable information about the clinical effects of Indian snakeroot for this purpose.\nAnxiety. It is unclear if oral Indian snakeroot is beneficial in patients with anxiety.\nA single, small, low-quality clinical study shows that taking Indian snakeroot crude root 300-2000 mg orally daily, or an Indian snakeroot extract (alseroxylon, Rauwiloid) 4-64 mg orally daily, for an average of 20 days reduces symptoms of anxiety when compared with baseline in patients with various psychiatric disorders, including schizophrenia, personality disorders, and psychoneurotic disorders. A moderate decrease in anxiety or complete remission occurred in 80% of patients taking the crude root, 78% of those taking the extract, and 79% of patients taking the constituent reserpine 0.75-14 mg (94330). The validity of this study is limited by the lack of a comparator group.\nless\nConstipation. Although there has been interest in using oral Indian snakeroot for constipation, there is insufficient reliable information about the clinical effects of Indian snakeroot for this purpose.\nEpilepsy. Although there has been interest in using oral Indian snakeroot for epilepsy, there is insufficient reliable information about the clinical effects of Indian snakeroot for this purpose.\nHypertension. It is unclear if oral Indian snakeroot is beneficial in patients with hypertension.\nPreliminary, low-quality, clinical research in adults with hypertension shows that taking Indian snakeroot 200-400 mg orally daily for up to 3 months reduces systolic and diastolic blood pressure by averages of 21-27 mmHg and 11-14 mmHg, respectively, when compared with baseline (94332, 94438, 94331, 94440). Some evidence suggests that taking crude Indian snakeroot 400 mg daily may be as effective as taking isolated reserpine 0.4 mg daily (94438). Some clinical trials have also studied a specific Indian snakeroot product (Serpina, Himalaya Drug Company) as 1-4 tablets daily for up to one year. However, the tablet strength was not reported (94331, 94438).\nless\nInsect bite. Although there has been interest in using oral Indian snakeroot for insect bites, there is insufficient reliable information about the clinical effects of Indian snakeroot for this purpose.\nInsomnia. Oral Indian snakeroot has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in adults with chronic insomnia shows that taking Indian snakeroot root extract 200 mg orally in a specific combination with valerian rhizome 200 mg and Tinospora cordifolia extract 200 mg for 21 days reduces sleep latency by 11 minutes and increases total sleep by 58 minutes when compared with the placebo run-in period (6051). It is unclear if this effect is due to Indian snakeroot, other ingredients, or the combination.\nless\nMalaria. Although there has been interest in using oral Indian snakeroot for malaria, there is insufficient reliable information about the clinical effects of Indian snakeroot for this purpose.\nPsychosis. Although there has been interest in using oral Indian snakeroot for psychosis, there is insufficient reliable information about the clinical effects of Indian snakeroot for this purpose.\nRheumatoid arthritis (RA). Although there has been interest in using oral Indian snakeroot for RA, there is insufficient reliable information about the clinical effects of Indian snakeroot for this purpose.\nSchizophrenia. Although there has been interest in using oral Indian snakeroot for schizophrenia, there is insufficient reliable information about the clinical effects of Indian snakeroot for this purpose.\nMore evidence is needed to rate Indian snakeroot for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\n\nTheoretically, taking Indian snakeroot with alcohol can cause additive sedation (18). Avoid concomitant use.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Indian snakeroot.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, taking Indian snakeroot might increase the risk of bleeding when used with antiplatelet or anticoagulant drugs.\nIndian snakeroot contains small amounts of the drug yohimbine. In vitro research shows that yohimbine inhibits platelet aggregation (86773, 86806, 86835, 86853).\nless\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, concomitant use of Indian snakeroot with antidiabetes drugs might increase the risk of hypoglycemia.\nAnimal research shows that Indian snakeroot lowers blood glucose levels (94344, 94353). This effect has not been reported in humans.\nless\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, concomitant use of Indian snakeroot and antihypertensive drugs might increase the risk of hypotension.\nIndian snakeroot, which contains reserpine, can reduce both systolic and diastolic blood pressure (94328, 94331, 94332).\nless\nANTIPSYCHOTIC DRUGS\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use might increase the risk of adverse effects.\nConcomitant use of neuroleptics with Indian snakeroot may potentiate the effects of these drugs, as well as the alkaloid constituents of Indian snakeroot (2, 18).\nless\nBETA-BLOCKERS\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking Indian snakeroot with beta-blockers might increase the risk of bradycardia and/or hypotension.\nIndian snakeroot contains small amounts of reserpine. Reserpine causes catecholamine-depletion (15). Concomitant use of Indian snakeroot and beta-blockers might increase the risk or bradycardia and/or hypotension.\nless\nCNS DEPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking Indian snakeroot might cause additive sedative effects.\nSedation and drowsiness have been reported in clinical trials using Indian snakeroot (94331, 94332, 94438, 94440).\nless\nCYTOCHROME P450 2D6 (CYP2D6) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, Indian snakeroot might inhibit CYP2D6 enzymes and reduce the metabolism of CYP2D6 substrates.\nIndian snakeroot contains small amounts of the drug yohimbine. In vitro research shows that yohimbine inhibits CYP2D6 enzyme activity (23117).\nless\nDIGOXIN (Lanoxin)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking Indian snakeroot with digoxin might increase the risk of bradycardia.\nBradycardia has been reported in clinical trials using Indian snakeroot (94331, 94440). Concomitant use of digoxin with Indian snakeroot might potentiate this effect.\nless\nEPHEDRINE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking Indian snakeroot with ephedrine might alter the effects and side effects of ephedrine.\nIndian snakeroot contains small amounts of reserpine. Reserpine reduces indirect sympathomimetic drug activity. However, another constituent of Indian snakeroot, yohimbine, has stimulant activity and may increase the risk of adverse effects with ephedrine (15, 18).\nless\nLEVODOPA\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking Indian snakeroot with levodopa may reduce the effectiveness of levodopa.\nExtrapyramidal motor symptoms and Parkinson-like symptoms have been reported in clinical trials using Indian snakeroot (94328, 94332). Concomitant use of Indian snakeroot with levodopa may reduce the effectiveness of levodopa and increase extrapyramidal motor symptoms (15, 18).\nless\nMONOAMINE OXIDASE INHIBITORS (MAOIs)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking Indian snakeroot with MAOIs might cause additive effects.\nYohimbine, a constituent of Indian snakeroot, has MAO inhibitory effects. At high doses, yohimbine is a non-selective inhibitor of MAO (11, 12).\nless\nSTIMULANT DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use might cause additive effects.\nYohimbine, a constituent of Indian snakeroot, has sympathomimetic effects and increases blood pressure in a dose-dependent manner. Theoretically, taking Indian snakeroot with stimulant drugs can have additive stimulant and hypertensive effects (11, 12, 105698).\nless\nTRICYCLIC ANTIDEPRESSANTS (TCAs)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use might alter the effects of Indian snakeroot and increase the risk of adverse effects.\nA small clinical study in patients taking TCAs for at least 4 weeks shows that receiving doses of intravenous yohimbine, a constituent of Indian snakeroot, 2.5-20 mg daily for up to 7 days precipitates severe anxiety, agitation, and tremor (105881). Also, concomitant use of TCAs with Indian snakeroot may decrease the effects of other rauwolfia alkaloids (15).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, Indian snakeroot may have antiplatelet effects in some people.\nIndian snakeroot contains small amounts of the drug yohimbine. In vitro research shows that yohimbine inhibits platelet aggregation (86773, 86806, 86835, 86853). Theoretically, Indian snakeroot might increase the risk of bleeding when used with other herbs and supplements that affect platelet aggregation. See other products with antiplatelet activity here. See products with anticoagulant activity here.\nless\nCARDIAC GLYCOSIDE-CONTAINING HERBS\nTheoretically, Indian snakeroot may cause bradycardia.\nBradycardia has been reported in clinical trials using Indian snakeroot (94331, 94440). Concomitant use of cardiac glycoside-containing natural ingredients with Indian snakeroot might potentiate this effect. See other cardiac glycoside-containing natural ingredients here.\nless\nEPHEDRA (Ma huang)\nTheoretically, Indian snakeroot might alter the effects and side effects of ephedra.\nIndian snakeroot contains resperine, which might reduce indirect-sympathomimetic drug activity. However, another constituent of Indian snakeroot, yohimbine, has stimulant activity and may increase the risk of adverse effects with ephedrine (15).\nless\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, Indian snakeroot might have hypoglycemic effects.\nAnimal research shows that Indian snakeroot lowers blood glucose levels (94344, 94353). Theoretically, Indian snakeroot might have additive effects with other herbs and supplements that decrease blood glucose levels. See other products with hypoglycemic potential here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nANXIETY\nIndian snakeroot contains small amounts of yohimbine. Yohimbine has been associated with reports of increased anxiety (17465, 86782). However, preliminary clinical research shows that Indian snakeroot and its extract may reduce anxiety symptoms (94330). Until more is known, use Indian snakeroot cautiously in patients with a history of anxiety.\nless\nCARDIOVASCULAR DISEASE (CVD)\nIndian snakeroot contains small amounts of reserpine and yohimbine. Yohimbine has been reported to cause tachycardia, increased blood pressure, and numerous cardiovascular adverse events (515, 17465, 103101, 101983, 101984). Conversely, reserpine can reduce both systolic and diastolic blood pressure (94328, 94331). Avoid use in patients with existing CVD or CVD risk factors.\nless\nDEPRESSION\nTheoretically, taking Indian snakeroot may worsen depression. Depression has been reported in clinical trials of Indian snakeroot, especially in people with a prior history (94332, 94438). Avoid use of Indian snakeroot in people with a history of depression.\nless\nELECTROCONVULSIVE THERAPY (ECT)\nIndian snakeroot is contraindicated during ECT. Indian snakeroot therapy should be discontinued at least 1 week before initiation of ECT (15).\nless\nGALLBLADDER DISEASE\nIndian snakeroot contains rauwolfia alkaloids. Rauwolfia alkaloids may precipitate biliary colic. Use cautiously in individuals with a history of gallstones (15).\nless\nGASTROINTESTINAL (GI) CONDITIONS\nReserpine, a constituent of Indian snakeroot, can cause irritation and ulceration in the gastrointestinal tract (15). Use Indian snakeroot cautiously in individuals with a history of GI conditions.\nless\nPERIOPERATIVE\nTheoretically, Indian snakeroot might interfere with blood glucose control during and after surgical procedures. Indian snakeroot might affect blood glucose levels (35751, 106339). Tell patients to discontinue Indian snakeroot at least 2 weeks before elective surgical procedures.\nless\nPHEOCHROMOCYTOMA\nIndian snakeroot contains small amounts of reserpine. Reserpine is contraindicated in people with pheochromocytoma due to catecholamine release and a risk of hypertensive crisis (18).\nless",
            "Interactions with Lab Tests": "EXPAND ALL\n|\nCOLLAPSE ALL\n17-HYDROXYCORTICOSTEROIDS\nTheoretically, taking Indian snakeroot might interfere with colorimetric assays of urinary 17-ketosteroids. Indian snakeroot contains rauwolfia alkaloids and small amounts of reserpine. Rauwolfia alkaloids interfere with colorimetric assays of urinary 17-hydroxycorticosteroid concentrations by the Glenn-Nelson technique. Reserpine also interferes with colorimetric assays of urinary 17-hydroxycorticosteroid concentrations which rely on the Porter-Silber reaction (15, 275).\nless\n17-KETOSTEROIDS\nTheoretically, taking Indian snakeroot might interfere with colorimetric assays of urinary 17-ketosteroids. Indian snakeroot contains rauwolfia alkaloids. Rauwolfia alkaloids interfere with colorimetric assays of urinary 17-ketosteroids by the Holtorff Koch modification of the Zimmerman reaction (15).\nless\nBILIRUBIN\nTheoretically, large doses of Indian snakeroot might cause falsely high serum bilirubin test results. Indian snakeroot contains small amounts of reserpine. Reserpine concentrations greater than 61 mg/L can cause falsely high serum bilirubin test results when measured by the Jendrassik and Grof method (275).\nless\nGUAIACOLS SPOT TEST\nTheoretically, Indian snakeroot might cause false-positive urine guaiacols spot test results. Indian snakeroot contains small amounts of reserpine. Reserpine can cause a false-positive reaction for urinary guaiacols with the screening test of Rogers (275).\nless\nTYRAMINE\nTheoretically, Indian snakeroot might cause false-negative tyramine test results. Indian snakeroot contains small amounts of reserpine. Reserpine may inhibit patient responsiveness to tyramine tests (275).\nless",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with Indian snakeroot.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Indian snakeroot.",
            "Mechanism of Action": "General\nThe applicable part of Indian snakeroot is the dried root (18). The whole root contains over 50 alkaloids (13). The active constituents of the whole root include the rauwolfia alkaloids. The highest concentration of alkaloids is found in the bark of the root. These constituents are found in lower levels in other parts of the plant (13, 94328). The yield of total alkaloids ranges from 0.7% to 3.3% of dry weight (94328). Indole and indole alkaloids found in Indian snakeroot include ajmaline, ajmalicine, aricine, canescine, coryanthine, isoajmaline, isorauhimbine, isoserine, isoserpiline, lankanescine, neoajmaline, papaverine, raubasine, raucaffricine, rauhimbine, raupine, rauwolfinine, recanescine, rescinnamine, reserpiline, reserpine, reserpinine, sarpagine, serpentine, serpentinine, thebaine, yohimbine, and yohimbinine (18, 94328). Although most scientific research has focused on the constituent reserpine, many of the other alkaloids have been shown to have biochemical effects in laboratory research (94328). The alkaloids serpentine, ajmaline, reserpine, and yohimbine are the alkaloids found in the highest levels in Indian snakeroot. Yohimbine levels are lower than the other three (94354, 94356). Indian snakeroot also contains stigmasterol (94350).\nAntidiabetic effects\nIn animal diabetic models, Indian snakeroot reduced glucose, insulin, hemoglobin A1c, and lipid levels (94344, 94353, 107947). The mechanism of action is not clear. However, Indian snakeroot is thought to inhibit the absorption of carbohydrates in the intestine or decrease insulin resistance (94353). Also, two constituents in Indian snakeroot, indobine and indobinine, might prevent downstream complications of diabetes by preventing toxic effects of high levels of glucose (94352).\nAntidiarrheal effects\nIndian snakeroot is traditionally used to reduce diarrhea. In an animal model, Indian snakeroot reduced diarrhea, possibly by increasing absorption of fluids from the intestinal tract (94351).\nCardiovascular effects\nIndian snakeroot reduces heart rate (13, 94331, 94440) and has anti-arrhythmic effects due to the alkaloid ajmaline which produces membrane stabilization (18).\nCentral nervous system effects\nIndian snakeroot demonstrates sedative and tranquilizing effects (15, 94331, 94332, 94438, 94440). Constituent alkaloids in Indian snakeroot also case a general sense of euphoria (13). The sedative effects of Indian snakeroot can result from the depletion of amine stores in the central nervous system (CNS) (13). The constituent reserpine appears to prevent the movement of intracellular neurotransmitters (94328).\nHypotensive effects\nIndian snakeroot demonstrates hypotensive effects (94331, 94332, 94328). Hypotensive effects are believed to be due to the depletion of both catecholamine and serotonin stores and to the prevention of reuptake into nerve endings (13, 18). The greater the proportion of alkaloids present, the greater the hypotensive activity (13).\nNeurologic effects\nReserpine and other alkaloids present in Indian snakeroot have sympatholytic activity, reducing stores of norepinephrine, dopamine, and serotonin. They release norepinephrine and other monoamines from storage in neurons and prevent reuptake into the nerve endings (18)."
        }
    },
    "Indigo pulchra": {
        "sections": {
            "Overview": "Indigo pulchra is a small shrub that grows in the savannah region of West Africa (94883). It has been traditionally used as a medicine (94882).",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the safety of indigo pulchra.\n\nPREGNANCY AND LACTATION: Insufficient reliable information is available; avoid using.",
            "Dosing & Administration": "Adult\nMalaria: Traditionally, the whole plant of indigo pulchra has been boiled and ingested (94882).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of indigo pulchra.",
            "Interactions with Drugs": "ANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, indigo pulchra might lower blood glucose levels (94889, 94890) and might have additive effects when used with antidiabetes drugs. This might increase the risk of hypoglycemia in some patients. Monitor blood glucose levels closely. Some antidiabetes drugs include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, metformin (Glucophage), pioglitazone (Actos), rosiglitazone (Avandia), and others.",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, indigo pulchra might lower blood glucose levels (94889, 94890) and might have additive effects when used with other herbs and supplements that also lower glucose levels. This might increase the risk of hypoglycemia in some patients. Some herbs and supplements with hypoglycemic effects include alpha-lipoic acid, bitter melon, chromium, devil's claw, fenugreek, garlic, guar gum, horse chestnut, Panax ginseng, psyllium, Siberian ginseng, and others.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nDIABETES\nTheoretically, indigo pulchra might lower blood glucose levels (94889, 94890) and might have additive effects when used with antidiabetes drugs. This might increase the risk of hypoglycemia in some patients. Monitor blood glucose levels closely.\nless\nSURGERY\nIndigo pulchra might affect blood glucose levels. Theoretically, indigo pulchra might interfere with blood glucose control during and after surgical procedures. Tell patients to discontinue indigo pulchra at least 2 weeks before elective surgical procedures.\nless",
            "Overdose": "Intraperitoneally, the median lethal dose (LD50) of indigo pulchra hydromethanolic leaf extract was 2,154 mg/kg and the LD50 of indigo pulchra saponin extract was 1,265 mg/kg in animal models (94883, 94889). Subcutaneously, the LD50 of indigo pulchra hydromethanolic extract is greater than 5000 mg/kg in animal models (94884, 94888).",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of indigo pulchra.",
            "Mechanism of Action": "General\nThe applicable parts of indigo pulchra are the leaves and the aerial parts. Active constituents of the leaves are thought to be saponins, tannins, alkaloids, and flavonoids such as quercetin and kaempferol. Indigo pulchra also contains carbohydrates, resins, and trace amounts of cardiac glycosides (94885, 94888).\nAnalgesic effects\nTraditionally, indigo pulchra has been used as an analgesic. Animal research shows that the indigo pulchra constituent prenyloxychalchone reduces experimentally induced peripheral pain (94887).\nAnti-inflammatory effects\nTraditionally, indigo pulchra has been used for swelling, rheumatic pain, and arthritic conditions. Animal research shows that intraperitoneal administration of indigo pulchra saponins reduces carrageenan-induced edema of the paw. Carrageenan-induced edema occurs due to the release of the chemicals histamine, prostaglandins and bradykinins. Theoretically, indigo pulchra saponins have an antagonistic effect on one or more of these chemicals (94883).\nAnti-malarial effects\nTraditionally, indigo pulchra has been used to treat malaria. Plasmodium berheigh is a parasite that causes malaria. Animal research shows that indigo pulchra leaf methanol and n-butanol extracts decrease the number of P. berheigh infected blood cells when compared to no treatment (94884).\nAntidiabetic effects\nAnimal research shows that the hydromethanolic leaf extract of indigo pulchra reduces blood glucose in rats with diabetes in a dose-dependent manner (94889). The ethylacetate and n-butanol extracts of indigo pulchra leaves have also been shown to reduce fasting blood glucose in rat models with diabetes (94890). Indigo pulchra leaf ethylacetate and n-butanol extracts demonstrate antioxidant effects in rat models with diabetes. Theoretically, the antioxidant effects can help reduce some complications of hyperglycemia (94891).\nGastrointestinal effects\nTraditionally, indigo pulchra was used to protect the gastrointestinal system and for diarrhea. Animal research shows that a methanol extract of indigo pulchra leaves reduces castor-oil induced diarrhea comparably to loperamide. Theoretically, indigo pulchra extract decreases diarrhea by reducing endogenous prostaglandin, thereby reducing permeability of the intestinal mucosa (94885, 94886). Additionally, animal research shows that hydromethanolic extract of indigo pulchra reduces ethanol-induced gastric mucosal damage and ulceration. Theoretically, this protective effect occurs because indigo pulchra extract reduces the volume and acidity of gastric juice (94888)."
        }
    },
    "Indium": {
        "sections": {
            "Overview": "Indium is a soft silver-white metal. It is chemically similar to aluminum and gallium. It is used industrially as indium-tin oxide for liquid crystal displays (111187).",
            "Safety": "LIKELY SAFE when indium (In-111) pentetreotide (OctreoScan) is administered intravenously by a healthcare professional as a diagnostic aid for localizing neuroendocrine tumors. Indium (In-111) pentetreotide is an FDA-approved prescription product (102824).\nPOSSIBLY UNSAFE when indium is used orally. Indium compounds are thought to be toxic to many organ systems (15117, 15121).\nLIKELY UNSAFE when indium is inhaled. Indium accumulates in the lungs and causes severe, potentially fatal interstitial lung disease (111188, 111189).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally. The effect of indium on the fetus or breast-feeding newborn is not known; however, indium compounds are thought to be toxic to many organ systems (15117, 15121); avoid using. ...when indium (In-111) pentetreotide is used intravenously. It is not known if it can harm the fetus, or if it is excreted in breast milk (102824).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, indium is considered to be toxic to numerous organ systems including the kidneys, liver, heart, and reproductive system (15117, 15121). It is possibly carcinogenic (111187). Different salt forms or compounds of indium can have different toxicological profiles.\nDermatologic\nTopically, indium can cause skin irritation (15121).\nless\nPulmonary/Respiratory\nOccupational exposure to indium by inhalation can lead to potentially fatal interstitial lung disease, characterized by pulmonary alveolar proteinosis, progressing to fibrosis with or without emphysema. The disease develops slowly with shortness of breath, chest tightness and pain, dry cough, dyspnea, and deteriorating pulmonary function tests. Abnormalities seen with high-resolution computed tomography include subpleural honeycomb, diffuse centrilobular emphysema, and diffuse reticulonodular infiltration. Serum indium levels are elevated, and severity is linked to the level and duration of exposure. Once exposure stops, accumulated indium clears extremely slowly from the lungs and the disease may not be reversible (111188, 111189).\nless",
            "Effectiveness": "Cancer diagnosis. Indium (In-111) pentetreotide injection (OctreoScan) is an FDA-approved prescription product for use in diagnosing primary and metastatic neuroendocrine tumors bearing somatostatin receptors (102824).\nMore evidence is needed to rate indium for its other uses.\nless",
            "Dosing & Administration": "Adult\nIntravenous:\nCancer diagnosis: Indium (In-111) pentetreotide for diagnostic use is provided in two vials that are combined and given as a single intravenous dose by a healthcare professional (102824).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of indium.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with indium.",
            "Pharmacokinetics": "Distribution\nWithin an hour of intravenous injection, indium (In-111) pentetreotide distributes to many body tissues and concentrates in tumors containing a high density of somatostatin receptors (102824).\nExcretion\nThe biological half-life of indium (In-111) pentetreotide is 6 hours. Over 90% of the injected dose is excreted in the urine within 2 days. Less than 2% is excreted in the feces (102824). Indium inhaled during occupational exposure accumulates in the lungs with an estimated elimination half-life of 8 years (111188).",
            "Mechanism of Action": "General\nIndium is a rare, soft silvery-white metal. It is used in some manufacturing processes, but there is no known biological role for indium in the human body, and serum levels are undetectable in healthy individuals. It causes severe pulmonary toxicity when inhaled during prolonged occupational exposure (111188, 111189).\nAnticancer effects\nIn vitro, indium-III salts appear to have cytotoxic activity against melanoma cells (15120).\nEnvironmental effects effects\nIndium has been released into the environment as a result of use of indium-tin oxide in the electronics industry. It has been detected in many crops, including grass, wheat, barley, perennial ryegrass, cabbage, garlic, water spinach, and beets. In highly acidic soil, indium is released from indium-tin oxide, then associates with iron hydroxides causing it to precipitate and undergo only limited translocation from roots to shoots to grain of crops such as rice and wheat (111187).\nInflammatory effects\nOccupational exposure to inhaled indium from indium-tin oxide processing at levels below the exposure limit recommended in several countries (0.1 mg/m3), is associated with relatively low serum indium levels (mean 0.36 mcg/mL) and, typically, no symptoms of lung disease. However, there is evidence of increased serum levels of pro-inflammatory markers, including granulocyte colony stimulating factor (G-CSF), interleukin (IL)-4, IL-5, tumor necrosis factor (TNF)-alpha, and TNF-beta. Levels of the anti-inflammatory cytokines IL-16 and tissue inhibitor of metalloprotease (TIMP)-1 are reduced. This suggests that inflammatory changes with the potential to cause lung disease occur even at low serum indium levels (111189)."
        }
    },
    "Indole-3-Carbinol": {
        "sections": {
            "Overview": "Indole-3-carbinol is derived from glucobrassicin, an indolyl-methyl glucosinolate found in cruciferous vegetables such as broccoli, cauliflower, Brussels sprouts, cabbage, kale, kohlrabi, bok choy, mustard greens, and turnips (47621, 93237). The content of glucobrassicin in vegetables varies depending on the plant strain, soil, rainfall, amount of sunlight, and other factors (93237). When the plant cells are damaged by cutting, crushing or cooking, glucobrassicin hydrolysis is catalyzed by the enzyme myrosinase (thioglucosidase), generating indole-3-carbinol, glucose, and thiocyanate (47621, 93238, 93242).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately in medicinal amounts. Doses up to 400 mg daily have been used safely for 3-76 months (7173, 93239, 93240, 93241). There is also some evidence that 400 mg twice daily can be used safely for 4 weeks (93242).\nCHILDREN: POSSIBLY SAFE when used orally and appropriately in medicinal amounts. There is limited evidence from 9 children with recurrent respiratory papillomatosis that indole-3-carbinol can be safely used in children ages 1.2-16 years for 12-76 months at doses of 6-17 mg/kg of body weight daily (7172, 93239).\nPREGNANCY AND LACTATION: There is insufficient reliable information available about the safety of indole-3-carbinol when used during pregnancy and lactation; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, indole-3-carbinol seems to be well tolerated.\nMost Common Adverse Effects\nOrally: Diarrhea, imbalance, nausea, rash, tremor, unsteadiness.\nDermatologic\nOrally, indole-3-carbinol has been associated with reports of rash (93242). A woman taking indole-3-carbinol 375 mg daily for treatment of systemic lupus erythematosus (SLE) developed a generalized maculopapular rash which resolved when indole-3-carbinol was discontinued and recurred when it was restarted (93240).\nless\nGastrointestinal\nOrally, indole-3-carbinol increases gastrointestinal motility and has been associated with diarrhea (93242, 93243).\nless\nNeurologic/CNS\nIndole-3-carbinol has been associated with reports of unsteadiness and imbalance, especially at higher doses (7172). An adult male taking 400 mg twice daily for treatment of recurrent respiratory papillomatosis developed imbalance and tremor after 10 days of treatment. This resolved when the dose was halved (93238). Two children who took 3 times the intended weight-based dose of indole-3-carbinol in one day developed unsteadiness and nausea (93238).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nBreast cancer. Although there has been interest in using oral indole-3-carbinol for breast cancer, there is insufficient reliable information about the clinical effects of indole-3-carbinol for this purpose.\nCervical dysplasia. It is unclear if oral indole-3-carbinol is beneficial in patients with cervical dysplasia.\nPreliminary clinical research shows that taking indole-3-carbinol 200-400 mg orally daily for 12 weeks is associated with complete regression of precancerous lesions in 45% to 50% of women with grade II or III, biopsy-proven cervical intraepithelial neoplasia (CIN, cervical dysplasia), the majority of whom are positive for human papilloma virus (HPV) infection (7173).\nless\nColorectal cancer. Although there has been interest in using oral indole-3-carbinol for colorectal cancer, there is insufficient reliable information about the clinical effects of indole-3-carbinol for this purpose.\nFibromyalgia. Although there has been interest in using oral indole-3-carbinol for fibromyalgia, there is insufficient reliable information about the clinical effects of indole-3-carbinol for this purpose.\nLiver disease. Although there has been interest in using oral indole-3-carbinol for liver disease, there is insufficient reliable information about the clinical effects of indole-3-carbinol for this purpose.\nNonmelanoma skin cancer. It is unclear if oral indole-3-carbinol is beneficial in patients with nonmelanoma skin cancer.\nPreliminary clinical research in patients with vulvar intraepithelial neoplasia (VIN), a precancerous condition that can progress to squamous cell carcinoma, shows that taking indole-3-carbinol 200 mg or 400 mg daily for 6 months improves symptoms and reduces lesion size and severity when compared with baseline. However, tissue biopsies taken from the women with the most severely affected areas did not show any improvement in grade of VIN (93241). The validity of this finding is limited by the small study size and lack of a comparator group. Additionally, it is unclear if treatment with indole-3-carbinol reduces the risk of progression to cancer.\nless\nOvarian cancer. It is unclear if oral indole-3-carbinol is beneficial in patients with ovarian cancer.\nPreliminary clinical research in patients with previously untreated stage III-IV ovarian cancer shows that taking indole-3-carbinol 200 mg orally twice daily with or without epigallocatechechin-3-gallate (EGCG) 200 mg twice daily, in conjunction with neoadjuvant chemotherapy and surgery, increases median overall survival and progression-free survival by 16 and 18 months, respectively, when compared with chemotherapy and surgery alone. The addition of indole-3-carbonol with or without EGCG also reduced the tumor recurrence rate by about 16% when compared with chemotherapy and surgery alone (98610).\nless\nRecurrent respiratory papillomatosis. It is unclear if oral indole-3-carbinol is beneficial in patients with recurrent respiratory papillomatosis.\nPreliminary clinical evidence shows that taking indole-3-carbinol 200 mg twice daily for a mean of 57.6 months (range 31 months to 76 months) after complete surgical removal of respiratory papillomas stops regrowth in about a third of patients and slows regrowth, reducing the need for repeated surgery, in another third (7172, 47645, 93239).\nless\nSystemic lupus erythematosus (SLE). It is unclear if oral indole-3-carbinol is beneficial in patients with SLE.\nPreliminary clinical research shows that taking indole-3-carbinol 125 mg orally three times daily for 3 months does not significantly decrease disease activity when compared with baseline in women aged 20-49 years with SLE (93240).\nless\nMore evidence is needed to rate indole-3-carbinol for these uses.",
            "Dosing & Administration": "Adult\nOral:\nIndole-3-carbinol has been commonly used at a dose of 200 mg twice daily for up to 5 years (7173, 47645, 93239, 93241, 98610). See Effectiveness section for condition-specific information.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of indole-3-carbinol.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, indole-3-carbinol might increase the risk of bleeding when used with antiplatelet or anticoagulant drugs.\nIn vitro research shows that indole-3-carbinol inhibits platelet aggregation (98611).\nless\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, indole-3-carbinol might increase the metabolism of CYP1A2 substrates and lower serum concentrations.\nAnimal research shows that indole-3-carbinol induces CYP1A2 enzymes (7187).\nless\nESTROGENS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nIndole-3-carbinol might interfere with the effects of estrogen therapy.\nPreliminary clinical and in vitro evidence shows that indole-3-carbinol has antiestrogenic activity (7173, 47621, 93238, 93240).\nless",
            "Interactions with Supplements": "ANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, concomitant use of indole-3-carbinol with herbs that affect platelet aggregation could increase the risk of bleeding.\nIn vitro research shows that indole-3-carbinol inhibits platelet aggregation (98611). See other products with antiplatelet activity here. See products with anticoagulant activity here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLEEDING CONDITIONS\nTheoretically, taking indole-3-carbinol might increase the risk of bleeding in individuals with bleeding disorders. In vitro research shows that indole-3-carbinol inhibits platelet aggregation (98611).\nless\nPERIOPERATIVE\nTheoretically, indole-3-carbinol might cause excessive bleeding if used perioperatively. In vitro research shows that indole-3-carbinol inhibits platelet aggregation (98611).Tell patients to discontinue indole-3-carbinol at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with indole-3-carbinol.",
            "Pharmacokinetics": "Absorption\nIn animal studies, indole-3-carbinol is reported to be absorbed rapidly (47645). Diindolylmethane (DIM), the main active metabolite of indole-3-carbinol, is formed in stomach acid and absorbed from the small intestine (93238).\nDistribution\nStudies using radiolabeled indole-3-carbinol in animals suggest that it is rapidly distributed to the liver, kidneys, heart, lungs, and brain, although this is thought to be mainly in the form of metabolites (47645).\nMetabolism\nIndole-3-carbinol is very unstable in stomach acid, being primarily metabolized to a DIM. Other active metabolites produced in the gut include indolo[3,2b]-carbazole (ICZ, a closed-ring dimer), 2,3-bis-[3-indolyl-methyl]indole (a linear trimer), 5,6,11,12,17,18-hexahydrocyclonal [1,2-b: 4,5-b':7,8-b:]triindole (a cyclic trimer), and ascorbigen, which is a condensation product of indole-3-carbinol and ascorbic acid (93236, 93237, 93238).\nExcretion\nIn animal studies, indole-3-carbinol is eliminated from the plasma and tissues within 1 hour, but metabolites such as DIM persist for several hours (47645, 93237). The majority of a dose of indole-3-carbinole and its metabolites is excreted in the urine (93238).",
            "Mechanism of Action": "General\nIndole-3-carbinol (I3C) is derived from glucobrassicin, an indolyl-methyl glucosinolate found in cruciferous vegetables such as broccoli, cauliflower, Brussels sprouts, cabbage, kale, kohlrabi, bok choy, mustard and collard greens, rutabagas, and turnips (7176, 47621, 93237, 98612). Indole-3-carbinol 350 mg to 500 mg is reported to be equivalent to approximately 300 grams to 500 grams of raw cabbage or Brussels sprouts (7173). When the plant cells are damaged by cutting, crushing or cooking, glucobrassicin comes in contact with the enzyme myrosinase (thioglucosidase) and is hydrolyzed to indole-3-carbinol, glucose and thiocyanate (47621, 93238, 93242). Food preparation methods, such as grinding, increase the availability of indole-3-carbinol from kale and broccoli. Microwaving increases the release of indole-3-carbinol in broccoli but has no effect on its release from kale (98612).\n\nIndole-3-carbinol is very unstable in stomach acid, being primarily metabolized to a biologically-active dimer called 3,3'-diindolylmethane (DIM). Other active metabolites produced in the gut include indolo[3,2b]-carbazole (ICZ, a closed-ring dimer), 2,3-bis-[3-indolyl-methyl]indole (a linear trimer), 5,6,11,12,17,18-hexahydrocyclonal [1,2-b: 4,5-b':7,8-b:]triindole (a cyclic trimer), and ascorbigen, which is a condensation product of I3C and ascorbic acid (93236, 93237, 93238). Animal studies indicate that parenterally administered indole-3-carbinol does not have the same activity as the orally administered compound because the active metabolites are not formed (7188, 93237, 93238).\nAntiestrogenic effects\nIndole-3-carbinol and its metabolites reduce estrogen receptor signaling and transcriptional activity, and compete with estrogen for binding sites in a dose-dependent manner (47621, 93238). Indole-3-carbinol, diindolylmethane (DIM), and indolo[3,2b]-carbazole (ICZ) also alter metabolism of estradiol by inducing cytochrome P450 (CYP) 1A1 and 1A2 enzymes (47645, 93237, 93238). Estradiol is normally broken down in the liver to 2-hydroxyestrone, 16-alpha-hydroxyestrone, and 4-hydroxyestrone (7173). 2-hydroxyestrone has practically no peripheral estrogenic activity, and exerts antiestrogenic and antiproliferative effects by competing with estradiol for estrogen receptor binding (7173, 47621, 93240). 16-alpha-hydroxyestrone has strong estrogenic activity, damages DNA and cellular proteins making it potentially carcinogenic, and promotes proliferation in breast cancer cell lines (7173, 93240). 4-hydroxyestrone is normally formed to a lesser extent, but is a potent carcinogen (7173). Induction of CYP-1A1 and 1A2 by indole-3-carbinol and its metabolites increases production of the antiestrogenic and more benign 2-hydroxyestrone, at the expense of 16-alpha-hydroxyestrone, and this change seems to correlate with anti-tumor activity (47645, 93237, 93238).\nAntifertility effects\nThere is some evidence that indole-3-carbinol can block ovulation in animals (93246).\nAntineoplastic effects\nThere is preliminary evidence in women at high risk for breast cancer that taking indole-3-carbinol 400-800 mg orally daily for 4 weeks is associated with a 4-fold increase in the activity of cytochrome P450 1A2 (CYP1A2) and a 66% increase in the ratio of 2-hydroxyestrone to 16-alpha-hydroxyestrone in the urine. These changes might reduce the risk of developing breast cancer (47645, 93242). In another study, taking indole-3-carbinol 400 mg orally daily for 3 months was associated with a sustained increase in the 2-hydroxyestrone to 16-alpha-hydroxyestrone ratio in the urine in 17 of 20 women (93243).\n\nIn animals, indole-3-carbinol and its metabolites inhibit tumors of the breasts, liver, cervix, lungs, and gastrointestinal tract which occur spontaneously or are induced by chemicals such as polycyclic aromatic hydrocarbons, nitroso compounds, heterocyclic aromatic amines, and aflatoxin (93236, 93237, 93242, 98613). In addition to antiestrogenic effects, which contribute to potential activity against breast cancer, indole-3-carbinol and its metabolites have a number of other actions which could inhibit formation and growth of tumors (93237). These mechanisms include inducing DNA repair proteins and inhibiting proliferative activity in cells with DNA damage, inducing G1 cell cycle arrest via modulation of cyclin-dependent kinases in cancer cells, and increasing apoptosis by inactivating nuclear factor kappa-B (NF-kB) signaling to downregulate transcription of anti-apoptotic genes (47621, 47645, 93236, 93238). The diindolylmethane (DIM) metabolite of indole-3-carbinol inhibits proliferation of prostate cancer cells by competing with dihydrotestosterone for receptor binding and preventing stimulation of DNA synthesis (993238). Activation of the aryl hydrocarbon receptor by indole-3-carbinol and DIM leads to transcription of genes for cytochrome P450 (CYP) enzymes, and induction of CYP1A1, 1A2, 1B1, and 3A1, and of phase II glutathione-S-transferases, which catalyze metabolism of carcinogens (7176, 7187, 47621, 47645). The efficiency of induction of CYP enzymes by indole-3-carbinol may be reduced by a high fat diet (93235).\n\nIn-vitro research shows that indole-3-carbinol is an inhibitor of a ubiquitin ligase enzyme called WWP1. This enzyme is often overexpressed in prostate, breast, and liver cancers, and inactivates PTEN, a potent tumor suppressor gene. Reactivating the PTEN gene with indole-3-carbinol could increase tumor suppression activity (102359).\nAntiviral effects\nIndole-3-carbinol inhibits replication of herpes simplex virus (HSV) in tissue cultures, possibly by interfering with cyclin-dependent kinases needed for HSV gene transcription (14155, 93238). Indole-3-carbinol also inhibits expression and growth of human papillomavirus (HPV), giving it potential activity against diseases such as cervical cancer and respiratory papillomatosis that are associated with HPV (7172, 7173, 7183). Activity of HPV in human cells is known to be promoted by 16-alpha-hydroxyestrone, levels of which are reduced by indole-3-carbinol when it induces formation of the alternative, antiproliferative 2-hydroxyestrone metabolite of estradiol (93238, 93239, 93241).\nNeurological effects\nIn an animal ischemia-reperfusion model, indole-3-carbinol improves cerebral blood flow, protecting against infarct and changes in behavioral and neurological functioning. This activity was thought to be due to the antioxidant effects of indole-3-carbinol (98611).\nPro-carcinogenic effects\nThere is some concern that indole-3-carbinol can increase production of the carcinogenic 4-hydroxestrone metabolite of estradiol via induction of cytochrome P450 1B1(CYP1B1) (93237). However, other sources question whether this occurs (47645). There is also concern that indole-3-carbinol given after carcinogen exposure, during the initiation phase of tumor induction, might act as a tumor promoting agent and increase the risk of developing a tumor (7184, 7185, 7186). Research in rats treated with dimethylhydrazine (DMH), a carcinogen, shows that taking indole-3-carbinol with synbiotics reduces the development of colorectal carcinoma, indicating a protective effect against DMH. However, when indole-3-carbinol and synbiotics were taken in conjunction with heme iron in rats treated with DMH, colorectal tumor volume and invasiveness increased (98613). The reason for this interaction is unclear. It is also unclear if taking indole-3-carbinol together with heme iron in the absence of carcinogen exposure would increase the risk for colorectal cancer. More research is needed to understand the implications of this finding.\nSystemic lupus erythematosus (SLE) effects\nA contributor to disease activity in SLE is thought to be increased production of the 16-alpha-hydroxyestrone metabolite of estradiol which has stronger estrogenic effects than the alternative metabolite, 2-hydroxyestrone. Indole-3-carbinol alters the balance in favor of the 2-hydroxylated metabolite via induction of cytochrome P450 1A1 (93240)."
        }
    },
    "Inosine": {
        "sections": {
            "Overview": "Inosine is a type of purine nucleoside found in RNA (370). In humans, inosine is a precursor to uric acid (95288, 95289, 95290, 95291).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately. Inosine has been used with apparent safety at doses of up to 3 grams daily for up to 24 months or at doses of up to 2 grams daily for 36 months (95287, 95289, 95290, 95291, 106854, 106857, 112396).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, inosine seems to be well tolerated.\nMost Common Adverse Effects\nOrally: Hyperuricemia, nephrolithiasis, uric acid crystals, urinary tract stones.\nSerious Adverse Effects (Rare)\nOrally: Hypertension, kidney dysfunction.\nCardiovascular\nOrally, inosine was reported to cause mild elevation of blood pressure in 6% of patients in one clinical trial (95289).\nless\nEndocrine\nOrally, inosine increases serum uric acid levels in a dose-dependent manner, which can cause non-symptomatic hyperuricemia (95288, 95289).\nless\nGastrointestinal\nOrally, inosine has been reported to cause nausea (95289, 106854).\nless\nGenitourinary\nOrally, inosine has been reported to cause uric acid crystals and symptomatic uric acid kidney stones. Uric acid kidney stones occurred more frequently when inosine was taken concurrently with calcium supplements (95287, 95289, 95290, 106854, 112395).\nless\nRenal\nOrally, inosine 1-2 grams daily has been reported to cause acute renal colic in patients with multiple sclerosis (95288). Inosine has also been reported to cause reversible reductions in kidney function (106854).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAmyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). It is unclear if oral inosine is beneficial for ALS.\nA small clinical trial in adults with ALS shows that supplementation with inosine 1000-3000 mg daily, either by mouth or via a feeding tube, for 20 weeks has no effect on survival, functional outcomes, or body weight compared with placebo (112395). The study may have been inadequately powered to detect a difference between groups.\nless\nAthletic performance. It is unclear if oral inosine improves athletic performance in experienced athletes.\nTwo small crossover studies in cyclists and endurance runners show that taking inosine 5-6 grams daily for 2-5 days does not improve athletic performance when compared with placebo (2369, 2370).\nless\nCancer. It is unclear if oral inosine is beneficial for cancer.\nA large open-label clinical trial in adults with malignant solid tumors shows that inosine 0.6 grams daily in combination with immune-checkpoint inhibitors does not improve tumor response rate or overall survival when compared with immune-checkpoint inhibitors alone; however, median progression-free survival increased by approximately 2.6 months (115627). The validity of these results is limited by the inclusion of multiple tumor types and different background treatment regimens, with or without chemotherapy.\nless\nDiabetic neuropathy. Oral inosine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA large clinical trial in adults with type 2 diabetes and peripheral neuropathy shows that administration of a combination product (Cytoflavin, POLYSAN) containing inosine, nicotinamide, riboflavin, and succinic acid intravenously for 10 days and then taking the same combination orally for 75 days reduces total neuropathy symptom scores compared with placebo. Specifically, intensity of paresthesia, numbness, and burning are most improved (110503). The total daily dose of inosine provided by the intravenous solution and oral tablets was 400 mg and 200 mg, respectively. It is unclear if the effects are due to inosine, other ingredients, or the combination.\nless\nMultiple sclerosis (MS). It is unclear if oral inosine is beneficial in patients with MS.\nLow serum uric acid levels have been associated with an increased risk of developing MS (95290). Clinical research shows that taking inosine increases serum uric acid levels in adults with MS. However, this increase has not been consistently associated with clinical improvement (95288, 95289, 95290, 95291). Taking inosine 3 grams daily for up to 24 months, in conjunction with interferon beta 1-alpha (IFN), does not seem to improve disability or clinical progression when compared with IFN alone (95288, 95289). However, some preliminary clinical research shows that taking inosine 1-2 grams daily for 36 months as monotherapy might improve MS relapse rate, but not disability scores, when compared with no treatment (95291). This inconsistency in outcomes may be related to the severity of disease in the studied population and the other treatments used.\nless\nParkinson disease. It is unclear if oral inosine is beneficial in patients with Parkinson disease.\nPreliminary clinical research in adults with Parkinson disease shows that taking inosine orally 1000-3000 mg daily for 2 years does not improve Parkinson disease functioning scores or prevent the need for additional drug therapy when compared with placebo. Inosine therapy was initiated as 1000 mg three times daily and titrated to a goal serum urate level of 7.1-8 mg/dL (106854). However, other preliminary clinical research in adults with Parkinson disease shows that taking inosine 500 mg orally twice daily in conjunction with febuxostat 20 mg twice daily for 57 days improves Parkinson disease motor scores by 12% when compared with baseline. The validity of this study is limited by the lack of a comparator group. In addition, it is unclear if this effect is due to inosine, febuxostat, or the combination (106852).\nless\nMore evidence is needed to rate inosine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nInosine has most often been used at a dose of 1-3 grams daily for up to 2 years. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of inosine.",
            "Interactions with Drugs": "ANTIGOUT DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nInosine might reduce the effects of antigout medications.\nInosine increases uric acid levels in the serum and urine, potentially resulting in hyperuricemia and reducing the effects of medications used for the prevention and treatment of gout (95287, 95288, 95289, 106852, 106854).\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "GOUT\nInosine increases uric acid levels in the serum and urine, potentially resulting in hyperuricemia (95287, 95288, 95289, 106852, 106854). Theoretically, taking inosine might aggravate gout.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxic effects of inosine.",
            "Pharmacokinetics": "Distribution\nFollowing oral intake of inosine, uric acid, the primary metabolite of inosine, is found in the blood and cerebrospinal fluid (95287). In a clinical trial in adults with Parkinson disease, taking an average dose of inosine 1800 mg daily increased serum uric acid levels by 44% when compared with baseline (106854).\nMetabolism\nWhen taken orally, inosine is primarily converted to uric acid (95287, 95288). Inosine is also converted to hypoxanthine and xanthine (95292).\nExcretion\nWhen taken orally, inosine increases urine levels of uric acid (95288, 95289). Preliminary clinical research in otherwise healthy adults taking a single oral dose of 1500 mg inosine shows that the renal excretion of uric acid is lower in obese subjects when compared with normal weight subjects (106856).",
            "Mechanism of Action": "General\nInosine is a type of purine nucleoside found in RNA (370). It is a precursor to uric acid, an antioxidant. When taken orally, uric acid is degraded rapidly by the gut microbiome, preventing absorption (95288, 95289). Inosine, which is converted in the body to uric acid, is bioavailable after oral administration, and is used as a substitute for oral uric acid supplementation (95289).\nBone effects\nIn observational studies, high uric acid levels have been associated with a decreased risk of developing osteoporosis. However, preliminary clinical research in postmenopausal adults shows that taking inosine orally 1000-1500 mg daily for 26 weeks does not improve serum levels of bone formation or bone resorption markers when compared with placebo. Taking inosine also did not improve femur or lumbar spine bone mineral density when compared with placebo. However, the study may have been inadequately powered to detect a difference between groups (106857).\nNeurological effects\nThere is interest in using inosine to increase uric acid levels in people with various neurologic disorders. Low uric acid levels have been associated with an increased risk of developing multiple sclerosis. In animals, increased serum levels of uric acid have been shown to reduce symptoms and pathological findings of multiple sclerosis. It is theorized that this is mediated by increased antioxidant effects against peroxynitrite radicals, which are found in brain lesions in individuals with multiple sclerosis. (95289). However, the clinical benefits of increased uric acid levels are inconsistent in adults with multiple sclerosis (95288, 95289, 95290, 95291).\n\nThere is also interest in using inosine to increase uric acid levels in patients with amyotrophic lateral sclerosis, as higher serum urate has been associated with prolonged survival in these patients (112395).\n\nLow serum and cerebral spinal fluid uric acid levels have also been associated with an increased rate of disease progression in Parkinson disease (95287, 106852, 106854). Some researchers believe uric acid may slow disease progression by acting as an antioxidant and free radical scavenger (106852, 106854). Clinical research shows that taking inosine increases serum uric acid levels in adults with Parkinson disease (95287, 95289, 106852, 106854). However, preliminary clinical research in adults with Parkinson disease shows that taking inosine for up to 2 years does not prevent disease progression when compared with placebo (106854). Based on these results, some researchers speculate that levels of both uric acid and hypoxanthine must be increased to delay disease progression (106852).\n\nThere is also interest in using inosine to treat bipolar disorder. Research in rats shows that taking inosine 10-25 mg/kg daily for 14 days attenuates ketamine-induced hyperlocomotion. This suggests that inosine might reduce mania symptoms; however, inosine supplementation did not appear to affect adenosine receptor activity (106853).\n\nThere is also interest in using inosine to treat Alzheimer disease. Research in rats shows that intraperitoneal injections of inosine, 50-100 mg/kg daily for 25 days, attenuated chemically-induced memory deficits when compared with control. Inosine injections also attenuated chemically-induced increases in acetylcholinesterase activity and markers of oxidative damage in the hippocampus and cerebral cortex (106855).\n\nLaboratory research shows that inosine might stimulate axon growth from uninjured nerve cells to injured nerve cells of the central nervous system. Further studies in humans are needed to establish whether this finding has significance in restoring function after spinal cord injuries (370).\n\nBecause oxidative stress is a factor in the development of peripheral neuropathy, it is theorized that the anti-oxidant effects of inosine could help protect peripheral nerve damage that occurs with type 2 diabetes (110503)."
        }
    },
    "Inositol": {
        "sections": {
            "Overview": "Inositol is a sugar alcohol found in foods such as cereals, corn, meat, citrus fruits, and legumes (91543, 91545, 95082). Inositol was once considered to be part of the B vitamin complex. However, it is now known that inositol is produced in the human body. Therefore, it is not considered to be an essential B vitamin and is instead referred to as a pseudovitamin (91555, 95082). Inositol can be found in nine different stereoisomer forms, but the isomers myo-inositol and D-chiro-inositol are the most relevant with regards to supplementation (91555, 95082, 95085).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately, short-term. Inositol has been used with apparent safety in doses up to 18 grams daily for up to 6 weeks or 6 grams daily for 10 weeks (2184, 2185, 2187, 95089). Myo-inositol 4 grams daily has also been used with apparent safety for 6 months (95085).\nThere is insufficient reliable information available about the safety of inositol when used topically.\nCHILDREN: POSSIBLY SAFE when used orally and appropriately. Inositol 80 mg/kg (maximum 2 grams) has been taken daily for up to 12 weeks in children aged 5-12 years (95092). ...when used enterally or intravenously and appropriately in premature infants for treating acute respiratory distress syndrome for up to 10 days (2191, 2192, 91546, 91551).\nCHILDREN: POSSIBLY UNSAFE when used enterally or intravenously for extended durations in premature infants. A large clinical study in infants born at less than 28 weeks' gestation found that myo-inositol 40 mg/kg, given intravenously and then enterally every 12 hours for up to 10 weeks, was associated with a small increased risk of death (98946). Long-term follow-up until 24 months corrected age confirms that the initial increase in mortality rate in the myo-inositol group remained stable; however, there was no difference in a composite outcome of death or survival with moderate or severe neurodevelopmental impairment, as well as no difference in the risk of retinopathy of prematurity, between those who received myo-inositol or control (108819).\nPREGNANCY: POSSIBLY SAFE when used orally and appropriately, short-term. Myo-inositol has been used with apparent safety in amounts up to 4000 mg daily during pregnancy (91548, 95082, 104688).\nLACTATION: Insufficient reliable information available; avoid using. Breast milk is rich in endogenous inositol (2138); however, the effects of exogenously administered inositol are not known.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally and intravenously, inositol seems to be well tolerated. Topically, no adverse effects have been reported, although a thorough evaluation of safety outcomes has not been conducted.\nMost Common Adverse Effects\nOrally: Diarrhea, gas, and nausea.\nGastrointestinal\nOrally, inositol may cause nausea, diarrhea, gas, and gastrointestinal discomfort (10387, 11972, 91547, 91549, 95089, 95090, 95092).\nless\nImmunologic\nOrally, inositol in combination with omega-3 fatty acids has been associated with reports of cold and allergy symptoms in children in clinical research (95092).\nless\nMusculoskeletal\nOrally, inositol in combination with omega-3 fatty acids has been associated with reports of tics and other musculoskeletal side effects in children in clinical research (95092).\nless\nNeurologic/CNS\nOrally, inositol may cause dizziness, tiredness, insomnia, agitation, and headache (10387, 11972, 95089, 95092). In combination with omega-3 fatty acids, inositol has been associated with reports of feelings of thirst in children in clinical research (95092).\nless\nPsychiatric\nIn one case report, a 36-year-old male with adequately controlled bipolar disorder was hospitalized with symptoms of mania after consuming several cans of an energy drink containing inositol, caffeine, taurine, and other ingredients (Red Bull Energy Drink) over a period of 4 days (14302). It is not known if this is related to inositol, caffeine, taurine, a different ingredient, or a combination of the ingredients.\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nMetabolic syndrome. Oral inositol seems to modestly improve lipid parameters, blood pressure, and insulin resistance in patients with metabolic syndrome.\nSome clinical research in postmenopausal adults with metabolic syndrome following a low-calorie diet shows that taking myo-inositol 2 grams twice daily for one year reduces total cholesterol by 29 mg/dL, triglycerides by 64 mg/dL, systolic and diastolic blood pressure by 9 mmHg and 6 mmHg, respectively, increases high-density lipoprotein (HDL) cholesterol by 6 mg/dL, and improves insulin resistance when compared with placebo. It did not reduce body mass index or waist circumference in these patients (91554). A meta-analysis of clinical studies in a mixed population shows similar effects on blood pressure, especially among postmenopausal adults with metabolic syndrome, at durations exceeding 8 weeks, and at doses of at least 4 grams (108820).\n\nInositol has also been evaluated in combination with other ingredients to treat metabolic syndrome. A clinical study in postmenopausal adults with metabolic syndrome and at risk for breast cancer shows that taking a combination of inositol and alpha-lipoic acid daily for 6 months, in combination with a low-calorie diet, reduces insulin resistance (HOMA-IR) by at least 20% when compared with a low-calorie diet alone. Also, taking inositol and alpha-lipoic acid seems to increase HDL cholesterol by about 6% and reduce triglycerides by 5% when compared to baseline (91543). Another small clinical study in adults with metabolic syndrome shows that taking a specific combination product containing D-chiro-inositol 40 mg, Ceylon cinnamon 250 mg, glucomannan 1000 mg, and inulin 200 mg orally daily for 4 months modestly improves total cholesterol levels and body weight, but not serum glycated hemoglobin, low-density lipoprotein levels, high-density lipoprotein levels, or triglyceride levels when compared with no intervention (114552).\nless\nPolycystic ovary syndrome (PCOS). Oral inositol, often in combination with folic acid, seems to improve some glycemic, lipid, metabolic, hormonal, and reproductive parameters in patients with PCOS. However, research is conflicting.\nOral inositol, most frequently in the forms of myo-inositol or D-chiro-inositol, has been evaluated for efficacy in a wide range of outcomes associated with PCOS including reproductive and pregnancy outcomes, metabolic parameters, and anthropomorphic measures. Often, inositol is taken in combination with folic acid or metformin.\n\nInositol has been investigated for its effect on metabolic parameters that are often altered in PCOS. A meta-analysis of 9 studies in patients with PCOS shows that taking myo-inositol or D-chiro-inositol with or without folic acid marginally decreases body mass index (BMI) by about 0.5 kg/m2 when compared with placebo (111670). Inositol has also been evaluated for its effect on glucose metabolism in adults with PCOS. Meta-analyses of about 10 studies show that taking myo-inositol or D-chiro-inositol with or without folic acid reduces fasting plasma glucose by 1-4 mg/dL (98944, 111670). However, evidence is conflicting on the effect of inositol on insulin levels and measures of insulin resistance (98944, 111670). Additionally, most studies show that inositol does not improve measures of glucose metabolism more than metformin. The effect of inositol on lipid profiles has also been studied. A meta-analysis of 2 clinical studies and other small clinical studies show that taking inositol as D-chiro-inositol with or without folic acid modestly reduces total cholesterol and triglycerides when compared with control (2028, 98944, 91552).\n\nSome studies have also investigated the effect of inositol on hormone levels. Meta-analyses show that inositol modulates androgen levels as shown by reduced total and free testosterone, androstenedione, and increased sex-hormone binding globulin when compared with placebo. (2028, 91552, 98944, 111670). The validity of these effects is limited by high heterogeneity in terms of inclusion and exclusion criteria, dose, and treatment duration within the included studies.\n\nMyo-inositol has also been compared with metformin in some clinical research, with some evidence of benefit (95085, 95086). Meta-analyses of small clinical studies show that taking myo-inositol 2-4 grams daily, with or without folic acid, for 12-24 weeks does not improve fasting blood glucose, fasting insulin, insulin resistance (HOMA-IR), BMI, waist-hip circumference, or androgen levels when compared with metformin 1.5-2.5 grams daily (100705, 108823, 111670, 111670). However, inositol seems to have a lower risk of adverse effects than metformin. These analyses are limited due to the small size, methodological issues, and high heterogeneity of the included studies. In combination with metformin, small clinical studies show that taking metformin, myo-inositol 550 mg, and D-chiro-inositol 150 mg twice daily is associated with improved lipid parameters and postprandial insulin levels when compared with metformin alone (108822).\n\nMeta-analyses and clinical studies have investigated the effect of inositol on ovulation, reproduction, and pregnancy outcomes. Some research suggests that inositol increases ovulation rate, promotes cycle normalization, and improves ovarian function in patients with PCOS (2028, 91552, 98944, 111670). A small clinical study shows that taking myo-inositol 4 grams and folic acid 400 mcg (Inofolic, Lo.Li.Pharma) daily for three spontaneous cycles induces ovulation in about 62% of individuals with anovulatory PCOS and insulin resistance. Adding clomiphene citrate with myo-inositol induces ovulation in about 72% of the patients who remain anovulatory after treatment with myo-inositol alone (91547). Another clinical study shows that taking a combination of inositol 2 grams, folic acid 200 mcg, and N-acetyl cysteine 600 mg (Ovaric HP, Just Pharma) twice daily for 12 months improves ovulation rates in PCOS patients with oligomenorrhea, regardless of insulin sensitivity at baseline (91553). Despite evidence that inositol improves ovulation rates, it does not appear to impact pregnancy rates (111670).\n\nSome research has also investigated the effects of taking both isomers of inositol concomitantly. Taking myo-inositol 550 mg plus D-chiro-inositol 13.8 mg (Inofolic Combi, Lo.Li.Pharma) twice daily, beginning 12 weeks before ovarian hyperstimulation and continuing throughout pregnancy, improves oocyte quality when compared to treatment with D-chiro-inositol alone. The combination appears to increase fertilization rate in patients aged 35 years or younger, but not those older than 35 years (91544). Other clinical research shows that taking myo-inositol 550 mg and D-chiro-inositol 150 mg twice daily for 12 weeks improves pregnancy rates and live birth rates by an additional 10% and 11%, respectively, when compared with myo-inositol 550 mg plus D-chiro-inositol 13.8 mg. The higher-dose combination also resulted in a 15% lower rate of ovarian hyperstimulation syndrome when compared with those taking the lower dose of D-chiro-inositol (102317). Lastly, other research shows that taking myo-inositol and D-chiro-inositol together may improve metabolic parameters faster than taking myo-inositol alone (91550).\n\nResearch has also evaluated the effects of inositol on other pertinent clinical outcomes in PCOS. Several small clinical studies show that taking the combination of myo-inositol and D-chiro-inositol, alone or in combination with metformin, improves menstrual cycle irregularity when compared with metformin alone, but not as much as a taking a combined hormonal contraceptive (108822, 108824). The validity of these findings is limited by the unblinded nature of the studies. Also, a small clinical study shows that taking metformin with myo-inositol 550 mg and D-chiro-inositol 150 mg twice daily is associated with improved acne, but not hirsutism, at 6 months, when compared with metformin alone (108822). The validity of these findings is limited by the unblinded nature of the study.\n\nMore research is needed to clarify the effect of inositol on anthropometric, metabolic, and endocrine outcomes in patients with PCOS.\nless\nPreterm labor. Oral inositol in combination with folic acid seems to prevent preterm labor in individuals at risk for gestational diabetes.\nA meta-analysis of five clinical trials in individuals at risk for gestational diabetes shows that taking myo-inositol plus folic acid daily, beginning during the first trimester and continuing throughout pregnancy, decreases the risk of preterm delivery by 64% when compared with folic acid alone. Patients in all but one study included in this analysis took myo-inositol 2 grams plus folic acid 200 mcg twice daily, while patients in the other study took myo-inositol 1100 mg plus D-chiro-inositol 27.6 mg and folic acid 400 mcg daily (100706). It's unclear if these results are generalizable to individuals with a low risk for gestational diabetes.\nless\nPOSSIBLY INEFFECTIVE\nAcute respiratory distress syndrome (ARDS). Oral or intravenous inositol does not seem to prevent ARDS in preterm infants and may be associated with worsened outcomes.\nHistorically, small clinical trials in infants with or at risk for ARDS have suggested that myo-inositol, given parenterally and enterally for 5-10 days, might improve survival and reduce the risk of death and serious complications (2191, 2192, 91546). However, a large, high-quality clinical study in infants born at less than 28 weeks' gestation at risk for ARDS shows that myo-inositol 40 mg/kg given intravenously and then enterally every 12 hours for up to 70 days does not reduce the risk of death or retinopathy of prematurity (ROP). In fact, the rate of death or type 1 ROP increased by 7% in the myo-inositol group when compared to the control group, and a higher incidence of adverse events in the myo-inositol group, including poor perfusion, hypotension, and infections, led to early trial discontinuation (98946). Long-term follow-up until 24 months corrected age confirms that the initial increase in mortality rate in the myo-inositol group remained stable; however, there was no difference in a composite outcome of death or survival with moderate or severe neurodevelopmental impairment, as well as no difference in the risk of ROP, between the treatment and control groups (108819). The most recent meta-analysis, which incorporates this large clinical study, concludes that inositol supplementation does not reduce the risk of death in infants at risk for ARDS (102319).\nless\nAnxiety. Oral inositol does not seem to be beneficial for patients with anxiety.\nA meta-analysis of four clinical trials shows that taking inositol orally does not improve anxiety severity in patients with anxiety disorders, including obsessive-compulsive disorder, panic disorder, or post-traumatic stress disorder, when compared with placebo (91549).\nless\nDepression. Oral inositol does not seem to be beneficial for patients with depression.\nGuidelines from the World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce state that inositol in doses up to 12 grams daily is not currently recommended as monotherapy or adjunctive use for major depressive disorder due to a lack of evidence for efficacy (110318). Additionally, a meta-analysis of seven clinical trials shows that inositol does not significantly improve symptoms of depression in patients with bipolar depression, major depressive disorder, or premenstrual dysphoric disorder (PMDD) (91549). While limited research shows that patients receiving inositol for 4 weeks may improve, patients initially responding to inositol seem to relapse rapidly upon discontinuation of treatment (2026, 2185). Additionally, taking inositol with a selective serotonin reuptake inhibitor (SSRI) doesn't appear to improve the effectiveness of SSRI therapy or improve depression in SSRI treatment failures (2025, 10851).\nless\nDiabetic neuropathy. Oral inositol does not seem to be beneficial for patients with diabetic neuropathy.\nMost preliminary clinical research shows that taking inositol orally doesn't improve the symptoms of diabetic neuropathy (2193, 2194, 2195).\nless\nRetinopathy of prematurity. Oral or intravenous inositol does not seem to prevent retinopathy of prematurity (ROP) in preterm infants.\nA meta-analysis of six clinical trials shows that myo-inositol, given parenterally and/or enterally, does not seem to reduce the risk of ROP when compared with placebo in preterm infants (100704). A large, high-quality clinical study included in this meta-analysis shows that myo-inositol 40 mg/kg given intravenously and then enterally every 12 hours for up to 70 days does not reduce the risk of death or ROP in infants born at less than 28 weeks' gestation. In fact, the rate of death or type 1 ROP increased by 7% in the myo-inositol group when compared with placebo and a higher incidence of adverse events in the myo-inositol group, including poor perfusion, hypotension, and infections, led to early trial discontinuation (98946). Long-term follow-up until 24 months corrected age confirms that the initial increase in mortality rate in the myo-inositol group remained stable; however, there was no difference in a composite outcome of death or survival with moderate or severe neurodevelopmental impairment, as well as no difference in the risk of ROP, between the treatment and control groups (108819).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAge-related testosterone deficiency. It is unclear if oral D-chiro-inositol is beneficial in patients with age-related testosterone deficiency.\nA very small clinical study in males aged 65-75 years with low-normal morning testosterone levels and signs and symptoms of androgen deficiency shows that taking D-chiro-inositol 600 mg twice daily for 30 days improves sexual function and physical strength when compared with baseline (108821). The validity of these findings is limited by the lack of a comparator group.\nless\nBipolar disorder. It is unclear if oral inositol is beneficial in patients with bipolar disorder.\nEvidence is conflicting on whether inositol helps treat bipolar disorder in children. One very small preliminary study in children aged 5-12 years with bipolar disorder not on concomitant mood-stabilizing medications shows that taking inositol 80 mg/kg (maximum 2 grams) daily for 12 weeks reduces manic symptoms when compared to baseline. Additionally, taking a combination of inositol 80 mg/kg and high eicosapentaenoic acid omega-3 fatty acid capsules (EPA; Nordic Naturals) 1650-3000 mg daily for 12 weeks reduces manic and depressive symptoms when compared to baseline (95092). However, another more recent study with the same intervention and protocol shows that the combination of inositol and high eicosapentaenoic acid omega-3 fatty acid reduces symptoms of depression, but does not improve manic symptoms, when compared with either ingredient taken alone (111676).\nless\nChemotherapy-induced leukopenia. Oral inositol has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in adults undergoing breast cancer surgery and adjuvant chemotherapy shows that taking inositol orally 390 mg twice daily and applying IP-6 gel 4% twice daily to the surgical site, starting 2 weeks before adjuvant chemotherapy and stopping 2 weeks after the last cycle, attenuates reductions in white and red blood cell counts when compared with no intervention. Using inositol and IP-6 also improves breast and arm symptom scores and some quality of life scores; however, these improvements were not consistent over time.\nless\nChild growth. Oral inositol has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA sub-analysis of a large randomized controlled trial shows that twice daily maternal use of a drink supplement containing myo-inositol 4 grams, folic acid, vitamins D, B6, and B12, zinc, lactobacillus rhamnosus, Bifidobacterium lactis, and other nutrients throughout pregnancy increases the likelihood of the infant being in the normal weight range after 2 years of follow up when compared with placebo. Infants of mothers using the drink supplement had a reduced likelihood of rapid weight gain when compared with placebo; other anthropomorphic measurements were similar between groups (115691). It is unclear if any effects are due to inositol, other ingredients, or the combination.\nless\nDiabetes. It is unclear if oral inositol is beneficial for the treatment of type 1 diabetes or the prevention of gestational diabetes.\nPreliminary clinical research in patients with type 1 diabetes and a body mass index of at least 25 kg/m2 shows that taking a specific combination product containing D-chiro-inositol and folic acid (Chirofol 500, LJ Pharma) daily for 6 months, along with insulin therapy, decreases glycated hemoglobin (HbA1c) by approximately 0.5% when compared to taking folic acid alone with insulin therapy. However, there was no difference between groups with respect to insulin resistance or body mass index (95088).\n\nMost research shows that taking inositol during pregnancy prevents gestational diabetes. However, most studies conducted to date are of low quality and it is unclear if the results are generalizable. Meta-analyses of 4-7 clinical studies in pregnant adults, some with overweight and obesity, shows that taking myo-inositol 2-4 g daily with folic acid (usually as Inofolic, Lo.Li. Pharma International) may reduce the relative risk of gestational diabetes by 57% to 92% and reduce insulin requirements in adults at risk for gestational diabetes. Inositol may also be associated with improved infant outcomes such as increased gestational age at birth and reduced preterm delivery, but does not seem to influence birth weight, NICU admission rate, neonatal hypoglycemia, the incidence of shoulder dystocia, macrosomia, or cesarian delivery when compared with control (100706, 103750, 104688, 111664, 111667, 111671, 111677, 114560). The validity of these findings is limited by significant heterogeneity within the included studies, concerns about blinding, and overall low-quality evidence. Research evaluating a lower daily dose of myo-inositol 1.1 grams with D-chiro-inositol 27.6 mg and folic acid 400 mcg (Inofolic Combi, Lo.Li. Pharma International) during pregnancy shows no effect on incidence of gestational diabetes when compared with folic acid alone in adults with a family history of diabetes (95082, 103750).\n\nSome evidence suggests that initiation of myo-inositol, in combination with vitamins and other ingredients, earlier during pregnancy (e.g., 7 weeks' gestation) may be associated with increased blood glucose levels at 28 weeks' gestation. Some researchers have postulated that the beneficial effects of myo-inositol may be optimized by initiating therapy later in pregnancy. However, this hypothesis has not been well researched (115694).\n\nIn patients eventually diagnosed with gestational diabetes, one small clinical study shows that taking myo-inositol 2 grams reduces the number of patients requiring insulin by at least 50% (104688), although another small clinical study shows that adding D-chiro-inositol, myo-inositol, or both to folic acid does not affect insulin resistance when compared with placebo (98945).\nless\nDyslipidemia. Although there has been interest in using oral inositol for hypercholesterolemia and hypertriglyceridemia, there is insufficient reliable information about the clinical effects of inositol for these conditions.\nErectile dysfunction (ED). Oral inositol has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nAnother very small study in males with overweight or obesity, mild ED, and normal to low androgen levels shows that taking a combination product containing myo-inositol 4000 mg, alpha-lipoic acid, folic acid, and apple (Sinopol Forte) improves measures of erectile dysfunction when compared with baseline (111674). The validity of these effects is limited by the small sample size and the lack of a comparator group, and it is unclear if these effects are due to inositol, other ingredients, or the combination.\nless\nHypertension. Although there has been interest in using oral inositol for hypertension, there is insufficient reliable information about the clinical effects of inositol for this condition.\nHypothyroidism. Inositol has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA meta-analysis of clinical and observational research in adults with hypothyroidism, subclinical hypothyroidism, and other thyroid disorders shows that taking a combination of inositol 600-1200 mg and selenium 83-166 mg orally daily for 6-12 months modestly improves thyroid stimulating hormone (TSH) levels and thyroxine levels when compared with control (114562). Clinical research in females aged 18 to 50 years with or at risk for subclinical hypothyroidism in Slovakia shows that taking myo-inositol 600 mg and selenium 83 mcg daily for 6 months reduces patient-reported hypothyroid symptoms including fatigue, menstrual cycle irregularity, and intolerance to heat or cold (110591). The interpretation of this result is limited by the lack of a control group. In addition, it is unclear if the effects in these studies are due to myo-inositol, selenium, or the combination.\nless\nInfertility. It is unclear if oral inositol is beneficial in adults undergoing intracytoplasmic sperm injection (ICSI) or in vitro fertilization (IVF).\nMany small studies report conflicting effects of oral myo-inositol on fertilization rates, implantation rates, and live birth rates in adults undergoing IVF or ICSI (103752, 108825, 111672). Many of these trials used a specific combination product containing myo-inositol 4 grams and folic acid 400 mcg (Inofolic, Lo.Li. Pharma International S.r.l) daily, starting 1-3 months before ICSI and continuing until ovulation (103752, 108825). Meta-analyses of up to 8 small randomized controlled trials in adults undergoing assisted reproduction (e.g., ICSI, IVF) with or without polycystic ovary syndrome (PCOS) shows that taking myo-inositol 2-4 grams orally daily, with or without folic acid, for 8-12 weeks modestly improves the number of oocytes obtained, but does not affect the miscarriage rate or clinical pregnancy rate, when compared with placebo (115693). The validity of this study is limited by moderate heterogeneity.\n\nThe effects of inositol on fertility have also been studied in patients with specific comorbidities. A case-control study in long-term survivors of lymphoma suggests that taking myo-inositol 400 mg and D-chiro-inositol 45 mg (Ovofert Fast, CRL Pharma) three times daily for 12 months is associated with reductions in follicle stimulating hormone (FSH), luteinizing hormone (LH), dyspareunia, and dysmenorrhea and a modest increase in antral follicle count of the right ovary when compared with control (111673). The validity of these effects is limited by a lack of blinding. Inositol has also been evaluated in females with PCOS. A meta-analysis of clinical studies in adults with PCOS undergoing IVF or ICSI shows that inositol does not improve pregnancy rates when compared to no treatment. However, inositol may increase clinical pregnancy rates when compared with metformin (111675).\n\nInositol has also been evaluated in combination with other ingredients. A large clinical study in females planning to conceive shows that taking a combination product containing myo-inositol 4 grams, vitamin D, riboflavin, vitamin B6, vitamin B12, zinc, and probiotics does not improve time-to-conception, clinical pregnancy rates, or live birth rates when compared with a standard micronutrient supplement. However, the supplement shortens time-to-conception in adults with overweight to durations equivalent to patients who are not overweight, but lengthens time to conception in adults with obesity when compared with placebo (111665). It is unclear whether these effects are due to inositol, other ingredients, or the combination.\nless\nInsomnia. It is unclear if oral inositol is beneficial for improving sleep during pregnancy.\nClinical research shows that taking myo-inositol 2 grams plus folic acid 200 mcg (Inofolic, Lo.Li. Pharma International) before bed for 10 weeks, starting at 14 weeks gestation, improves overall measures of sleep quality by a small amount when compared with folic acid alone. However, this improvement was not maintained until 37-38 weeks' gestation. Also, the study was not limited to patients with poor sleep quality during pregnancy, but to any healthy pregnant individual (104687).\nless\nLithium-induced side effects. It is unclear if oral inositol is beneficial for reducing lithium-induced side effects.\nA small clinical study suggests that taking inositol 6 grams daily for 10 weeks may improve psoriasis associated with lithium therapy when compared with baseline (11972). However, taking inositol orally does not seem to improve other lithium-induced adverse effects, such as tremor, thirst, and changes in thyroid and adrenal function (2027).\nless\nLung cancer. It is unclear if oral inositol is beneficial for slowing the rate of bronchial dysplasia.\nPreliminary clinical research in smokers with bronchial dysplasia considered at high risk for lung cancer shows that taking myo-inositol (Tsuno Food Industries Co., Ltd.) 9 grams orally once daily for 2 weeks then twice daily for 6 months, does not increase the rate of complete or partial response when compared with placebo (95090).\nless\nMastalgia. Inositol has only been evaluated in combination with other ingredients for cyclic mastalgia; its effect when used alone is unclear.\nA small retrospective study in females with cyclic mastalgia suggests that applying a specific product containing inositol, Boswellia serrata, and betaine (Eumastos Gel, Lo.Li. Pharma s.r.l.) 2.5 grams topically once daily from the 10th to the 25th day of the menstrual cycle for three months is associated with reductions in mastalgia pain scores when compared with a control cohort (115695). The validity of this finding is limited by the retrospective nature of the study and the lack of a placebo control.\nless\nNonalcoholic fatty liver disease (NAFLD). It is unclear if oral inositol is beneficial for NAFLD.\nA small clinical study in adults with NAFLD and obesity shows that taking myo-inositol powder 4 grams daily for 8 weeks does not improve liver health markers, such as liver function test levels or liver steatosis, but does improve some components of lipid profiles, glycemic indices, and anthropometric measures when compared to baseline (111304) However, this study may have been inadequately powered to detect differences in some of the outcomes.\nless\nObesity. It is unclear if oral inositol is beneficial in patients with overweight or obesity.\nA meta-analysis of 15 clinical studies in adults shows that taking inositol 600-4450 mg daily for 6-48 weeks decreases body mass index (BMI) by about 0.4 kg/m2. Subgroup analysis suggests that myo-inositol may be beneficial at a dosage less than 1000 mg for less than 12 weeks, especially in patients with polycystic ovary syndrome (PCOS) and overweight or obesity, with higher baseline BMI, and above 40 years of age (111666). However, the validity of this finding is limited by significant heterogeneity in the included studies.\nless\nObsessive-compulsive disorder (OCD). It is unclear if oral inositol is beneficial in patients with OCD.\nOne preliminary clinical study in adults with OCD shows that taking inositol 18 grams daily for 6 weeks improves Yale-Brown Obsessive Compulsive Scale scores when compared with placebo (2186). However, taking inositol does not seem to improve the severity or type of OCD symptoms in patients already taking a selective serotonin reuptake inhibitor (91556). Both of these studies were small, and treatment was administered for only 6 weeks.\nless\nPanic disorder. Oral inositol seems to improve symptoms of panic disorder.\nA very small clinical study shows that taking inositol 12 grams daily reduces the severity and rate of panic attacks and the severity of agoraphobia over 4 weeks of treatment when compared with placebo (2184). Another very small clinical study shows that taking inositol 18 grams daily for one month may be as effective as fluvoxamine 150 mg daily for treatment of panic disorder (10387). However, the one-month duration may not have provided adequate time to see the full effects of fluvoxamine.\nless\nPostpartum complications. Inositol has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA post-hoc analysis of a clinical study suggests that higher blood levels of myo-inositol early in pregnancy are associated with less postpartum blood loss when compared with lower blood levels of myo-insositol (115692). The effects of inositol supplementation are unclear.\nless\nPost-traumatic stress disorder (PTSD). It is unclear if oral inositol is beneficial in patients with PTSD.\nPreliminary clinical research shows that taking inositol 12 grams daily for 4 weeks does not improve distress when compared with placebo in patients with PTSD (91557).\nless\nPregnancy-induced hypertension. It is unclear if oral inositol is beneficial for preventing hypertension during pregnancy.\nIn patients with a body mass index (BMI) between 25-29.9 kg/m2, preliminary clinical research shows that taking myo-inositol 2 grams plus folic acid 200 mcg (Inofolic, Lo.Li. Pharma International) twice daily, beginning during the first trimester and continuing throughout pregnancy, decreases the incidence of pregnancy-induced hypertension by 66% when compared with folic acid alone (104688).\nless\nPsoriasis. It is unclear if oral or topical inositol is beneficial for improving symptoms of psoriasis.\nOne small clinical study shows that taking inositol 6 grams daily for 10 weeks does not improve symptoms of psoriasis in a small group of patients when compared to baseline. However, taking this dose of inositol has a moderate effect on overall symptoms in patients with psoriasis related to lithium use (11972). Preliminary clinical research also shows that topical use of D-chiro-inositol is unlikely to be beneficial for reducing overall symptoms of psoriasis. Topical application of inositol 0.25% or 1% for 6 weeks improves overall symptoms when compared with baseline. However, the inositol-containing creams were no more effective than the control cream (104686).\n\nInositol has also been evaluated in combination with other ingredients. A small prospective observational study in adults with mild plaque psoriasis suggests that applying amino-inositol and urea 40% cream (Inosit U40, Biogena) 1-2 times daily for 4 weeks is associated with reductions in the severity and extent of psoriasis symptoms and improvements in quality of life measures when compared to baseline (111668). The validity of these effects is limited by a small sample size, a lack of a comparator group, insufficient blinding, and the observational study design.\nless\nTrichotillomania. It is unclear if oral inositol is beneficial for reducing hair pulling.\nPreliminary clinical research shows that taking inositol in doses ranging from 6-18 grams daily over a period of 10 weeks is no more effective than placebo in reducing subjective or clinician-documented symptoms of hair pulling in patients with trichotillomania (95089).\nless\nMore evidence is needed to rate inositol for these uses.",
            "Dosing & Administration": "Adult\nOral:\nInositol is typically used in doses of 1-4 grams daily, often in combination with folic acid 200-400 mcg daily. See Effectiveness section for condition-specific information.\nTopical:\nResearch is limited; typical dosing is unavailable.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nInositol can be found in nine different stereoisomer forms, but the isomers myo-inositol and D-chiro-inositol are most commonly used in supplements (91555, 95082, 95085).",
            "Interactions with Drugs": "ANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nA (High-quality meta-analysis (quantitative systematic review))\nTheoretically, taking inositol with antidiabetes drugs might increase the risk of hypoglycemia.\nClinical research shows that inositol lowers blood glucose levels and glycated hemoglobin (HbA1c) levels in patients with diabetes (95083, 95084, 95088).\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, inositol might have hypoglycemic effects.\nInositol can lower blood glucose levels (95083, 95084, 95088). Theoretically, inositol might have additive effects with other herbs and supplements with hypoglycemic potential. See other products with hypoglycemic activity here.\nless",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Nutrient Depletions": "CARBAMAZEPINE (Tegretol)\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nCarbamazepine might modestly reduce inositol levels.\nCarbamazepine reduces inositol levels in the brain, probably by inhibiting an enzyme involved in inositol synthesis (15515, 15516, 15517). Levels of inositol in the systemic circulation are determined primarily by dietary intake (15516), and are unlikely to be affected significantly by carbamazepine. The effect of carbamazepine on brain inositol levels might contribute to its therapeutic effect in bipolar disorder (15515, 15516). The effect of inositol supplements on the efficacy of carbamazepine is unknown.\nless\nLITHIUM\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nLithium might modestly reduce inositol levels.\nLithium reduces inositol levels in the brain by inhibiting the inositol monophosphatase enzyme, which is involved in synthesis of inositol (15513, 15514, 15515, 15516). Levels of inositol in the systemic circulation are determined primarily by dietary intake (15516), and do not seem to be significantly affected by lithium. The effect of lithium on brain inositol levels might contribute to its therapeutic effect in bipolar disorder (11972, 15514, 15515, 15516). Animal research suggests that inositol supplementation may reduce the therapeutic effects of lithium (15517), whereas dietary inositol restriction may augment the effects of lithium (15513). It has also been suggested that reduction of tissue inositol levels might contribute to adverse effects of lithium; a small study reported benefit with inositol supplements in lithium-induced psoriasis (11972).\nless\nVALPROATE\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nValproate might modestly reduce inositol levels.\nValproic acid reduces inositol levels in the brain by inhibiting the inositol phosphate synthase enzyme, which is involved in synthesis of inositol (15515, 15516, 15517). Levels of inositol in the systemic circulation are determined primarily by dietary intake (15516), and are unlikely to be affected significantly by valproic acid. The effect of valproic acid on brain inositol levels might contribute to its therapeutic effect in bipolar disorder (15515, 15516). The effect of inositol supplements on the efficacy of valproic acid is unknown.\nless",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with inositol.",
            "Pharmacokinetics": "Absorption\nOrally, inositol is transported across the intestinal mucosa and absorbed almost completely (91551). In preterm infants, a single intravenous dose of inositol 60 mg/kg or 120 mg/kg increased serum concentration of inositol in a dose-dependent manner. The increase in serum concentration of inositol following intravenous administration appears to persist for 24-36 hours (91551).\nMetabolism\nInositol is metabolized by myo-inositol oxidase, which is located at the renal cortex (91551). However, metabolism is complex and appears to change in utero, at birth, and is affected by enteral intake and endogenous controls (95093). Some evidence from clinical research suggests that the half-life of a one-time dose of intravenous inositol is 5.22 hours, with multiple doses is 7.9 hours, and overall is 6.31 hours in preterm infants (91551, 95093). However, other clinical research suggests that the half-life of inositol in preterm infants is 4-5 days. Reasons for the discrepancy may be due to enteral intake of human milk in the latter study, which may have contributed to elevated serum inositol levels despite discontinuation of IV treatment (2192). Additionally, inositol is endogenously synthesized, which could also lead to discrepancies (95093).\nExcretion\nClearance of inositol in preterm infants is estimated to be 0.06 L/Kg/hr (91551, 95093). Because myo-inositol oxidase, the enzyme that metabolizes inositol, is less active in newborns, urinary excretion of inositol is higher in premature and term infants compared to infants that are a few weeks old (91551, 95093).",
            "Mechanism of Action": "General\nEndogenous inositol is an essential component of cell membrane phospholipids. It has weak lipotropic activity, and can move fat out of liver and intestine cells (2187). Inositol has a variety of stereoisomers, including myo-inositol and D-chiro-inositol. Myo-inositol is the most abundant form in the central nervous system (CNS). Biological function varies among the isomers (2047, 2048). Myo-inositol is a source of second messengers such as diacylglycerol. It is required for growth of human cells (95090).\nAnti-carcinogenic effects\nDysplasia in the central airways and peripheral lung is a risk marker for lung cancer, and there is an interest in using myo-inositol for preventing lung cancer. However, early clinical research shows that taking myo-inositol (Tsuno Food Industries Co., Ltd.) 9 grams orally once daily for 2 weeks then twice daily for 6 months, does not significantly affect bronchial dysplasia in smokers with bronchial dysplasia considered high risk for lung cancer, compared to placebo. There was also no difference in Ki-67 (a marker of proliferation) in the bronchial biopsies with dysplasia between groups post-treatment. However, myo-inositol lead to a significant decrease in interleukin-6 (IL-6) in the bronchoalveolar lavage fluid (BAL), with a trend towards decreasing oxidant level. Increased baseline plasma and BAL levels of Clara cell protein-16 (an antiinflammatory protein secreted by bronchiolar cells) were associated with positive outcomes as well as decreased levels of plasma myeloperoxidase (95090).\n\nIn smokers with epithelial bronchial dysplasia, the PI3K pathway is activated. The PI3K/Akt pathway regulates cell proliferation and survival. PI3K gene expression in normal epithelium decreased in patients who experienced a complete response to myo-inositol, suggesting that myo-inositiol inhibits PI3K signaling. This was not seen in non-responders nor in the placebo group (95090).\nCentral nervous system (CNS) effects\nThere is interest in using inositol for various psychiatric disorders. Decreased brain levels of inositol have been seen in patients suffering from depression, anxiety and compulsive disorders (95089, 95092).\n\nInositol is a constituent of the intracellular phosphatidyl inositol second messenger system, which is linked to several neurotransmitters including alpha 1 noradrenergic, serotonin, dopamine, norepinephrine, glutamate and cholinergic receptors (10850, 11972, 95089, 95092). Inositol may play a role in the interactions between G protein-coupled receptors and their ligands particularly in the serotonergic pathway (95089, 95092). Inositol might reverse desensitization of serotonin receptors (2187). Limited clinical evidence suggests exogenous inositol may have benefits similar to selective-serotonin-reuptake inhibitors (SSRIs) in conditions such as panic disorder, depression, and obsessive-compulsive disorder.\nDermatologic effects\nSupplemental inositol seems to help psoriasis that is made worse or triggered by lithium therapy. The mechanism is unknown, but lithium seems to cause a reduction of inositol in both the brain and other tissues. Supplementation with inositol doesn't seem to adversely affect the efficacy of lithium for bipolar disorder (11972).\nFertility effects\nThere is interest in using inositol for infertility. In patients with polycystic ovary syndrome (PCOS), clinical research shows that taking myo-inositol, D-chiro-inositol, or a combination of these two forms, seems to improve ovulation and pregnancy rates (91544, 91550, 91553, 102317). In patients with oligoasthenospermia, clinical research shows that treating sperm with myo-inositol in vitro increases sperm motility. This increased motility results in an 18% increased rate of pregnancy during intrauterine insemination when compared with control (102318).\nGrowth effects\nThere is interest in using inositol for growth. Preliminary clinical research in children with idiopathic short stature shows that taking an inositol and vitamin B solution, 10 mL twice daily, for 12 months modestly increases height when compared to baseline. Improvements were larger in those that also completed stretching exercises (112280).\nInsulin sensitizing effects\nIn laboratory and animal studies, it has been shown that insulin resistance is directly related to a deficiency in D-chiro-inositol and an imbalance with myo-inositol. (95086, 95088). D-chiro-inositol acts as a second messenger of insulin signaling and is an insulin sensitizer. Laboratory research suggests that it possesses insulin-mimetic activity and, in peripheral tissues, leads to disposal of intracellular glucose and glycogen storage (95088). Inositol is also a precursor for phosphoinositides. Phosphoinositides play a role in cell signaling and are also secondary messengers involved in glucose metabolism and insulin like effects. Inositol is also a precursor for inositol phosphoglycans (IPG). There are two groups, the P-type and A-type, which are antagonists of each other. The P-type are involved in the activation of glycolysis, while the A type suppresses steps of glycolysis. Insulin resistance leads to increases in urinary inositol metabolites, mostly the A-type. This alters the ratio of A to P-type, leading to a suppression of pyruvate dehydrogenase. Providing inositol supplements in theory, shifts the ratio of A and P-type back to normal (95082, 95083). Furthermore, inositol may increase levels of adipocytokines, particularly adiponectin, which are negatively correlated with glucose and insulin concentrations. When insulin binds to receptors, it may stimulate the intracellular transport of inositol phosphoglycan. Myo-inositol may activate lipogenesis via stimulation of acetyl-CoA-carboxylase (95083).\n\nIt's thought that a defect in the availability or metabolism of inositol or IPGs may play a role in insulin resistance in patients with polycystic ovary syndrome (PCOS) (95085). As such, there is interest in using inositol in patients with PCOS. Researchers think that inositol induces ovulation in these patients by improving insulin sensitivity. It also produces the second messenger inositol triphosphate which is involved in regulation of certain hormones such as thyroid stimulating hormone and follicle-stimulating hormone as well (95084, 95085). Reduced insulin resistance is also thought to be responsible for improving other symptoms associated with PCOS, including hypertension, hyperlipidemia, hyperglycemia, obesity, and increased serum testosterone concentrations (2028). Additionally, patients with insulin resistance, including those with impaired glucose tolerance and type 2 diabetes, might have D-chiro-inositol deficiency (2028)."
        }
    },
    "Inositol Nicotinate": {
        "sections": {
            "Overview": "Inositol nicotinate consists of six nicotinic acid molecules crossed-linked together with an inositol molecule (13200). It is an alternative form of vitamin B3, or niacin, that is claimed to decrease flushing. However, this benefit has not been demonstrated in clinical trials. Inositol nicotinate has been traditionally used to improve blood circulation.",
            "Safety": "POSSIBLY SAFE when used orally and appropriately (496). Inositol nicotinate has been used with apparent safety at a dose up to 4 grams daily for up to 3 months (498, 1544, 1545, 55857, 55858, 55860).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, inositol nicotinate is generally well tolerated.\nMost Common Adverse Effects\nOrally: Abdominal pain, constipation, diarrhea, flushing, heartburn, liver enzyme elevation, nausea, vomiting.\nCardiovascular\nOrally, inositol nicotinate is converted to niacin and is therefore likely to cause similar side effects as niacin (496). A prostaglandin-mediated flushing reaction is a common adverse effect of oral niacin. A large pooled analysis of clinical studies shows that up to 70% of people may experience flushing with oral niacin (96211). Although flushing can occur with doses of niacin as low as 30 mg daily, it is more common with the larger doses of 500-2000 mg used for treatment of dyslipidemia (4889, 26089, 93341, 93345). Inositol nicotinate is often promoted as a \"no-flush\" niacin; however, this benefit has not been demonstrated in clinical trials.\nless\nDermatologic\nOrally, inositol nicotinate is converted to niacin and is therefore likely to cause similar side effects as niacin, including pruritus (496).\nless\nEndocrine\nOrally, inositol nicotinate is converted to niacin and is therefore likely to cause similar side effects as niacin (496). Niacin can impair glucose tolerance in a dose-dependent manner. Dosages of niacin 3-5 grams daily appear to increase blood glucose in patients with or without diabetes, while dosages of 1.5 grams or less have minimal effects (12033). Because inositol nicotinate is converted to niacin, it may also impair glucose tolerance (496).\nless\nGastrointestinal\nOrally, inositol nicotinate is converted to niacin and is therefore likely to cause similar side effects as niacin, including gastrointestinal complaints such as nausea, vomiting, bloating, heartburn, diarrhea, and constipation (496). These adverse effects from niacin may be reduced by taking it with meals or antacids, and usually disappear within two weeks of continued therapy (4851, 11690, 26094).\nless\nHematologic\nOrally, inositol nicotinate is converted to niacin and is therefore likely to cause similar side effects as niacin, including hyperuricemia (496).\nless\nHepatic\nOrally, inositol nicotinate is converted to niacin and is therefore likely to cause similar side effects as niacin (496). Niacin is associated with elevated liver function tests and jaundice, especially with doses of 3 grams daily or more, and when doses are rapidly increased (4458, 4863, 6243, 11690). Because inositol nicotinate is converted to niacin, it may also cause hepatotoxicity (496)\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nRaynaud syndrome. Small clinical studies suggest that oral inositol nicotinate may modestly improve symptoms in patients with Raynaud syndrome.\nSeveral small clinical trials in adults with Raynaud syndrome shows that taking a specific inositol nicotinate product (Hexopal, Sterling Winthrop) 3-4 grams daily orally for 8-12 weeks modestly improves symptom frequency and severity, including pain, coldness, and vasospasm (498, 1544, 1545). Several weeks of treatment may be necessary before the full beneficial effects are seen (1544, 1545).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAcne. Although there has been interest in using oral inositol nicotinate for acne, there is insufficient reliable information about the clinical effects of inositol nicotinate for this purpose.\nAnxiety. Although there has been interest in using oral inositol nicotinate for anxiety, there is insufficient reliable information about the clinical effects of inositol nicotinate for this purpose.\nCerebrovascular disease. Although there has been interest in using oral inositol nicotinate for cerebrovascular disease, there is insufficient reliable information about the clinical effects of inositol nicotinate for this purpose.\nHyperlipidemia. Although there has been interest in using oral inositol nicotinate for hyperlipidemia, there is insufficient reliable information about the clinical effects of inositol nicotinate for this purpose.\nHypertension. Although there has been interest in using oral inositol nicotinate for hypertension, there is insufficient reliable information about the clinical effects of inositol nicotinate for this purpose.\nIntermittent claudication. It is unclear if oral inositol nicotinate is beneficial in patients with intermittent claudication.\nThree, low-quality, clinical studies in adults with intermittent claudication show that taking a specific inositol nicotinate product (Hexopal, Winthrop Laboratories) 4 grams orally, divided in 2-4 doses daily, for 3 months modestly improves walking distance, claudication time, and pressure indices and reduces the severity of walking problems when compared with baseline. However, the studies show conflicting effects of inositol nicotinate when compared with placebo. Differences in smoking status and changes in smoking habits throughout the studies may explain the differing results; however, more data is needed to confirm (55857, 55858, 55860). Preliminary subgroup analyses also suggest that inositol nicotinate may be less effective in patients with severe or mild intermittent claudication when compared with moderate disease (55860).\nless\nMigraine headache. Although there has been interest in using oral inositol nicotinate for migraine headache, there is insufficient reliable information about the clinical effects of inositol nicotinate for this purpose.\nPeripheral arterial disease (PAD). Although there has been interest in using oral inositol nicotinate for PAD, there is insufficient reliable information about the clinical effects of inositol nicotinate for this purpose.\nPsoriasis. Although there has been interest in using oral inositol nicotinate for psoriasis, there is insufficient reliable information about the clinical effects of inositol nicotinate for this purpose.\nRestless legs syndrome (RLS). Although there has been interest in using oral inositol nicotinate for RLS, there is insufficient reliable information about the clinical effects of inositol nicotinate for this purpose.\nSchizophrenia. Although there has been interest in using oral inositol nicotinate for schizophrenia, there is insufficient reliable information about the clinical effects of inositol nicotinate for this purpose.\nScleroderma. Although there has been interest in using oral inositol nicotinate for scleroderma, there is insufficient reliable information about the clinical effects of inositol nicotinate for this purpose.\nMore evidence is needed to rate inositol nicotinate for these uses.",
            "Dosing & Administration": "Adult\nOral:\nInositol nicotinate has most commonly been used in doses of 3-4 grams daily for up to 3 months. See Effectiveness section for condition-specific information.\n\nTheoretically, concomitant ingestion of hot drinks with inositol nicotinate may worsen flushing. Flushing from niacin, a metabolite of inositol nicotinate, can be magnified by concomitant ingestion of hot drinks (6243).\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of inositol nicotinate.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use of inositol nicotinate with anticoagulant or antiplatelet drugs might increase the risk of bleeding.\nInositol nicotinate has fibrinolytic effects, which may increase the risk of bleeding when used concomitantly with anticoagulant/antiplatelet drugs (496, 1544).\nless\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, inositol nicotinate might increase blood glucose levels and may diminish the effects of antidiabetes drugs.\nInositol nicotinate is metabolized to niacin in the body (496). Niacin can cause hyperglycemia, abnormal glucose tolerance, and glycosuria. Increased blood glucose monitoring may be necessary, particularly early in the course of treatment (4859, 4860, 12033).\nless\nHMG-CoA REDUCTASE INHIBITORS (\"Statins\")\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, concomitant use of inositol nicotinate and statins might increase the risk of myopathy and rhabdomyolysis.\nInositol nicotinate is metabolized to niacin in the body (496). Some case reports have raised concerns that niacin might increase the risk of myopathy and rhabdomyolysis when combined with statins (14508, 25918) However, a significantly increased risk of myopathy has not been demonstrated in clinical trials (7388, 11689, 12033, 14509).\nless\nTRANSDERMAL NICOTINE (Nicoderm)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, concomitant use of inositol nicotinate and transdermal nicotine might increase the risk of flushing and dizziness.\nInositol nicotinate is metabolized to niacin in the body. Inositol nicotinate and nicotine can both cause flushing and dizziness (496, 96211).\nless",
            "Interactions with Supplements": "ANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, inositol nicotinate might increase the risk of bleeding.\nInositol nicotinate has fibrinolytic effects (496, 1544), which may theoretically increase the risk of bleeding when used concomitantly with anticoagulant/antiplatelet herbs and supplements. See other products with antiplatelet activity here. See products with anticoagulant activity here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nALLERGIES\nTheoretically, inositol nicotinate might exacerbate allergies due to additive histamine release. Inositol nicotinate is metabolized to niacin in the body. Niacin-induced vasodilation and flushing may be related to histamine and/or prostacyclin release (15, 496).\nless\nANGINA\nInositol nicotinate is metabolized to niacin in the body. Niacin causes vasodilation. Use with caution in patients with unstable angina (15, 496, 104993).\nless\nBLEEDING DISORDERS\nTheoretically, inositol nicotinate might increase the risk of bleeding and bruising when used by patients with bleeding disorders. Inositol nicotinate has fibrinolytic effects, which may increase the risk of bleeding (496, 1544).\nless\nDIABETES\nInositol nicotinate is metabolized to niacin in the body. Niacin can interfere with blood glucose control, requiring dosing adjustment of antidiabetic agents. Niacin taken in high doses can cause hyperglycemia, abnormal glucose tolerance, and glycosuria. Increased blood glucose monitoring may be necessary, particularly early in the course of treatment (4859, 4860, 12033).\nless\nGALLBLADDER DISEASE\nInositol nicotinate is metabolized to niacin in the body. There is concern that niacin might exacerbate active gallbladder disease (15, 496); use with caution.\nless\nGOUT\nInositol nicotinate is metabolized to niacin in the body. Large amounts of niacin might precipitate gout (12033); use with caution.\nless\nHYPOTENSION\nInositol nicotinate is metabolized to niacin in the body. There is concern that niacin might exacerbate uncorrected hypotension or orthostatic hypotension. Niacin induces vasodilation and might have additive effects in patients with a predisposition to hypotension (15, 496, 4863, 12033, 93341).\nless\nKIDNEY DISEASE\nInositol nicotinate is metabolized to niacin in the body. Niacin is excreted unchanged in the urine and might accumulate in patients with kidney disease (15, 496); use with caution.\nless\nLIVER DISEASE\nInositol nicotinate is metabolized to niacin in the body. There is concern that large doses of niacin might worsen preexisting liver disease. Niacin has been associated with liver damage. Avoid large amounts in patients with a history of liver disease (12026, 12033).\nless\nNIACIN HYPERSENSITIVITY\nInositol nicotinate is metabolized to niacin in the body (15, 496).\nless\nPEPTIC ULCER DISEASE\nInositol nicotinate is metabolized to niacin in the body. There is concern that large amounts of niacin might activate peptic ulcer disease. Niacin is contraindicated in patients with active peptic ulcer disease and should be used with caution in patients with a history of peptic ulcer disease (15, 496, 104993).\nless\nPERIOPERATIVE\nTheoretically, inositol nicotinate may increase the risk of bleeding during surgery. Inositol nicotinate may have fibrinolytic effects (496, 1544). Tell patients to discontinue inositol nicotinate at least 2 weeks before elective surgical procedures.\nless\nTENDON XANTHOMAS\nInositol nicotinate is metabolized to niacin in the body. Some case reports suggests that taking niacin might result in adverse changes in existing xanthomas in some patients, possibly resulting in infection (93348).\nless\nTHYROID DISORDERS\nInositol nicotinate is metabolized to niacin in the body. Evidence from clinical research and case reports suggests that taking niacin can reduce levels of thyroxine-binding globulin by up to 25% and can moderately reduce levels of thyroxine (T4) (25916, 25925, 25926, 25928).\nless",
            "Interactions with Lab Tests": "EXPAND ALL\n|\nCOLLAPSE ALL\nCATECHOLAMINES\nNiacin, a metabolite of inositol nicotinate, can falsely increase some urinary catecholamine fluorometric assay results. Niacin produces fluorescent substances in the urine, which can falsely elevate test results (15, 104993).\nless\nGLUCOSE\nNiacin, a metabolite of inositol nicotinate, can cause a false-positive reaction with urine glucose tests that rely on cupric sulfate solution (Benedict's reagent) (15, 104993).\nless\nURINE DRUG SCREEN\nNiacin, a metabolite of inositol nicotinate, is sometimes taken to prevent positive urine drug screens in people who take illicit drugs such as marijuana and others; however, there is no reliable evidence that niacin or inositol nicotinate works for this purpose.\nless",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with inositol nicotinate.",
            "Pharmacokinetics": "Absorption\nAfter oral intake, the bioavailability of inositol nicotinate is about 30% lower than that of niacin or niacinamide, which are almost completely absorbed. About 70% of oral inositol nicotinate is absorbed from the gastrointestinal tract (13200). Peak serum levels of nicotinic acid are not achieved until about 10-12 hours after the dose (496). A single dose of inositol nicotinate 1600 mg produces peak free nicotinic acid levels of about 0.6 mcmol/L. This is much lower than the peak level of 244 mcmol/L produced from a single 1000 mg dose of regular niacin (13200).\nMetabolism\nAfter oral intake, the hydrolysis of inositol nicotinate into free nicotinic acid and inositol molecules occurs slowly (496).",
            "Mechanism of Action": "General\nInositol nicotinate consists of six molecules of nicotinic acid (niacin) cross-linked to an inositol molecule (13200).\nCirculatory effects\nIt may take several weeks of therapy to see the full beneficial effects of inositol nicotinate in peripheral vascular disorders such as Raynaud syndrome, suggesting that fibrinolysis, lipid lowering, and vasodilatory action contribute to its beneficial effects (1544, 1545)."
        }
    },
    "Inulin": {
        "sections": {
            "Overview": "Inulin, first discovered in the 1800s, is a type of prebiotic, a non-digestible food fiber fermented by bacteria in the colon (93718, 93724, 93728). It is an oligosaccharide composed of approximately 60 chains of glucose and fructose molecules. It is found in various plant roots and tubers and is used as a food additive to increase bulk and palatability (8449, 10412, 10414, 93719).",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. Inulin has Generally Recognized As Safe status (GRAS) in the US (93728).\nPOSSIBLY SAFE when used orally and appropriately in supplemental doses, short-term. Doses of 8-18 grams daily have been used safely for up to 24 weeks (7604, 7605, 7606, 7607, 8451, 93716, 93719, 93726, 103200, 107936, 107935, 107938). Also, 20 grams daily has been used with apparent safety for up to 3 weeks (96836, 96850). There is insufficient reliable information available about the safety of inulin when used long-term.\nCHILDREN: LIKELY SAFE when used orally in amounts commonly found in foods. Inulin has Generally Recognized As Safe status (GRAS) in the US (93728).\nCHILDREN: POSSIBLY SAFE when used orally and appropriately in supplemental doses, short-term. Clinical studies have used doses of 3-6 grams daily for 10 days in children 3-6 years of age and 5-13 grams daily for up to 6 months in children 7-15 years of age with apparent safety (96847, 110598, 110602). ...when used in infant formula. A formula containing chicory fructans (Orafti Synergy1, BENEO GmbH), approximately 50% of which were inulin, has been used with apparent safety in infants for 8-12 months (93717, 107937).\nPREGNANCY AND LACTATION: LIKELY SAFE when used orally in amounts commonly found in foods (93728). There is insufficient reliable information available about using inulin in medicinal amounts during pregnancy or lactation; avoid use.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, inulin is well tolerated.\nMost Common Adverse Effects\nOrally: Bloating, constipation, diarrhea, flatulence, and gastrointestinal cramps.\nSerious Adverse Effects (Rare)\nOrally: Anaphylaxis has occurred following consumption of foods high in inulin.\nGastrointestinal\nOrally, inulin may cause flatulence, bloating, diarrhea, constipation, and gastrointestinal cramps, especially at doses over 30 grams (7604, 8450, 8509, 93716, 93721, 93724, 96836, 96850, 96851, 99843)(107936, 107940, 107941, 110602).\nless\nImmunologic\nSevere allergic reactions to inulin-containing foods have been reported. There is one report of anaphylaxis following consumption of foods with a high concentration of inulin including salsify, artichoke leaves, and margarine (7608).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nConstipation. Most clinical research shows that oral inulin modestly improves stool frequency, but may not improve discomfort, in adults and children with constipation.\nA meta-analysis of clinical research in adults with constipation shows that consuming inulin improves stool frequency by approximately 0.7 stools per week. It also seems to improve stool transit time, consistency, and hardness, but does not reduce pain or bloating (93718). Additional clinical research shows that taking a specific type of inulin (OraftiGR, BENEO GmbH) 12 grams daily in three divided doses for 4 weeks increases stool frequency by approximately one stool per week when compared with a maltodextrin control. Taking inulin also reduces the number of patients experiencing hard and lumpy stools by 13%, but does not improve symptoms of bloating, distension, physical discomfort, or gas (96850). In children aged 2-5 years, one small clinical study shows that taking a specific combination of two inulin products (Orafti P95 oligofructose and Orafti GR inulin, BENEO GmbH), 2 grams twice daily in a dairy liquid for 6 weeks, improves the softness of stools, but not pain with stooling or stool frequency, when compared with a maltodextrin control (96848).\n\nResearch in older adults is conflicting. One small study shows that taking inulin 20-40 grams daily for 19 days increases the number of stools from 1-2 per week to 8-9 per week (10415). However, other preliminary clinical research in this population shows that taking a specific inulin supplement (Fibruline Instant, Cosucra Groupe Warcoing) 15 grams daily in yogurt or stewed fruit for 4 weeks does not improve bowel symptoms, stool frequency, or stool consistency (93724).\nless\nDiabetes. Short-term use of oral inulin along with antidiabetes drugs may improve glycemic control in some patients with type 2 diabetes; however, the benefits of long-term use are unclear.\nTwo meta-analyses of clinical research in normal weight and obese patients with type 2 diabetes show that taking inulin 0.8-10 grams orally daily for 6-12 weeks reduces glycated hemoglobin (HbA1c) by 0.65% and fasting plasma glucose by 16 mg/dL when compared with control. Taking inulin also improved HOMA-IR, a measure of insulin resistance, when compared with control. Researchers did not evaluate the most effective dose of inulin; however, most studies used 8.4-10 grams daily (103198, 105533). In females treated with metformin and glyburide, taking inulin 10 grams daily for 8 weeks reduces fasting blood glucose by 15 mg/dL and HbA1c by 1% when compared with placebo (93719). Population research in adults has also found that high dietary intake of inulin over 8 years of follow up is associated with a 6% lower risk of type 2 diabetes when compared with low dietary intake (110515).\n\nInulin has also been studied in combination with other supplements. Preliminary clinical research in elderly patients with diabetes shows that drinking a milk powder product supplemented with inulin and resistant dextrin 30 grams before breakfast and 15 grams before dinner for 12 weeks decreases fasting plasma glucose by 17 mg/dL, HbA1c by 0.38%, postprandial glucose by 27 mg/dL, body weight by 0.8 kg, and systolic and diastolic blood pressure by 5 mmHg when compared with placebo (99843). Other clinical research in adults with type 2 diabetes shows that taking a specific combination product (Orafti Synergy1, BENEO GmbH), containing 50% inulin and 50% fructo-oligosaccharides, 8 grams orally twice daily for 6 weeks does not reduce body weight or caloric intake or increase satiety scores when compared with placebo (107934).\nless\nObesity. Oral inulin might modestly improve short-term weight loss. Additional research is needed to determine the long-term effects of inulin on weight loss and weight maintenance in overweight or obese individuals.\nSome clinical research in overweight and obese females with diabetes shows that taking inulin 10 grams daily for 8 weeks results in weight loss of 2.6 kg, compared with no weight loss in those taking placebo (93719). Preliminary clinical research in overweight or obese patients with prediabetes shows that taking a specific brand of inulin (Orafti Synergy 1, BENEO GmbH) 30 grams orally daily for 6 weeks reduces body weight by 0.4 kg, compared with a 0.4 kg increase in those in the control group (93721).\n\nPreliminary clinical research in adults with obesity shows that taking inulin 16 grams orally daily for 3 months moderately reduces body weight and body mass index (BMI) when compared with placebo. However, these effects were most prominent in subjects that also increased physical activity (110514). Additional preliminary clinical research in adults with overweight shows that adding 18 grams of inulin powder to green tea daily increases weight loss when compared with green tea alone. Over six weeks, individuals taking inulin lost 2 kg, compared with no weight loss in those taking green tea. Weight loss was maintained for at least 2 weeks (93726).\n\nClinical trials in children show conflicting results. In children aged 7-12 years, a small clinical study shows that taking a specific oligofructose-enriched inulin product (Orafti Synergy1, BENEO GmbH) 8 grams orally in water before one meal daily for 16 weeks decreases weight gain by 2.4-fold and attenuates an increase in BMI when compared with placebo (96847). However, other preliminary clinical research in children with obesity aged 7-15 years shows that taking inulin extract 13 grams orally daily for 6 months does not reduce body weight or BMI when compared with placebo (110598).\n\nHowever, other clinical research shows that taking inulin orally in combination with other ingredients might not improve weight loss. Combining inulin, chromium picolinate, capsicum, L-phenylalanine, and other nutrients with caloric reduction and exercise doesn't seem to reduce weight in moderately obese patients when compared to caloric reduction and exercise alone (7607). Another preliminary clinical trial shows that taking inulin 10 grams with maltodextrin 10 grams daily for 12 weeks does not reduce body weight or improve body composition when compared with placebo in adults with overweight or obesity following a calorie-restricted diet (103202). Preliminary clinical research in adults with obesity also shows that consuming a seafood-based dietary product fortified with inulin 1.7 grams, fish oil 370 mg (containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and bifidobacterium animalis daily for 12 weeks does not lower body weight, waist circumference, abdominal fat, serum cholesterol levels, or blood pressure when compared with placebo. However, consuming the product modestly improved some markers of insulin resistance (110600).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAlcohol use disorder. It is unclear if oral inulin is beneficial in patients with alcohol use disorder.\nPreliminary clinical research in adults with alcohol use disorder who were recently admitted to the hospital shows that taking a specific inulin product (Fibruline, Cosucra) 4-16 grams orally daily for 17 days does not improve liver function tests when compared with placebo. Some liver function tests were also worse in those treated with inulin (110601).\nless\nAntibiotic-associated diarrhea. Oral inulin has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in children aged 6 months to 14 years receiving antibiotics for common infections shows that taking a combination of inulin and fructo-oligosaccharides, up to 5 grams daily depending on age, does not reduce the rate of antibiotic-associated diarrhea (93720).\nless\nCeliac disease. Small clinical studies suggest that patients with celiac disease who take oral inulin may have a lower risk of vitamin and mineral deficiency.\nPreliminary clinical research in a small number of children and adolescents with vitamin and mineral malabsorption due to celiac disease shows that taking a specific oligofructose-enriched inulin product (Orafti Synergy 1, BENEO GmbH) 10 grams daily for 3 months improves the absorption of vitamin D, vitamin E, and iron, but not vitamin A (99841, 99842). Levels of 25-hydroxy vitamin D and vitamin E increased by 42% and 19%, respectively, compared with no significant improvements in those taking placebo (99842). Although taking inulin did not improve serum ferritin levels, it did decrease serum hepcidin concentrations by 61% when compared with baseline, while no significant improvement was reported with placebo. Hepcidin is a regulator of iron homeostasis, and increased levels are associated with iron-deficiency anemia (99841).\nless\nChild growth. Oral inulin has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in healthy, exclusively formula-fed, infants less than 4 months of age shows that supplementing formula with 0.8 grams/dL of a specific combination product (Orafti Synergy1, Beneo-Orafti) containing 50% inulin and 50% fructo-oligosaccharide until 12 months of age does not improve markers of child growth, including body weight, length, and head circumference, when compared with placebo. The combination product was associated with a reduced duration of fever during infectious episodes, but not with a reduction in the number of infections. It is unclear if any potential effects are due to inulin, fructo-oligosaccharide, or the combination (107937).\nless\nChronic kidney disease (CKD). It is unclear if oral inulin is beneficial in patients with CKD.\nIn adults with CKD, adding inulin 19 grams daily for 6 months to a low-protein diet reduces serum insulin, fasting plasma glucose, total serum cholesterol, triglycerides, and markers of systemic inflammation, while increasing serum high density lipoprotein (HDL) cholesterol, when compared with baseline (105534). However, it is unclear if similar changes occur with a low-protein diet alone, or if the rate of progression of CKD is reduced. Population research in adults has found that high dietary intake of inulin over 8 years of follow up is not associated with a lower risk of CKD when compared with low dietary intake (110515).\nless\nHypercholesterolemia. It is unclear if oral inulin reduces cholesterol levels in patients with hypercholesterolemia.\nResearch in patients with hypercholesterolemia has shown mixed results, with some studies showing a small decrease and others showing no improvement in serum cholesterol levels (7604, 8450, 10412, 10413, 96849). A typical dose of inulin used is 6 grams orally three times daily for up to 6 weeks (10412). A meta-analysis of healthy, dyslipidemic, overweight or diabetic patients shows that inulin reduces levels of low-density lipoprotein (LDL) cholesterol by approximately 5% (96849). Another meta-analysis of randomized clinical trials in the same population shows that taking inulin 1.5-30 grams daily for 2-12 weeks reduces LDL cholesterol levels by 7 mg/dL and increases high-density lipoprotein cholesterol levels by 2 mg/mL when compared with control. However, this meta-analysis also included data from patients treated with fructo-oligosaccharides instead of inulin (107940).\nless\nHypertension. It is unclear if oral inulin is beneficial in patients with hypertension.\nPopulation research in adults has found that high dietary intake of inulin over 8 years of follow up is associated with a 21% lower risk of hypertension when compared with low dietary intake (110515).\nless\nHypertriglyceridemia. It is unclear if oral inulin is beneficial in patients with hypertriglyceridemia.\nA meta-analysis of clinical trials in normal and moderately hyperlipidemic patients suggests that taking inulin-type fructans at an approximate average dose of 14 grams daily reduces triglyceride levels by about 15 mg/dL when compared with control (93737). However, other research, including a meta-analysis of healthy, dyslipidemic, overweight or diabetic patients shows that taking inulin 1.5-30 grams daily for 2-12 weeks does not reduce triglyceride levels when compared with control. However, these negative studies are limited by small sample sizes and inclusion of data from patients treated with fructo-oligosaccharides instead of inulin (7604, 107940).\nless\nImpaired glucose tolerance (prediabetes). Several small clinical studies suggest that oral inulin is not beneficial in patients with prediabetes.\nPreliminary clinical research in adults with prediabetes shows that taking inulin 15 grams orally daily for 24 weeks does not improve fasting blood glucose, glycated hemoglobin (HbA1c), or lipid levels when compared with placebo. However, taking inulin modestly improved markers of insulin resistance (107938). Two other, small, clinical trials show that taking specific inulin products (Orafti Synergy 1, BENEO GmbH or Frutafit IQ, Sensus American) 10-30 grams daily for 6 weeks does not improve blood glucose, insulin resistance, glucose homeostasis, or insulin sensitivity when compared with placebo (93721, 107936). However, these studies may have been inadequately powered to detect a difference between groups.\nless\nIron deficiency anemia. Oral inulin has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in young adult females with iron deficiency anemia shows that taking inulin 963 mg/kg and iron supplementation orally daily for 3 months modestly improves serum hemoglobin, hematocrit, and iron levels when compared with a control group consuming iron-fortified flour (110599).\nless\nMenopausal symptoms. It is unclear if oral inulin is beneficial in patients with hypertriglyceridemia.\nPreliminary clinical research in adults experiencing menopause shows that consuming yogurt enriched with a specific inulin (Frutafit TEX, Sensus Company) 1.5% daily for 6 weeks moderately improves menopausal symptom scores, including depression, anxiety, and vasomotor symptoms, when compared with yogurt alone (107659).\nless\nNonalcoholic fatty liver disease (NAFLD). Taking oral inulin alone does not seem to improve liver transaminase levels in patients with NAFLD.\nPreliminary clinical research in patients with NAFLD shows that taking metronidazole 400 mg twice daily for one week plus inulin 4 grams twice daily for 12 weeks reduces levels of alanine aminotransferase and aspartate aminotransferase when compared with placebo. However, when inulin is taken without metronidazole, these measures are not improved (103200).\nless\nPolycystic ovary syndrome (PCOS). It is unclear if oral inulin is beneficial in patients with PCOS.\nPreliminary clinical research in overweight or obese females with PCOS shows that taking specific products containing inulin (FrutaFit TEX, Sensus American) or inulin and fructo-oligosaccharides (FrutaFit IQ, Sensus American) 10 grams orally once daily for 12 weeks does not reduce systolic or diastolic blood pressure when compared with placebo. However, the validity of this study is limited by the inclusion of subjects with and without hypertension at baseline (107941).\nless\nMore evidence is needed to rate inulin for these uses.",
            "Dosing & Administration": "Adult\nOral:\nInulin has been commonly used in doses of 10-40 grams daily for 4-8 weeks. See Effectiveness section for condition-specific information.\nChildren\nOral:\nInulin has been used in various combination products. Typical dosing for inulin alone is unavailable. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nIn one clinical trial, a specific inulin product (Fibruline Instant; Cosucra Groupe Warcoing) containing 15 grams inulin per sachet was standardized to contain a minimum of 90% dietary fiber (93724). In another study, inulin powder contained over 85% fructo-oligosaccharides, with an average chain length of seven monomers (93726).",
            "Interactions with Drugs": "ANTIDIABETES DRUGS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMODERATE\nOccurrence\nUNLIKELY\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, inulin might increase the risk of hypoglycemia with antidiabetes drugs.\nSome clinical research shows that inulin improves glycemic control in patients with diabetes; however, it is unclear if it has hypoglycemic effects (93719, 99843, 103198).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nCALCIUM\nInulin may increase calcium absorption, although this effect is not likely to be clinically significant.\nAnimal research shows that taking inulin with calcium modestly increases calcium absorption (103719, 103720). However, inulin appears to have no clinically significant effect on the absorption of dietary calcium. Inulin does not seem to affect ionized calcium, parathyroid hormone levels, or calcium excretion (8451, 10274).\nless\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, inulin might have hypoglycemic effects.\nTaking inulin with other supplements with hypoglycemic potential might increase the risk of hypoglycemia. Inulin improves glycemic control in some patients and might lower blood glucose levels (93719, 99843, 103198). See other products with hypoglycemic potential here.\nless\nMAGNESIUM\nInulin may increase magnesium absorption.\nAnimal research shows that taking inulin with magnesium modestly increases magnesium absorption (103719, 103720).\nless",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with inulin.",
            "Pharmacokinetics": "Absorption\nInulin is not digested or absorbed. Instead it promotes the growth of specific types of bacteria in the large intestine (7605, 8447, 10414, 96836, 96847). These bacteria produce short-chain fatty acids that are absorbed and metabolized (8449).",
            "Mechanism of Action": "General\nInulin is an oligosaccharide, composed of up to approximately 60 chains of glucose and fructose molecules. The major sources of inulin in the diet are wheat, onions, bananas, leaks, artichokes, and asparagus (10412, 10414). For supplements, inulin is usually obtained by hot water extraction from chicory root (7606, 93724). Because it contributes very little in dietary calories, inulin is used as a food additive to increase bulk and palatability (8449). Inulin is related to short-chain oligosaccharides (SCOs), which are often referred to as fructo-oligosaccharides (FOS). Partial hydrolysis of the longer chain inulin yields SCOs, which are usually 2 to 7 sugar molecules in length and have many of the same effects as inulin (7606). Inulin-like fructans consist of inulin, oligofructose, and fructo-oligosaccharides (FOS) (96849).\nAnti-inflammatory effects\nSome research suggests that inulin decreases levels of some inflammatory markers, including C-reactive protein (CRP), tumor necrosis factor-alpha, and interleukin (IL)-6 (93719, 96847). The anti-inflammatory effects of inulin may be related to its prebiotic effects (93719). A small clinical study in overweight or obese females with PCOS shows that taking inulin 10 grams orally once daily for 12 weeks reduces serum levels of CRP, but not nitric oxide or endothelin-1, when compared with placebo (107941).\nAntihypertensive effects\nPreliminary clinical research in patients with breast cancer undergoing chemotherapy shows that taking inulin 15 grams daily for 21 days decreases systolic blood pressure by 9.6 mmHg but does not improve diastolic blood pressure when compared with placebo (103199). The mechanism of inulin's antihypertensive effect is unclear.\nGastrointestinal effects\nThere is interest in using inulin to improve colonic inflammation and gastrointestinal symptoms. Preliminary clinical research in healthy adults shows that consuming a diet high in short-chain fatty acids, including inulin 8 grams, high amylose maize starch 20 grams, and apple cider vinegar daily, does not improve bowel movements or stool scores when compared with a diet low in short-chain fatty acids. However, the diet high in short-chain fatty acids did modestly reduce blood levels of circulating B cells and T cells (110603).\n\nMany studies in generally healthy infants, children, and adults show that taking inulin orally for 7-252 days increases the gastrointestinal abundance of Bifidobacterium and stool frequency when compared with control. However, these effects were not demonstrated in groups with baseline gastrointestinal disorders. In addition, the validity of these results is limited by high heterogeneity (110514, 110516).\nGlycemic effects\nInulin is considered a non-digestible carbohydrate. Because of this, it does not contribute to the glycemic response upon consumption. Replacing digestible carbohydrates in foods with inulin leads to a lower post-prandial glycemic response (99845). Inulin has been shown to upregulate gene expression and secretion of ghrelin and somatostatin, which might improve glycemic control through regulation of food intake and delayed gastric emptying, respectively (99843).\nHypolipidemic effects\nInulin is fermented in the gut to short-chain fatty acids, which promote the oxidation of fat (99844). Inulin decreases serum triglycerides by decreasing fatty acid synthesis and reducing production of very low density lipoproteins (7604, 8448).\nPrebiotic effects\nInulin has a prebiotic effect, meaning that it is not digested or absorbed, but instead promotes the growth of specific types of bacteria in the large intestine. Inulin has been suggested to preferentially promote the growth of bifidobacteria and lactobacillus (10414, 93717, 93724, 96836, 96847, 96848). Some clinical research in humans shows that taking oral inulin increases gut and fecal microbiota diversity; however, not all research agrees (107939).\n\nFermentation of inulin decreases fecal pH and increases fecal volume (7605, 8447, 10414). The products of fermentation are short-chain fatty acids that are absorbed and metabolized (8449). In human research, an increase in measurable short-chain fatty acids was not observed, possibly due to quick absorption (96836, 107939).\n\nInulin also appears to increase levels of plasma isoflavones in patients given soy isoflavone supplements. The prebiotic effects of inulin potentially play a role. It is possible that inulin increases the growth of bacteria that produce the enzyme glucosidase, resulting in easier absorption of the isoflavones (93725).\nWeight loss effects\nInulin's' effects on body weight are thought to be due to increased expression of glucagon-like peptide 1 (GLP-1) and reduced plasma ghrelin levels. Increased expression and secretion of GLP-1 produces delayed gastric emptying and increased feelings of satiety. Reduced ghrelin levels may reduce hunger (93722, 93723). However, in older adults with overweight or obesity, taking inulin 10 grams prior to a meal does not decrease energy intake at the meal (96851)."
        }
    },
    "Iodine": {
        "sections": {
            "Overview": "Iodine is a nonmetallic trace element that is needed for the production of thyroid hormone (16747, 91396). Iodine deficiency is a common world health problem and is thought to be the most common preventable cause of intellectual disability. The addition of iodine to salt has greatly reduced the prevalence of deficiency in the US and Canada (7135, 16747). Dietary sources of iodine other than iodized salt include seaweed and other marine products, eggs, and cow's milk (91396, 91398).",
            "Safety": "LIKELY SAFE when used orally and appropriately. Iodine is safe in amounts that do not exceed the tolerable upper intake level (UL) of 1100 mcg daily (7135, 103070). Higher doses can be safely used with appropriate medical monitoring (2197, 7080). In some regions of the world, such as Japan, daily dietary intake is estimated to be as high as 5,280-13,800 mcg without adverse outcomes (16747). ...when used topically and appropriately, as a 2% solution. A 2% iodine solution is an FDA-approved prescription product (15).\nPOSSIBLY UNSAFE when used orally in high doses. Tell patients to avoid prolonged use of doses exceeding the UL of 1100 mcg daily without proper medical supervision. There is concern that higher intake can increase the risk of side effects such as thyroid dysfunction, as well as thyroiditis, thyroid papillary cancer, thyrotoxicosis, and atrial fibrillation (7135, 55962, 56013). However, in some regions of the world such as Japan, daily dietary intake is estimated to be as high as 5,280-13,800 mcg without adverse outcomes (16747).\nCHILDREN: LIKELY SAFE when used orally and appropriately (7135). Iodine is safe in amounts that do not exceed the tolerable upper intake level (UL) of 200 mcg daily for children 1-3 years, 300 mcg daily for children 4-8 years, 600 mcg daily for children 9-13 years, and 900 mcg daily for adolescents (7135). ...when used topically as a 2% solution (15). Iodine is an FDA-approved prescription product.\nCHILDREN: POSSIBLY UNSAFE when used orally in doses exceeding the UL (7135, 108709). Higher intake can cause thyroid dysfunction (7135) and may be associated with a modest reduction in intelligence (108709).\nPREGNANCY AND LACTATION: LIKELY SAFE when used orally and appropriately. Iodine is safe in amounts that do not exceed the tolerable upper intake level (UL) of 1100 mcg daily in those 18 years and older or 900 mcg daily in those 14-18 years of age (7135, 103070). Iodine needs increase during pregnancy and lactation and adequate intakes should begin as soon as a patient is aware of the pregnancy, or earlier in areas of potential deficiency (17920). ...when used topically as a 2% solution (15). Iodine is an FDA-approved prescription product.\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally in doses exceeding the UL. Higher intake can cause thyroid dysfunction (7135). Also, higher intakes during pregnancy cause increased iodine levels in breast milk and infant blood samples. Higher iodine intake during pregnancy has also been associated with an increased risk of congenital hypothyroidism and reduced mental and physical development in the offspring (56089, 91390, 91394, 91395).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, iodine is well tolerated when taken in amounts that do not exceed the tolerable upper intake level (UL) or when used therapeutically with appropriate medical monitoring (2197, 7080, 7135).\nMost Common Adverse Effects\nOrally: Abdominal upset, diarrhea, goiter, headache, hyperthyroidism, hypothyroidism, metallic taste, nausea, rhinorrhea, thyroid adenoma.\n\nTopically: Burns, dermatitis, irritation.\nSerious Adverse Effects (Rare)\nAll ROAs: Hypersensitivity reactions such as anaphylaxis and angioedema.\nDermatologic\nOrally, taking iodine chronically or in large amounts has been reported to cause acneform skin lesions called iododerma (2138). In one case, a patient developed iododerma after consuming a specific product (Hoxsey's Brown Tonic) containing an unspecified quantity of potassium iodide. After several months of consumption, the patient developed acneform skin lesions on the nose, cheeks, and upper back and presented with a urine iodine level of 7,455,647 ug/L (reference range: 34-523 ug/L). After discontinuation of potassium iodide, the lesions resolved gradually over the course of several weeks (95431).\n\nTopically, iodine may stain skin, irritate tissues, and cause sensitization in some individuals (15, 56106). Iodine burns are associated with application of 7% hydroalcoholic solution (15). Povidone-iodine may cause contact dermatitis or irritant reactions in some people. However, patch testing with potassium iodide is usually negative in these patients, indicating that contact dermatitis caused by topical iodine does not indicate a propensity for reaction to oral potassium iodide (93001).\nless\nEndocrine\nProlonged use and/or large oral doses of iodine intake can cause thyroid gland hyperplasia, thyroid adenoma, goiter, and hypothyroidism (15, 56013, 56089, 91397, 91398, 99793, 99795). In another case report, an infant presented with reversible hypothyroidism at birth because the mother had consumed excessive seaweed soup during and after pregnancy, which resulted in excessive iodine consumption (99795). Iodine has also been linked to rare cases of adverse events. In one case report, a 56-year-old male developed thyrotoxic hypokalemic paralysis thought to be related to excessive intake of iodine (91401).\n\nTopically, using povidone-iodine (PI) 1% solution as a gargle and nasal spray, in addition to intranasal application of PI 10% ointment over 5 days, can precipitate subclinical hypothyroidism, with elevated thyroid stimulating hormone (TSH) and normal thyroid hormone levels. TSH levels seem to normalize about 7-12 days after stopping topical PI application (105877).\nless\nGastrointestinal\nOrally, the commonly reported adverse effects of a saturated solution of potassium iodide (SSKI) are nausea (14%), abdominal pain (14%), metallic taste (4%), and diarrhea (4%) (17561). These side effects can be minimized by avoiding quick dosage increases (17574). Taking iodine chronically or in large amounts has also been reported to cause soreness in teeth and gums, burning in mouth and throat, increased salivation, swelling of parotid and submaxillary glands, inflammation of the respiratory tract, gastric upset, and diarrhea (15, 2138).\n\nIntranasally, applying povidone-iodine 1% solution along with a 10% ointment can cause unpleasant nasal tingling (105877).\nless\nImmunologic\nPeople who are allergic to iodine-containing foods or drugs are sometimes stated to have \"iodine allergy\", but the actual allergen is another agent such as seafood proteins or radiocontrast media (93001). However, some people can be hypersensitive to iodine when used orally. Symptoms of hypersensitivity can include angioedema, cutaneous and mucosal hemorrhage, fever, arthralgia, lymph node enlargement, eosinophilia, urticaria, erythema, and thrombotic thrombocytopenic purpura (15, 17561). Other reported side effects include potassium toxicity, metabolic acidosis, pustular psoriasis, and vasculitis (17574). However, such sensitivity is very rare (93001). Orally, iodine hypersensitivity can cause fatal periarteritis (15).\nless\nNeurologic/CNS\nOrally, common side effects of a saturated solution of potassium iodide (SSKI) have included headache (7%) (17561). Side effects can be minimized by avoiding quick dosage increases (17574).\n\nHigh intake of iodine may be associated with adverse cognitive outcomes in children. Observational research in children aged 7-14 years has found that those consuming drinking water with iodine concentrations above 900 mcg/L daily, which exceeds the tolerable upper intake level, is associated with a 1.6-point reduction in intelligence level when compared with those consuming water with iodine concentrations below 300 mcg/L (108709).\nless\nOcular/Otic\nOrally, taking iodine chronically or in large amounts has been reported to cause eye irritation and eyelid swelling (15, 2138).\nless\nPulmonary/Respiratory\nOrally, common side effects of a saturated solution of potassium iodide (SSKI) included rhinorrhea (11%) (17561). Side effects can be minimized by avoiding quick dosage increases (17574). Taking iodine chronically or in large amounts has also been reported to cause coryza, sneezing, cough, and pulmonary edema (15, 2138). Ophthalmically, povidone-iodine 5% solution 3 drops administered in each eye has been reported to slow respiration by about 18 seconds (range 4 to 96 seconds) when compared with saline control in children ages 2-17 years undergoing strabismus surgery (103077).\nless\nRenal\nWhen povidone-iodine was used in renal pelvic instillation sclerotherapy, one patient (2%) had significant flank pain during treatment (55970).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nLIKELY EFFECTIVE\nIodine deficiency. Oral iodine supplements, including iodized salt, are effective for improving iodine status and reducing goiter size in adults and children. Iodine supplementation is also recommended during pregnancy in areas at risk for iodine deficiency.\nIodine deficiency is associated with several adverse outcomes. The earliest clinical symptom of iodine deficiency is low circulating thyroid hormone and thyroid stimulating hormone (TSH), followed by thyroid goiter (7135, 16747, 91398). Iodine deficiency and subsequent hypothyroidism can lead to anovulation, infertility, autoimmune thyroiditis, and gestational hypertension. Iodine deficiency is also associated with increased risk of thyroid cancer (16747). Clinical research shows that taking iodine supplements, including iodized salt, improves iodine status and reduces goiter size in adults with iodine deficiency (16747, 55919, 103071). Studies also show that taking iodine supplementation, including iodized salt, in areas of endemic iodine deficiency, reduces goiter size in children (16747, 55919).\n\nWhen taken during pregnancy for iodine deficiency, iodine supplements and iodized salt reduce both maternal and newborn thyroid size and thyroglobulin; however, the effect on maternal TSH is inconsistent (91399, 103070). Although some clinical studies and one analysis show that perinatal use of iodine has no effect on the incidence of thyroid disorders during pregnancy (91399, 97240, 97241), one analysis shows that iodine supplementation reduces the risk of postpartum hyperthyroidism by 68% when compared with placebo (97240). Taking iodine supplementation before 12 weeks' gestation appears to be more effective than when taken later in pregnancy. Perinatal iodine supplementation has no effect on preterm birth rate (97240, 97241). Evidence is limited to females with mild-moderate iodine deficiency; the routine use of iodine supplementation during pregnancy has not been extensively studied. For example, the effect of perinatal supplementation on newborn neurocognitive development is conflicting and the evidence is generally low quality (55976, 97241, 105880, 108706). Despite the limited evidence, iodine supplementation is recommended in areas at risk of deficiency.\nless\nRadiation exposure. Oral potassium iodide prevents thyroid uptake of radioactive iodine. However, it does not protect against other sources of radiation.\nTaking potassium iodide is effective for preventing the uptake of radioactive iodine by the thyroid (7517, 7518). Doses of potassium iodide protect for about 24 hours. Therefore, it should be taken daily until the risk of radiation exposure no longer exists (17575, 17576).\nless\nPOSSIBLY EFFECTIVE\nConjunctivitis. Ophthalmic povidone-iodine solution seems to reduce the risk of conjunctivitis in infants. It may also improve the resolution of acute conjunctivitis in adults. It is unclear if it is beneficial in patients with adenoviral conjunctivitis.\nA meta-analysis of low-quality clinical trials shows that povidone-iodine solutions are more effective than silver nitrate for preventing neonatal conjunctivitis. However, povidone-iodine solutions are not more effective than erythromycin or chloramphenicol (56084). Povidone-iodine in combination with dexamethasone also seems to be helpful in adults. A clinical trial in patients with acute viral conjunctivitis shows that applying povidone-iodine 0.6% with dexamethasone 0.1% four times daily for 4 days improves clinical symptoms and eradiation of viral counts when compared with placebo control (103075).\n\nA small clinical study in adults with adenoviral conjunctivitis shows that administering 4-5 drops of a povidone-iodine 5% eye drop solution within 4 days of symptom onset decreases viral load, mucoid discharge, and bulbar edema and redness on day 4 of a 21-day follow-up period, but at no other time points, when compared with a single dose of artificial tears (108705). Due to the single-dose nature of this study, the effects of continued administration are unclear.\nless\nDiabetic foot ulcers. Topical iodine seems to help with the management of diabetic foot ulcer wounds.\nA small clinical study in patients with diabetic foot ulcers shows that topically applying cadexomer iodine ointment (Iodosorb) for 12 weeks seems to improve healing to a similar degree as using standard treatment with gentamicin solution, streptokinase, and/or dry saline gauze (2200).\nless\nEndometritis. Topical application of iodine prior to cesarean delivery seems to reduce the risk of endometritis.\nA meta-analysis of eight clinical trials shows that vaginally applying povidone-iodine 1% to 10% solution immediately before cesarean delivery reduces the risk of post-cesarean endometritis by 62% when compared with saline or no cleaning. It also reduces postoperative fever by 13% and wound infection by 23% (99794). These findings are consistent with other meta-analyses (56080, 103076). There seems to be no difference in benefit whether povidone-iodine 1%, 5%, or 10% is used. A network meta-analysis of clinical studies in patients having cesarean delivery suggests that povidone-iodine is no better at preventing endometritis than using chlorhexidine or metronidazole; however, there may not have been sufficient power to detect a difference (103076).\nless\nFibrocystic breast disease. Oral iodine seems to reduce breast pain in patients with fibrocystic breast disease.\nPreliminary clinical research in patients with fibrocystic breast disease shows that taking sodium iodide, protein bound iodide, or molecular iodine for 6 months or longer improves mastalgia and reduces breast nodules when compared with baseline or control. Molecular iodine in doses of 70-90 mcg/kg appears to be more effective and better tolerated than the other forms (2197). Another clinical study in patients with cyclic mastalgia due to fibrocystic breast disease shows that taking tablets containing molecular iodine 3000-6000 mcg daily for 5 months reduces pain, tenderness, and nodularity in patients with cyclic mastalgia when compared with placebo. However, a lower dose of 1500 mcg daily does not appear to be beneficial (55960).\nless\nOral mucositis. Rinsing the mouth with a povidone-iodine solution may prevent oral mucositis from radiochemotherapy.\nSmall clinical studies in patients receiving radiation and chemotherapy for cancer shows that using an oral povidone-iodine rinse seems to reduce the risk for oral mucositis when compared with using sterile water (2198, 2199).\nless\nPeriodontitis. Rinsing with povidone-iodine solution in addition to scaling and root planing seems to be modestly beneficial in patients with periodontitis.\nA meta-analysis of mostly small clinical studies in patients with chronic periodontitis suggests that rinsing with povidone-iodine 0.1% to 10% during scaling and root planing modestly reduces the periodontal pocket depth when compared with rinsing with water or saline solution (56072).\nless\nPostoperative infection. Povidone-iodine antisepsis prevents postoperative infection when compared with inactive controls such as normal saline and water. However, it is unclear how it compares to active controls such as chlorhexidine; practice guidelines are conflicting.\nA meta-analysis of clinical research shows that intraoperative application of povidone-iodine reduces the risk of surgical site infection by approximately 40% when compared with saline or no irrigation (56088). However, research comparing povidone-iodine with other antiseptics such as chlorhexidine is conflicting, as are official guidelines for surgical antisepsis. Many of these discrepancies seem to be related to the presence or absence of alcohol in the preparation. A meta-analysis of clinical research comparing aqueous or alcohol-based povidone-iodine shows that using alcohol-based chlorhexidine for skin antisepsis is more effective for preventing postoperative surgical site infections and may be associated with a lower overall positive culture rate. However, since evidence for both aqueous and alcohol-based solutions of povidone-iodine were included in this study, it is unclear if this may have affected outcomes (108710). The National Institute for Health and Care Excellence (NICE) Guideline recommends chlorhexidine solution as the first choice for preparing the skin for surgery, with povidone-iodine solution as a second-line option. The antiseptic solutions are recommended to be alcohol-based as long as the surgical site is not near a mucous membrane (105906). The World Health Organization (WHO) guidelines also recommend alcohol-based chlorhexidine solutions over either alcohol-based or aqueous povidone-iodine for preventing surgical site infections. However, some experts have expressed concern that these recommendations are based on faulty evidence, as some studies used povidone-iodine preparations with lower alcohol amounts than their comparator groups (105898). In fact, the guideline from the Centers for Disease Control and Prevention (CDC) does not differentiate between povidone-iodine and chlorhexidine antiseptic solutions as long as they are alcohol-based (105905).\nless\nThyroid storm. Oral iodine is recommended as an adjunct to standard treatment for thyroid storm.\nThe American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE) recommend a multimodality approach for treating thyroid storm that includes taking five drops of a saturated solution of potassium iodine every 6 hours (15, 92699).\nless\nVenous leg ulcers. Topical cadexomer iodine seems to improve the healing of venous leg ulcers; however, it is unclear if applying povidone-iodine is beneficial.\nA meta-analysis of four small clinical studies in patients with venous leg ulcers shows that applying cadexomer iodine results in complete healing of ulcers in 33% of patients after 4-12 weeks, compared with only 15% of patients receiving standard care alone. However, use of cadexomer iodine was associated with more adverse effects than standard care. Furthermore, preliminary clinical research shows that applying cadexomer iodine is comparable to hydrocolloid dressing, paraffin gauze dressing, dextranomer, and silver-impregnated dressings for improving the rate of complete healing. A meta-analysis of preliminary clinical research show that povidone-iodine has comparable healing rates when compared with amoxicillin, hydrocolloid dressings, and moist or foam dressings (99798). These findings were consistent with an older version of this meta-analysis (56076).\nless\nThyroid nodules. Combining oral iodine with thyroxine seems to improve the resolution of thyroid nodules.\nA clinical study in patients with benign nodular thyroid disease and possible iodine deficiency shows that taking iodized salt 200 mcg daily in addition to thyroxine 1.5 mcg/kg daily after surgery seems to reduce the size of the thyroid remnant by 40%, compared with a 10% reduction in patients given thyroxine alone (55927). Also, one large clinical trial in patients with nodular goiter shows that taking potassium iodide 150 mcg daily in combination with levothyroxine 50-100 mcg daily for 12 months reduces nodule volume by about 17%, compared with 7% in the group using levothyroxine alone (91392).\nless\nPOSSIBLY INEFFECTIVE\nCatheter-related infections. Topical povidone-iodine seems to be less effective than chlorhexidine for preventing infections from intravascular catheters. Furthermore, it does not seem to reduce the risk of catheter-related urinary tract infections.\nOne meta-analysis of clinical research shows that topical application of povidone-iodine reduces the risk of bloodstream infections when applied at the insertion site of hemodialysis central venous catheters (55883). However, disinfecting catheter insertion sites using povidone-iodine seems to be less effective for preventing blood stream infections in patients receiving central venous, pulmonary artery, or peripheral artery catheters when compared with chlorhexidine solutions (55883, 55916).\n\nIn addition, periurethral cleansing with povidone-iodine 10% prior to bladder catheterization, as well as bladder irrigation with povidone-iodine 2% prior to urinary catheter removal, does not seem to reduce the risk of urinary tract infections when compared with placebo (56058, 56126).\nless\nPrematurity. Maternal iodine supplementation does not seem to impact neurological development in premature infants.\nA meta-analysis of two clinical trials in premature infants shows that adding iodine to enteral or parenteral feeds does not improve mental, visual, or auditory development or reduce the risk of death when compared with no iodine supplementation (99797).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nChyluria. It is unclear if topical iodine is beneficial in patients with chyluria.\nA small clinical study in patients with chyluria suggests that using povidone-iodine 0.2% solution as a sclerosant in renal pelvic instillation sclerotherapy (RPIS) may be as effective as using silver nitrate 1% (55970).\nless\nCorneal ulceration. It is unclear if topical iodine is beneficial in patients with corneal ulceration.\nPreliminary clinical research shows that administering povidone-iodine 2.5% eye drops every two hours for two weeks in addition to standard antibiotic therapy does not reduce visual impairment in patients with corneal ulcers when compared with standard antibiotic therapy alone (55971).\nless\nCoronavirus disease 2019 (COVID-19). It is unclear if rinsing with a povidone-iodine mouthwash and using a povidone-iodine nasal spray and ointment can reduce the spread of COVID-19.\nA small clinical study in adults with PCR-confirmed COVID-19 shows that orally swishing and gargling 25 mL of povidone-iodine (PI) 1% solution, then, into each nostril, spraying 2.5 mL of PI 1% solution and applying one dab of PI 10% ointment, and repeating this 4 times daily for 5 days does not seem to alter the quantity of viral RNA over time when compared with control (105877). The validity of this finding is limited because all study participants achieved negative viral titers on the third day of the study.\nless\nCutaneous sporotrichosis. It is unclear if topical iodine is beneficial in patients with cutaneous sporotrichosis; research is conflicting.\nAnecdotal reports and case series suggest that taking saturated solution of potassium iodide (SSKI) orally is effective for most patients when used alone or in combination with another antifungal, including terbinafine or itraconazole (17562, 17563, 17564, 17565, 17566, 17567, 17568, 17569, 17570, 17571) (17572, 17573). In one non-controlled clinical study, treatment with SSKI, starting with 3 drops (150 mg potassium iodide) daily and titrating up, resulted in symptom resolution in about 90% of patients after about 33 days of treatment (17561). However, some patients are not able to take SSKI due to intolerable side effects (17561, 17572).\nless\nHyperthyroidism. It is unclear if oral potassium iodide is beneficial for patients with Graves' disease undergoing total thyroidectomy.\nA retrospective study in patients with Graves' disease undergoing total thyroidectomy shows that preoperative administration of saturated solution of potassium iodide (SSKI) 5% does not reduce the rate of postoperative complications, such as transient or permanent hypoparathyroidism, transient recurrent laryngeal nerve (RLN) palsy, definitive RLN palsy, and cervical hematoma, when compared with no preoperative administration (108707).\nless\nInfant development. It is unclear if maternal iodine supplementation impacts neurological development in infants.\nThree-year follow-up data from a clinical study in infants and breastfeeding females shows that maternal supplementation of iodine 150 mcg daily improves child cognitive scores, but does not affect language or motor scores, when compared with placebo. Supplementation with a higher dose of 300 mcg daily yielded similar cognitive, language, and motor scores as the 150 mcg dose (108706). This finding aligns with the daily recommended dietary allowance (RDA) of 290 mcg during lactation, which is sometimes achieved by augmenting the diet with a 150-mcg iodine supplement (7135).\nless\nRhinosinusitis. It is unclear if topical iodine is beneficial in patients with rhinosinusitis.\nA small prospective cohort study in patients with recalcitrant chronic rhinosinusitis has found that using a povidone-iodine 0.08% nasal rinse every other day for 7 weeks in addition to standard therapy improves symptoms and reduces signs of infection when compared with baseline (103074). However, one small clinical study in patients with a history of sinus surgery and acute exacerbations of chronic sinusitis shows that receiving povidone-iodine nasal irrigations twice daily for 30 days is no different than irrigations with mupirocin or normal saline for improving nasal symptoms. However, mupirocin tended to reduce bacteria count to a greater extent than the povidone-iodine solution (105878). This finding is limited due to small study size and potential lack of power to detect differences between groups.\nless\nThyroid cancer. It is unclear if dietary iodine is associated with complications in patients with papillary thyroid cancer.\nA retrospective study in patients in China with papillary thyroid cancer has found that dietary intake of iodine resulting in serum concentrations greater than 90 mcg/L is associated with a 75% increased risk of cervical lymph node metastases when compared with concentrations less than 45 mcg/L (108708). Actual dietary intake of iodine was not reported, limiting the validity of this finding.\nless\nVentilator-associated pneumonia (VAP). It is unclear if oral iodine rinse is beneficial for the prevention of VAP.\nA small clinical study in patients with severe head trauma suggests that regularly rinsing the throat with 20 mL of povidone-iodine 10% solution decreases the risk for VAP when compared with using a saline rinse (56003).\nless\nWound healing. It is unclear if topical iodine is beneficial for wound healing.\nA meta-analysis of clinical research shows that topical iodine, as cadexomer iodine or povidone-iodine, is superior to non-antiseptic dressings and some antiseptic agents, such as silver sulfadiazine, for reducing wound size. However, iodine seems to be less effective than local antibiotics such as rifamycin (56083).\nless\nPostoperative bleeding. It is unclear if topical iodine is beneficial in patients with postoperative bleeding.\nA small clinical study suggests that irrigating extraction sockets with povidone-iodine 1% stops bleeding in a greater number of patients following tooth extraction when compared with a saline solution (56011).\nless\nMore evidence is needed to rate iodine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: The National Academy of Medicine has set the daily recommended dietary allowance (RDA) for adults at 150 mcg daily (7135). During pregnancy, the RDA is 220 mcg daily; during lactation, the RDA is 290 mcg daily (7135). Dosing of supplemental iodine varies; see Effectiveness section for condition-specific information.\n\nConsuming goitrogens, which are present in raw cruciferous vegetables, may interfere with the uptake of iodine by the thyroid (20777).\nTopical:\nIodine, in the form of povidone-iodine and cadexomer iodine, has been used in various topical formulations, such as eye drops, irrigation solution, mouthwash, ointment, and scrubs. See Effectiveness section for condition-specific information.\nChildren\nOral:\nGeneral: The National Academy of Medicine has set daily adequate intake (AI) levels of iodine for infants at 110 mcg daily for 0-6 months of age and 130 mcg daily for 7-12 months of age (7135). For children, the daily recommended dietary allowance (RDA) by age is: 1-8 years, 90 mcg daily; 9-13 years, 120 mcg daily; 14 years and older, 150 mcg daily (7135). During pregnancy, the RDA is 220 mcg daily; during lactation, the RDA is 290 mcg daily (7135). Dosing of supplemental iodine varies; see Effectiveness section for condition-specific information.\nStandardization & Formulation\nIodine exists in several forms including potassium and sodium salts, as well as inorganic or organic forms (16747). Potassium iodide is one of the most common salt forms used. It is made up of 76% halogen iodine and 23% alkali metal potassium. This form of iodine is usually used as a saturated solution of potassium iodide (SSKI), which contains 47 mg of potassium iodide per drop of solution (17574). Lugol's solution is another common form of iodine. It contains 5% molecular iodine and 10% potassium iodide in solution (16747).\n\nIn clinical trials, iodine is often taken orally as iodized salt (55919, 91399). Topically, iodine is often applied as solutions or ointments containing povidone-iodine 0.1% to 10% (2198, 2199, 2200, 56072). Chemically, povidone-iodine is a stable complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine (92700). A specific povidone-iodine 10% solution (Betadine 10% solution) has been used as a throat rinse and for colonic irrigation (56003, 56153).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nAMIODARONE (Cordarone)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nCombining iodine with amiodarone might cause excessively high iodine levels.\nAmiodarone contains 37.3% iodine and can increase iodine levels. Concomitant use with iodine might increase the risk of having excessive iodine levels and adversely affecting thyroid function (7135, 17574). Monitor thyroid function.\nless\nANTITHYROID DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIodine might alter the effects of antithyroid drugs.\nIodine in high doses has been reported to cause both hyperthyroidism and hypothyroidism, depending on the individual's past medical history. Taking iodine while using antithyroid drugs could alter the effects of the antithyroid drugs (2138, 17574).\nless\nLITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nCombining iodine with lithium might have additive hypothyroid effects.\nLithium can inhibit thyroid function. Several case reports suggest that concomitant use of lithium and potassium iodide can reduce thyroid function in otherwise healthy adults (17574). Monitor thyroid function.\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nDERMATITIS HERPETIFORMIS\nIodine can exacerbate dermatitis herpetiformis (17574, 17575, 20758). Avoid iodine in these patients.\nless\nTHYROID DISEASE\nExcessive iodine can exacerbate thyroid dysfunction. Prolonged use or excessive amounts of iodides may cause or exacerbate thyroid gland hyperplasia, thyroid adenoma, Graves' disease, goiter, and hypothyroidism (15, 91393). Patients with autoimmune thyroid disease (AITD) may have increased sensitivity to the adverse effects of iodine (7135, 91393). Also, a retrospective study in patients with papillary thyroid cancer has found that dietary intake of iodine resulting in serum concentrations greater than 90 mcg/L is associated with a 75% increased risk of cervical lymph node metastases when compared with concentrations less than 45 mcg/L (108708).\nless",
            "Interactions with Lab Tests": "None.",
            "Overdose": "Presentation\nOrally, taking iodine chronically or in large amounts can cause various adverse effects, including soreness in teeth and gums, burning in mouth and throat, increased salivation, coryza, eye irritation and eyelid swelling, pulmonary edema, swelling of parotid and submaxillary glands, inflammation of the respiratory tract, acneform skin lesions, gastric upset, diarrhea, anorexia, and depression (15, 2138).\n\nSystemic exposure to povidone-iodine intended for topical use can cause toxicity with symptoms of nausea, vomiting, diarrhea, metabolic acidosis, hypotension, tachycardia, and cyanosis. In one case report, a 17-year-old male reported to the emergency room with hypoxia, hypotension, and bradycardia after accidentally consuming povidone-iodine that was mistaken for a coffee drink (15, 2138, 105879).\n\nOrally, overdose with potassium iodate 187 mg/kg or more can cause retinal toxicity and vision loss. In one case report, a 42-year-old male ingested 2 cups of pure iodine as a suicide attempt and was admitted to the emergency room with bilateral irreversible vision loss (105700).\nTreatment\nToxicity from systemic exposure to povidone-iodine has been treated with emergency endotracheal intubation along with intravenous furosemide for edema (105879). Vision loss from potassium iodate toxicity has been treated with prednisolone and vitamins B1, B2, and B6, increasing vision recovery in some patients (105700).",
            "Pharmacokinetics": "Absorption\nWhen taken orally, iodine is absorbed through the stomach and duodenum (17920). Iodine absorption from milk with high intrinsic iodine (inorganic iodide), milk fortified with iodine, and aqueous iodine solution, seems to be about the same (range 72% to 98%) in humans (103078). From seaweed, oral potassium iodide has been found to be almost completely (96.4%) absorbed in humans (55922). When applied topically, iodine can be absorbed through intact skin (56056, 91396).\nDistribution\nThe thyroid gland concentrates about 30% of the body's iodine (7135, 17574), which is incorporated into thyroid hormones (91396, 17920). Iodine comprises 65% of thyroxine (T4) and 59% of triiodothyronine (T3) (16747). Lesser amounts of iodine are found in the salivary glands, breast, choroid plexus, and gastric mucosa tissues (7135, 17574). Iodine is also available in breast milk (55888).\nMetabolism\nWhen taken orally, iodine is converted to iodide (91396).\nExcretion\nIodine is excreted mainly in the urine, with small amounts in feces, sweat, and saliva (16747, 7135, 17574, 16747, 91396, 91397). Loss in urine appears to increase during pregnancy (17920).",
            "Mechanism of Action": "General\nIodine is an essential nutrient in humans. The iodine content of most foods is low and is affected by agricultural factors such as soil quality and climate. Most iodine is found in the oceans. Coastal soils have higher soil concentrations of iodine than inland soils. Marine animals concentrate iodine from seawater and have a higher content than most other foods (7135). Seaweed, which is commonly consumed in Asian cultures, also contains a high concentration of iodine (16747). Processed foods may add to dietary iodine due to the addition of iodate to salt. In North America, average daily iodine intake is 167 mcg. In other regions, such as Japan, average daily intake is estimated to be about 5280 mcg to 13,800 mcg (16747).\nAntimicrobial effects\nWhen used topically, iodine oxidizes organic substrates, killing microorganisms (15).\nAntioxidant effects\nIn some tissues, iodine can have an antioxidant effect (16747, 91396). It is thought that in the presence of hydrogen peroxide, peroxidase, and some unsaturated fatty acids, iodine donates an electron, thus decreasing damage due to oxygen free radicals (91396).\nEndocrine effects\nThe thyroid gland in humans concentrates about 30% of the body's iodine for thyroid hormone synthesis (7135, 17574). Iodine comprises 65% of thyroxine (T4) and 59% of triiodothyronine (T3). These iodine-rich thyroid hormones control many biochemical reactions, particularly protein synthesis and enzymatic processes. In people with hyperthyroidism, iodine inhibits the release and synthesis of thyroid hormone (16747).\nHemostatic effects\nClinical research suggests that povidone-iodine solution helps stops bleeding associated with tooth extraction. This effect has been attributed to the oxidizing potential of iodine resulting in corrosion, as well as the thickening and granulating properties of povidone (56011).\nNeurological effects\nThyroid hormone is responsible for myelination of the developing central nervous system. As a result, iodine deficiency is associated with intellectual disability, which in some cases can be severe (7135). Most developed countries, including the US and Canada, screen for hypothyroidism at birth (7135).\nRadioprotective effects\nIodine in the form of potassium iodide can block or reduce the accumulation of radioactive iodine and damage to the thyroid gland if taken prior to or immediately following exposure to radioactive iodine (7517, 7518).\nRespiratory effects\nIodide salts, such as potassium iodide, might increase respiratory tract secretions and thereby decrease mucus viscosity, but there is limited supporting evidence for this effect (15)."
        }
    },
    "IP-6": {
        "sections": {
            "Overview": "Inositol hexaphosphate (IP-6) is a polyphosphorylated carbohydrate. IP-6 is present in high amounts in plant foods like cereals, legumes, seeds, and nuts. It is also produced in the human body (97608, 97609).\n\nKEY HIGHLIGHTS\nMost commonly used for treating and preventing various types of cancer, but there is insufficient reliable evidence to rate its effectiveness for these or other conditions.\nLikely safe when consumed in the amounts found in food. Possibly safe when used orally and appropriately, short-term. Side effects are rare.\nNo known major interactions.",
            "Safety": "LIKELY SAFE when consumed in amounts commonly found in foods (1854).\nPOSSIBLY SAFE when used orally and appropriately, short-term. IP-6 600 mg twice daily has been used with apparent safety for up to 2 weeks (102320).\n\nThere is insufficient reliable information available about the safety of IP-6 when used orally in higher doses or for longer than 2 weeks or when used topically.\nPREGNANCY AND LACTATION: LIKELY SAFE when consumed in amounts commonly found in foods (1854). There is insufficient reliable information available about the safety of IP-6 when used in amounts greater than those found in foods; avoid using.",
            "Adverse Effects": "General\nOrally, IP-6 is well tolerated when consumed in amounts commonly found in foods (1854). No adverse effects have been reported when IP-6 is used in medicinal amounts; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nChemotherapy-induced leukopenia. Two very small clinical studies show that topical application with IP-6 200 mg or oral intake of IP-6 plus inositol 6 grams daily for 6 months attenuates a reduction in white and red blood cell counts when compared with a control group. Some patients also reported an improvement in quality of life (97608, 97609).\nIn addition, a small clinical study in adults undergoing breast cancer surgery and adjuvant chemotherapy shows that applying IP-6 gel 4% twice daily to the surgical site and taking inositol orally 390 mg twice daily, starting 2 weeks before adjuvant chemotherapy and stopping 2 weeks after the last cycle, attenuates the reduction in white and red blood cell counts when compared with no intervention. Using IP-6 and inositol also improved breast and arm symptom scores, and some quality of life scores; however, these improvements were not consistently demonstrated over time. It is unclear if any effects are due to IP-6, inositol, or the combination (106680).\nless\nGout. Preliminary clinical research in adults with asymptomatic hyperuricemia shows that taking IP-6 600 mg twice daily for two weeks reduces fasting uric acid levels when compared with control. It is unclear if this reduction in uric acid levels would result in symptom improvement in patients with symptomatic gout (102320).\nMore evidence is needed to rate IP-6 for these uses.",
            "Dosing & Administration": "Adult\nOral:\nChemotherapy-induced leukopenia: A combination of IP-6 plus inositol, taken as 6 grams daily in two divided doses for 6 months, has been used (97609).\n\nGout: IP-6 600 mg twice daily for two weeks has been used in patients with asymptomatic hyperuricemia (102320).\nTopical:\nChemotherapy-induced leukopenia: 5 grams of a 4% topical formulation providing IP-6 200 mg once to twice daily for 6-18 months has been used alone or in combination with oral inositol 390 mg twice daily (97608, 106680).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of IP-6.",
            "Interactions with Drugs": "ANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nUNLIKELY\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, concomitant use of IP-6 with drugs that affect platelet aggregation may increase the risk of bleeding. In vitro IP-6 can inhibit platelet aggregation (1867). This effect has not been demonstrated in humans.",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, concomitant use of IP-6 with herbs that affect platelet aggregation might increase the risk of bleeding. In vitro IP-6 can inhibit platelet aggregation (1867). This effect has not been demonstrated in humans. Herbs with potential anticoagulant or antiplatelet properties include angelica, clove, danshen, garlic, ginger, ginkgo, Panax ginseng, red clover, turmeric, and others.\nCALCIUM\nConcurrent use of IP-6 may decrease mineral absorption. IP-6 can chelate multivalent metal ions in the gastrointestinal tract, forming insoluble salts and decreasing mineral absorption (1858).\nIRON\nConcurrent use of IP-6 may decrease mineral absorption. IP-6 can chelate multivalent metal ions in the gastrointestinal tract, forming insoluble salts and decreasing mineral absorption (1858).\nZINC\nConcurrent use of IP-6 may decrease mineral absorption. IP-6 can chelate multivalent metal ions in the gastrointestinal tract, forming insoluble salts and decreasing mineral absorption (1858).",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nCLOTTING DISORDERS\nTheoretically, IP-6 may increase risk of bleeding (1867). In vitro, IP-6 can inhibit platelet aggregation (1867). This effect has not been demonstrated in humans.\nless\nIRON-DEFICIENCY ANEMIA\nIP-6 might decrease dietary and supplemental iron absorption. IP-6 chelates multivalent metal ions in the gastrointestinal tract, preventing absorption (1858).\nless\nOSTEOPOROSIS/OSTEOPENIA (Paget's Disease)\nIP-6 may decrease dietary and supplemental calcium absorption. IP-6 chelates multivalent metal ions in the gastrointestinal tract, preventing absorption (1858).\nless\nSURGERY\nIP-6 has antiplatelet effects. IP-6 might cause excessive bleeding if used perioperatively. Tell patients to discontinue IP-6 at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of IP-6.",
            "Pharmacokinetics": "Absorption\nSome scientists have claimed that dietary or supplemental IP-6 is absorbed by the intestinal mucosa and transported in the plasma (97612). However, other scientists claim that the structure of the molecule would require a transporter, although no transporters have been found. The most recent evidence involving a direct measurement of IP-6 suggests that it is not detectable in human plasma.\nMetabolism\nDietary or supplemental IP-6 is most likely metabolized in the gut to inositol prior to absorption (97610, 97611).",
            "Mechanism of Action": "General\nIP-6 is the hexaphosphate ester of inositol. It is the major phosphorus storage compound in plants, comprising from 1-7% of the dry weight of most cereals, nuts, and legumes (1855, 1858). IP-6 is an inositol phosphate, a water-soluble form of inositol that is involved in cellular signaling. Other inositol phosphates that occur naturally in human and other cells include IP-7, IP-8, and IP-3. These differ from inositides, the lipid-soluble inositol compounds, which are also involved in signaling. Although IP-6 is found in all cells, it is found in mammalian cells in much smaller amounts than plant cells (1857, 97610).\nAnti-cancer effects\nThere is interest in using IP-6 for cancer. Preliminary evidence suggests that the ability of IP-6 to chelate minerals might decrease iron-mediated colon cancer risk (1858). Laboratory research shows that IP-6 inhibits cancer cell proliferation and increases cancer cell differentiation, sometimes resulting in reversion to a normal phenotype (1859). IP-6 has demonstrated anticancer activity in models of breast, colon, liver, prostate, and hematological cancers in vitro (1860, 1861, 1862, 1863, 1864, 1865, 13042). IP-6 is thought to potentially have antiangiogenic activity. In vitro, IP-6 inhibits experimentally induced angiogenesis (13041). In vitro, IP-6 has demonstrated a synergistic effect when used in combination with doxorubicin or tamoxifen for inhibiting growth of breast cancer cells (13256).\nAntioxidant effects\nIP-6 chelates minerals, including iron. This inhibits the ability of iron to catalyze hydroxyl radical formation. This activity plays a role in the effects of IP-6 in models of heart and lung injuries, inflammation, and ulcers (97608). As a natural antioxidant, IP-6 added to food reduces lipid peroxidation and retards spoilage (1855, 1858).\nCellular effects\nThe cellular functions of IP-6 include signal transduction and cellular proliferation and differentiation. In the cell, IP-6 is involved in ion channels, protein trafficking, exocytosis, endocytosis, DNA repair, and protein folding (1857, 97608, 97609, 97610). One of the main roles for IP-6 seems to be transporting mRNA out of the nucleus and into the cytoplasm (97610).\nChemoprotective effects\nThere is interest in using IP-6 to reduce cyclophosphamide-induced testicular toxicities. Animal research in rats treated with cyclophosphamide shows that fortifying water with IP-6 2% for 2 weeks increases sperm count and motility and increases testicular testosterone, luteinizing hormone, and follicle-stimulating hormone levels when compared with control. These effects are thought to be due to chelation and/or antioxidant activity, but this has not been well studied (106681).\nHypolipidemic effects\nLaboratory research suggests that IP-6 lowers serum cholesterol and triglycerides, possibly by chelating minerals (1858, 1868).\nRenal effects\nIn the urine, IP-6 can reduce the formation of calcium and oxalate crystals (10297). IP-6 appears to reduce the concentration of calcium and the formation of calcium crystals in renal papillary tissue (10298)."
        }
    },
    "Ipecac": {
        "sections": {
            "Overview": "Ipecac is a small, perennial shrub that is native to regions of Brazil, as well as to areas of Central America, including Nicaragua, Costa Rica, and Panama (103803). The dried root is used to make a syrup that is used in medicine (56443). Although ipecac is possibly safe when small amounts are used, misuse can lead to serious toxicity, including cardiomyopathy and death (6, 12, 19, 56412, 56460, 56467).",
            "Safety": "POSSIBLY SAFE when the rhizome or syrup of ipecac is used orally and appropriately, as a single dose. A single 15-30 mL dose of syrup containing 10-21 mg ipecac has been used with apparent safety in clinical research (12, 56419, 103744).\nPOSSIBLY UNSAFE when in contact with skin or when inhaled. The constituent emetine is a skin irritant, and ipecac powder is a respiratory irritant (6, 18).\nLIKELY UNSAFE when used orally long-term or in amounts greater than 30 mL. Misuse can lead to serious toxicity, including cardiomyopathy and death. Chronic ingestion of ipecac 30 mL (21 mg) 2-3 times daily for 5 months has been associated with cardiomyopathy. The acute lethal dose of ipecac is 850-1780 mL (600-1250 mg) (6, 12, 19, 56412, 56460, 56467). ...when a total dose of more than 1 gram is injected, it can cause nervous system symptoms, blood in the urine, and circulatory collapse (6).\nCHILDREN: POSSIBLY SAFE when used orally and appropriately as an emetic (272, 11349).\nCHILDREN: LIKELY UNSAFE when used orally in large doses and in infants under 1 year old (12, 19). Children are more sensitive to large doses and effects on the nervous system than adults (19).\nPREGNANCY: LIKELY UNSAFE when used orally; ipecac is a potential uterine stimulant (12, 19).\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, ipecac syrup can cause nausea, vomiting, diarrhea, GI irritation, dizziness, hypotension, dyspnea, and tachycardia. Rarely, it can also cause intracerebral hemorrhage, pneumomediastinum, retropneumoperitoneum, esophageal bleeding (3, 6, 11, 13, 15, 18, 56390, 56440, 56447, 56448)(56449, 56464). Chronic use is associated with myopathies and death (6, 18, 56391, 56412, 56413, 56414, 56416, 56421, 56422, 56424)(56433, 56441, 56446, 56459, 56462, 56467). Overdose is associated with erosion of GI tract mucous membranes, cardiac arrhythmias, disorders of respiratory function, convulsions, shock, and coma (18).\n\nTopically, emetine is a skin irritant (6).\n\nWhen inhaled, ipecac powder is a respiratory irritant and can result in allergic symptoms such as rhinitis, as well as aspiration pneumonitis (18, 56406, 56445).\n\nIntravenously, emetine may cause inflammation of the muscle tissue at the injection site with chronic administration. In total doses over 1 gram, it can lead to gastrointestinal and nervous system symptoms, hematuria and circulatory collapse (6).\nCardiovascular\nOrally, ipecac can cause hypotension, dyspnea, and tachycardia (11, 56440). Chronic use is associated with cardiac myopathy and death related to heart failure (6, 18, 56391, 56409, 56424, 56467). Overdose is associated with shock and cardiac arrhythmias (18).\n\nIntravenously, ipecac in total doses over 1 gram can lead to circulatory collapse (6).\nless\nDermatologic\nTopically, emetine, a constituent of ipecac syrup, is a skin irritant (6).\nless\nGastrointestinal\nOrally, ipecac causes nausea, vomiting, diarrhea, and GI irritation (3, 6, 11, 13, 15, 18, 56390, 56464). In some cases, these adverse effects are severe. There is a case report of a pneumomediastinum (air in the membrane around the heart) and retropneumoperitoneum (air behind the chest cavity) indicative of esophageal rupture following administration of a therapeutic dose of ipecac (56448). There is also a case report of esophageal bleeding following therapeutic use of ipecac (56447). Overdose is associated with erosion of GI tract mucous membranes (18).\n\nIntravenously, ipecac in total doses over 1 gram can lead to gastrointestinal symptoms (6).\nless\nHematologic\nOrally, a case of intracerebral hemorrhage related to the use of ipecac syrup has been reported in an elderly patient (56449).\nless\nImmunologic\nWhen inhaled, ipecac powder has resulted in occupational allergy symptoms, such as rhinitis (56445).\nless\nMusculoskeletal\nOrally, progressive muscular weakness has occurred following ipecac abuse, in some cases resulting in death. Discontinuation of ipecac seems to reverse the myopathy (56391, 56412, 56413, 56414, 56416, 56421, 56422, 56424, 56433, 56441)(56446, 56459, 56462).\n\nIntravenously, emetine may cause inflammation of the muscle tissue at the injection site with chronic administration (6).\nless\nNeurologic/CNS\nOrally, ipecac may cause dizziness (11). Overdose is associated with convulsions and coma (18).\n\nIntravenously, ipecac in total doses over 1 gram can lead to nervous system symptoms (6).\nless\nPulmonary/Respiratory\nOrally, ipecac causes dyspnea (11). Overdose is associated with disorders of respiratory function (18).\n\nWhen inhaled, ipecac powder is a respiratory irritant and can result in aspiration pneumonitis (18, 56406).\nless\nRenal\nIntravenously, ipecac in total doses over 1 gram can lead to hematuria (6).\nless",
            "Effectiveness": "Poisoning. Historically, ipecac syrup was commonly used to manage poisoning (15, 56380, 56387, 56403, 56415). However, the American Academy of Pediatrics, American Academy of Clinical Toxicologists, and European Association of Poisons Centres and Clinical Toxicologists state that ipecac should not be used routinely for poisoning due to a lack of evidence of improved outcomes over available alternatives and an increased risk for adverse consequences (11349, 12394, 56389).\nResearch shows that inducing emesis with oral ipecac syrup within 10 minutes of poison ingestion can remove 28% to 54% of the poison dose from the patient (56408, 56419, 56455). However, as the interval between poison ingestion and ipecac-induced emesis is extended, the percentage of poison dose recovered declines, approaching zero after 90 minutes (56454, 56466). Furthermore, ipecac syrup does not appear to be more effective than activated charcoal (103744). While some research shows that taking 30 mL of ipecac syrup within one hour of poison ingestion can reduce absorption of poisons by about the same amount as taking 50-60 grams of activated charcoal (56411), most research shows that ipecac syrup is less effective than activated charcoal (56427, 56442, 56444). Also, using ipecac followed by activated charcoal after cessation of vomiting does not provide any benefit over earlier administration of activated charcoal alone (56403, 56451, 103744), and may increase patient recovery times (56392). Finally, there are also adverse consequences of ipecac use, including an increased risk for aspiration pneumonia and the need to delay administration of activated charcoal, poison-specific oral antidotes, or fluids for whole bowel irrigation after ipecac administration in order to avoid emesis of these treatments (12394, 56392, 56406, 56444, 103744).\n\nThere is insufficient reliable information available about the effectiveness of ipecac for its other uses.\nless",
            "Dosing & Administration": "Adult\nOral:\nGeneral: As an expectorant, 0.4-1.4 mL ipecac syrup (USP) is used (12). As an emetic, 15 mL ipecac syrup (USP) followed by 1-2 glasses of water is used (12); may repeat once in 20 minutes if no results (12, 13).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of ipecac.",
            "Interactions with Drugs": "ACTIVATED CHARCOAL\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nActivated charcoal adsorbs and inactivates syrup of ipecac; avoid co-administration (506).",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nGI CONDITIONS\nIpecac can irritate the gastrointestinal tract. Contraindicated in individuals with infectious or inflammatory gastrointestinal conditions (19).\nless\nHEART DISEASES\nUse of ipecac is contraindicated due to the cardiotoxic potential of emetine and its depressive effect on the heart (6, 12, 19).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Cases of death have been associated with ipecac use. Most of these cases are due to chronic oral use (56409, 56421, 56425, 56438, 56446). In human adults, the acute lethal dose of ipecac is 850-1780 mL (600-1250 mg) by mouth (56467). Furthermore, there is a case report of a child with gastric rupture and death associated with the therapeutic use of 15 mL ipecac syrup in the hospital emergency room (56425).",
            "Pharmacokinetics": "Absorption\nThe ipecac alkaloids, emetine, and cephaeline, are rapidly absorbed. These constituents can be detected within 5-10 minutes of dosing, with maximum levels in under 60 minutes (56381, 56383).\nDistribution\nIpecac alkaloids are found extensively distributed throughout the body (56381).\nExcretion\nEmetine and cephaeline are excreted in urine, most in under 3 hours after administration. However, emetine can be detected in the urine up to 60 days following administration (56381, 56383, 56390).",
            "Mechanism of Action": "General\nThe applicable part of ipecac is the root. Ipecac contains the alkaloids, emetine, and cephaeline (13, 56443).\nEmetic effects\nIpecac produces emesis by central and peripheral mechanisms. Constituents in ipecac irritate the GI mucosa and stimulating the emetic chemoreceptors in the brain (6, 13, 56456)."
        }
    },
    "Iporuru": {
        "sections": {
            "Overview": "Iporuru is a shrubby tree native to tropical Africa and the Amazonian rainforest. The bark has traditionally been used as medicine for various gastrointestinal and genitourinary conditions, as well as for its purported antiparasitic, cathartic, diuretic, emetic, and aphrodiasic effects. It has also been used as a hallucinogen (18).",
            "Safety": "There is insufficient reliable information available about the safety of iporuru.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNone reported; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nDiabetes. Although there has been interest in using oral iporuru for diabetes, there is insufficient reliable information about the clinical effects of iporuru for this purpose.\nJoint pain. Although there has been interest in using topical iporuru for joint pain, there is insufficient reliable information about the clinical effects of iporuru for this purpose.\nPain (acute). Although there has been interest in using oral iporuru for acute pain, there is insufficient reliable information about the clinical effects of iporuru for this purpose.\nRespiratory tract infections. Although there has been interest in using oral iporuru for respiratory tract infections, there is insufficient reliable information about the clinical effects of iporuru for this purpose.\nMore evidence is needed to rate iporuru for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\n\nIporuru has traditionally been prepared as a tea, with 1 teaspoon of dried leaf added to 4 ounces of boiling water and taken 1-3 times daily.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of iporuru.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nDeaths have been reported when iporuru is used in high doses (exact dose unknown) for hallucinogenic effects (18).\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with iporuru.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of iporuru.",
            "Mechanism of Action": "General\nThe applicable parts of iporuru are the bark, leaf, and root. There is insufficient reliable information available about the possible mechanism of action of iporuru."
        }
    },
    "Ipriflavone": {
        "sections": {
            "Overview": "Ipriflavone is a semisynthetic isoflavone manufactured in the laboratory from daidzein, a compound derived from soy (431). It is used as a prescription medication for osteoporosis in some countries, but is classified as a dietary supplement in the United States (101219).",
            "Safety": "LIKELY SAFE when used orally and appropriately. Ipriflavone seems to be safe when used for up to 3 years (427, 428, 430, 431, 432, 433, 1196, 2169, 2170, 2171, 2172) (2173, 2174, 2175, 4749, 10228, 104208). However, there is concern that ipriflavone can cause subclinical lymphocytopenia in some patients when taken for greater than 6 months (1196, 104208).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, ipriflavone is generally well-tolerated. However, some patients taking ipriflavone can experience epigastric pain, diarrhea, and dizziness (432, 104208). There is some concern that ipriflavone can cause lymphocytopenia when used for at least 6 months (1196, 104208).\nGastrointestinal\nOrally, ipriflavone can cause epigastric pain and diarrhea in some people (432, 104208).\nless\nHematologic\nOrally, ipriflavone was associated with subclinical lymphocytopenia in about 13% of patients in one study. A decrease in lymphocyte counts to less than 500/mcL seems to be most likely to occur after at least 6 months of treatment, although some patients develop lymphocytopenia after a longer duration of use (1196). Lymphocyte counts seem to normalize in most patients within 12 months after discontinuing ipriflavone (1196, 104208).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nLIKELY EFFECTIVE\nOsteoporosis. Most clinical research shows that ipriflavone can prevent loss of bone mineral density (BMD) in postmenopausal adults when taken in combination with calcium 1000 mg daily, with or without estrogen. It may also be beneficial in other patients, including oophorectomized adults and those with vitamin D deficiency.\nMost research in postmenopausal adults with osteoporosis shows that taking ipriflavone orally in combination with calcium 1000 mg daily can prevent loss of BMD or low bone mass (430, 432, 433, 2169, 2170, 2175, 104208), and may actually increase BMD in some patients (428, 2173, 2175, 4756, 104208). A meta-analysis of the available clinical research suggests that concomitant calcium must be used in doses of at least 1000 mg daily in order to obtain benefit. A subgroup analysis of four clinical studies utilizing calcium in doses of 500-800 mg daily found no effect on BMD (104208). Taking ipriflavone plus calcium or vitamin D prophylactically also seems to help prevent osteoporosis in postmenopausal adults (2171, 2174, 104208). Ipriflavone can also significantly reduce osteoporotic pain and seems to be as effective as inhaled calcitonin (432, 2175, 4756, 4757). However, using ipriflavone in combination with low-dose estrogen seems to be more beneficial than ipriflavone alone for preventing osteoporosis. Ipriflavone plus conjugated estrogen 0.3 mg daily and calcium 500-1000 mg daily seems to consistently increase BMD in postmenopausal adults (427, 2171, 2172).\n\nIpriflavone has also been evaluated in other populations. In oophorectomized adults, taking ipriflavone in combination with conjugated estrogen 0.625 mg daily can decrease loss of BMD better than estrogen or ipriflavone alone (4749). Ipriflavone also seems to prevent loss of BMD induced by the gonadotropin hormone-releasing hormone agonist, leuprolide (Lupron) (10228). Adding calcium provides further benefit (4746).\nless\nPaget disease. There is some evidence that ipriflavone 600 mg or 1200 mg given orally for 30 days can reduce bone pain, serum alkaline phosphatase levels, and hydroxyproline/creatinine excretion in patients with Paget disease (2176).\nThere is insufficient reliable information available about the effectiveness of ipriflavone for its other uses.\nless",
            "Dosing & Administration": "Adult\nOral:\nOsteoporosis: For postmenopausal osteoporosis, ipriflavone 200 mg three times daily has been used in combination with calcium 1000 mg daily (2169, 2170, 2171, 2172, 2173, 2175, 104208). For reducing drug-induced bone mineral loss, ipriflavone 600 mg daily has been used (10228).\n\nPaget disease: Ipriflavone 600-1200 mg daily has been used (2176).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of ipriflavone.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nIpriflavone is thought to competitively inhibit cytochrome P450 1A2 (CYP1A2) (2178). Theoretically, concurrent use of ipriflavone and drugs metabolized by these enzymes might result in decreased drug elimination, increased serum levels, and potential toxicity. Some drugs metabolized by CYP1A2 include clozapine (Clozaril), cyclobenzaprine (Flexeril), fluvoxamine (Luvox), haloperidol (Haldol), imipramine (Tofranil), mexiletine (Mexitil), olanzapine (Zyprexa), Pentazocine (Talwin), propranolol (Inderal), tacrine (Cognex), theophylline (Slo-bid, Theo-Dur, others), zileuton (Zyflo), Zolmitriptan (Zomig), and others.\nCYTOCHROME P450 2C9 (CYP2C9) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nIpriflavone is thought to competitively inhibit cytochrome P450 2C9 (CYP2C9) (2178). Theoretically, concurrent use of ipriflavone and drugs metabolized by these enzymes might result in decreased drug elimination, increased serum levels, and potential toxicity. Some drugs metabolized by CYP2C9 include amitriptyline (Elavil), diazepam (Valium), estradiol (Estrace), tacrine (Cognex), verapamil (Calan), warfarin (Coumadin), zileuton (Zyflo), and others.\nIMMUNOSUPPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nA (High-quality randomized controlled trial (RCT))\nConcurrent use of ipriflavone and immunosuppressant drugs might have additive effects on inhibiting immune function. Some patients taking ipriflavone experience subclinical lymphocytopenia (1196); avoid concurrent use. Immunosuppressant drugs include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone (Deltasone, Orasone), and other corticosteroids (glucocorticoids).\nTHEOPHYLLINE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Anecdotal evidence)\nConcomitant use of theophylline and ipriflavone can increase serum theophylline levels. Increased theophylline levels have occurred in two cases after patients started taking ipriflavone (2178, 6604). Ipriflavone is thought to decrease theophylline metabolism through competitive inhibition of the cytochrome P450 1A2 (CYP1A2) enzyme (2178, 6604).",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "IMMUNOSUPPRESSION\nIpriflavone has been reported to cause lymphocytopenia in some patients when used for at least 6 months (1196, 104208). Theoretically, ipriflavone might have additive immunosuppressive effects in immunosuppressed patients; use with caution.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of ipriflavone.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of ipriflavone.",
            "Mechanism of Action": "General\nIpriflavone is a semisynthetic isoflavone manufactured in the laboratory from daidzein, a compound derived from soy (431).\nBone effects\nIpriflavone enhances osteoblast function and inhibits parathyroid hormone (PTH)-stimulated bone resorption, mainly by inhibiting recruitment and maturation of osteoclasts, and enhancing alkaline phosphatase activity in osteoblast cells (2173, 2176, 2179, 104208). Clinical research suggests that ipriflavone prevents bone density loss without suppressing the rate of bone formation (426). It does not appear to have direct estrogenic activity in postmenopausal adults, but might potentiate the effects of estrogen on bone, and stimulate estrogen-induced calcitonin secretion (434, 2179). Research in postmenopausal adults suggests that using ipriflavone in combination with conjugated estrogens for osteoporosis might allow for use of a lower estrogen dose (427, 2171, 2172). In patients with renal osteodystrophy, research shows that taking ipriflavone 400-600 mg daily increases calcitonin levels after one month (2177).\nCognitive effects\nIn a mouse model of diabetic cognitive impairment, ipriflavone functions as a nonsteroidal glucocorticoid receptor antagonist to improve short-term working memory and exploratory behavior. It also ameliorates dysfunctions of spatial working memory, spatial learning, and long-term memory (108753).\nImmunologic effects\nWhen added to blood from healthy individuals or those with peanut or milk allergies, ipriflavone suppresses basophil degranulation in response to an allergen stimulus. However, taking ipriflavone orally, 200 mg daily for 4 weeks in combination with genistein, does not affect basophil degranulation or skin prick test results in individuals with peanut or tree nut allergies (101219)."
        }
    },
    "Iron": {
        "sections": {
            "Overview": "Iron is a trace mineral found in two ionic forms in the body. It exists in a reduced state as ferrous iron and in an oxidized state as ferric iron. Most of the iron in the body is found in the hemoglobin of red blood cells and in the myoglobin of muscle cells (1093). Iron is found in various foods, including beef, liver, lamb, pork, ham, chicken, fish, and beans (9540, 9541). Historically, iron has been used to treat various skin conditions, cystitis, diarrhea, edema, excessive lacrimation, fevers, gout, hemorrhoids, perianal fistulas, tuberculosis, and other disorders (56539).",
            "Safety": "LIKELY SAFE when used orally and appropriately. For people age 14 and older with adequate iron stores, iron supplements are safe when used in doses below the tolerable upper intake level (UL) of 45 mg per day of elemental iron. The UL is not meant to apply to those who receive iron under medical supervision (7135, 96621). To treat iron deficiency, most people can safely take up to 300 mg elemental iron per day (15). ...when used intravenously and appropriately. Ferric carboxymaltose 200 mg and iron sucrose 200 mg have been given intravenously for up to 10 doses with no reported serious adverse effects (91179). A meta-analysis of clinical studies of hemodialysis patients shows that administering high-dose intravenous (IV) iron does not increase the risk of hospitalization, infection, cardiovascular events, or death when compared with low-dose IV iron, oral iron, or no iron treatment (102861). A more recent meta-analysis of clinical studies of all patient populations shows that administering IV iron does not increase the risk of hospital length of stay or mortality, although the risk of infection is increased by 16% when compared with oral iron or no iron (110186). Another meta-analysis of 3 large clinical trials in patients with heart failure shows that IV ferric carboxymaltose at a dose of around 1500 mg every 6 months for a year does not increase the incidence of adverse effects when compared with placebo (113901). Despite these findings, there are rare reports of hypophosphatemia and/or osteomalacia (112603, 112608, 112609, 112610, 113905).\nLIKELY UNSAFE when used orally in excessive doses. Doses of 30 mg/kg are associated with acute toxicity. Long-term use of high doses of iron can cause hemosiderosis and multiple organ damage. The estimated lethal dose of iron is 180-300 mg/kg; however, doses as low as 60 mg/kg have also been lethal (15).\nCHILDREN: LIKELY SAFE when used orally and appropriately (7135, 91183, 112601).\nCHILDREN: LIKELY UNSAFE when used orally in excessive amounts. Tell patients who are not iron-deficient not to use doses above the tolerable upper intake level (UL) of 40 mg per day of elemental iron for infants and children aged 0-13 years and 45 mg per day for children aged 14-18 years. Higher doses frequently cause gastrointestinal side effects such as constipation and nausea (7135, 20097). Iron is the most common cause of pediatric poisoning deaths. Doses as low as 60 mg/kg can be fatal (15).\nPREGNANCY AND LACTATION: LIKELY SAFE when used orally and appropriately. Iron is safe during pregnancy and breast-feeding in patients with adequate iron stores when used in doses below the tolerable upper intake level (UL) of 45 mg daily of elemental iron (7135, 96625, 110180).\nPREGNANCY AND LACTATION: LIKELY UNSAFE when used orally in high doses. Tell patients who are not iron deficient to avoid exceeding the tolerable upper intake level (UL) of 45 mg daily of elemental iron. Higher doses frequently cause gastrointestinal side effects such as nausea and vomiting (7135) and might increase the risk of preterm labor (100969). High hemoglobin concentrations at the time of delivery are associated with adverse pregnancy outcomes (7135, 20109).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally or intravenously, iron is generally well tolerated when used appropriately.\nMost Common Adverse Effects\nOrally: Abdominal pain, constipation, diarrhea, gastrointestinal irritation, nausea, and vomiting.\nSerious Adverse Effects (Rare)\nOrally: Case reports have raised concerns about oral or gastric ulcerations.\n\nIntravenously: Case reports have raised concerns about hypophosphatemia and osteomalacia.\nCardiovascular\nThere is debate regarding the association between coronary heart disease (CHD) or myocardial infarction (MI) and high iron intake or high body iron stores. Some observational studies have reported that high body iron stores are associated with increased risk of MI and CHD (1492, 9542, 9544, 9545, 15175). Some observational studies reported that only high heme iron intake from dietary sources such as red meat are associated with increased risk of MI and CHD (1492, 9546, 15174, 15205, 15206, 91180). However, the majority of research has found no association between serum iron levels and cardiovascular disease (1097, 1099, 9543, 9547, 9548, 9549, 9550, 56469, 56683).\n\nThere is one case of Kounis syndrome, also referred to as allergic angina or allergic myocardial infarction, in a 39-year-old female patient without previous coronary artery disease given intravenous ferric carboxymaltose. The patient experienced anaphylactic symptoms, including headache, abdominal pain, and breathing difficulties, 3 minutes after starting the infusion. She was further diagnosed with non-ST-elevation myocardial infarction (112607).\n\nThere is also a case of a 56-year-old female, negative for HFE mutation homozygosity, diagnosed with acquired iron overload cardiomyopathy after starting ferrous sulfate 325 mg twice daily 3 years prior for iron deficiency secondary to alcoholic cirrhosis with esophageal varices and encephalopathy. The patient had no follow-up care over the 3 years and denied any blood transfusions over that time (113906).\nless\nDermatologic\nCutaneous hemosiderosis, or skin staining, has been reported following intravenous (IV) iron infusion in various case reports. Most of these cases are due to extravasation following iron infusion (112605, 112611). In one case, extravasation has occurred following iron derisomaltose infusion in a 41-year-old female with chronic kidney disease (112605). Rarely, diffuse cutaneous hermosiderosis has occurred. In one case, a 31-year-old female with excessive sweating developed cutaneous hemosiderosis in the armpits following an (IV) iron polymaltose infusion (112611).\nless\nEndocrine\nPopulation research in females shows that higher ferritin levels are associated with an approximately 1.5-fold higher odds of developing gestational diabetes. Increased dietary intake of heme-iron, but not non-heme iron, is also associated with an increased risk for gestational diabetes. The effects of iron supplementation could not be determined from the evaluated research (96618). However, in a sub-analysis of a large clinical trial in pregnant adults, daily supplementation with iron 100 mg from 14 weeks gestation until delivery did not affect the frequency or severity of glucose intolerance or gestational weight gain (96619).\n\nIntravenous (IV) iron may trigger hypophosphatemia in some patients (113905). A meta-analysis of clinical studies in adults with iron deficiency anemia shows that IV ferric carboxymaltose is associated with a higher risk of hypophosphatemia when compared with other IV formulations (i.e. iron dextran, iron isomaltoside, iron sucrose, and ferumoxytol) (115899). Severe hypophosphatemia requiring IV phosphate has also occurred following IV ferric carboxymaltose (112608, 112610).\n\nAdditionally, cases of osteomalacia related to hypophosphatemia subsequent to parenteral iron administration have been rarely reported (112603, 112609).\nless\nGastrointestinal\nOrally, iron can cause dry mouth, gastrointestinal irritation, heartburn, abdominal pain, constipation, diarrhea, nausea, or vomiting (96621, 102864, 104680, 104684, 110179, 110185, 110188, 110189, 110192, 115894). These adverse effects are uncommon at doses below the tolerable upper intake level (UL) of 45 mg per day of elemental iron in adults with normal iron stores (7135). Higher doses can be taken safely in adults with iron deficiency, but gastrointestinal side effects may occur (1095, 20118, 20119, 56698, 102864). Taking iron supplements with food seems to reduce gastrointestinal side effects (7135). However, food can also significantly reduce iron absorption. Iron should be taken on an empty stomach, unless it cannot be tolerated.\n\nThere are several formulations of iron products such as ferrous sulfate, ferrous gluconate, ferrous fumarate, and others. Manufacturers of some formulations, such as polysaccharide-iron complex products (Niferex-150, etc), claim to be better tolerated than other formulations; however, there is no reliable evidence to support this claim. Gastrointestinal tolerability relates mostly to the elemental iron dose rather than the formulation (17500).\n\nEnteric-coated or controlled-release iron formulations might reduce nausea for some patients, however, these products also have lower absorption rates (17500).\n\nLiquid oral preparations can blacken and stain teeth (20118).\n\nIron can also cause oral ulcerations and ulcerations of the gastric mucosa (56684, 91182, 96622, 110179). In one case report, an 87-year-old female with Alzheimer disease experienced a mucosal ulceration, possibly due to holding a crushed ferrous sulfate 80 mg tablet in the mouth for too long prior to swallowing (91182). The ulceration was resolved after discontinuing iron supplementation. In another case report, a 76-year old male suffered gastric mucosal injury after taking a ferrous sulfate tablet daily for 4 years (56684). In a third case report, a 14-year-old female developed gastritis involving symptoms of upper digestive hemorrhage, nausea, melena, and stomach pain. The hemorrhage was attributed to supplementation with ferrous sulfate 2 hours after meals for the prior 2 weeks (96622). In one case report, a 43-year old female developed atrophic gastritis with non-bleeding ulcerations five days after starting oral ferrous sulfate 325 mg twice daily (110179).\n\nIntravenously, iron can cause gastrointestinal symptoms such as nausea and diarrhea (104684, 110192, 115894).\nless\nHematologic\nOrally, iron supplements have been associated with hemochromatosis. In one case report, a 56-year-old female, negative for HFE mutation homozygosity, was diagnosed with acquired hemochromatosis after starting ferrous sulfate 325 mg twice daily 3 years prior, without follow-up care, for a previous iron deficiency secondary to alcoholic cirrhosis with esophageal varices and encephalopathy (113906).\nless\nImmunologic\nAlthough there is some clinical research associating iron supplementation with an increased rate of malaria infection (56796, 95432), the strongest evidence to date does not support this association, at least for areas where antimalarial treatment is available (95433, 96623). In an analysis of 14 trials, iron supplementation was not associated with an increased risk of malaria (96623). In a sub-analysis of 7 preliminary clinical studies, the effect of iron supplementation was dependent upon the access to services for antimalarial treatment. In areas where anemia is common and services are available, iron supplementation is associated with a 9% reduced risk of clinical malaria. In an area where services are unavailable, iron supplementation was associated with a 16% increased risk in malaria incidence (96623). The difference in these findings is likely associated with the use of malaria prevention methods.\n\nA meta-analysis of clinical studies of all patient populations shows that administering intravenous (IV) iron, usually iron sucrose and ferric carboxymaltose, increases the risk of infection by 16% when compared with oral iron or no iron. However, sub-analyses suggest this increased risk is limited to patients with inflammatory bowel disease (IBD) (110186). Additionally, a meta-analysis in adults with cancer-associated anemia shows that IV iron does not increase the risk of infection when compared with oral iron or no iron therapy (115892).\n\nIntravenously, iron has rarely resulted in allergic reactions, including anaphylactoid reactions (110185, 110192, 112606, 112607). There is one case of Kounis syndrome, also referred to as allergic angina or allergic myocardial infarction, in a 39-year-old female patient without previous coronary artery disease given IV ferric carboxymaltose. The patient experienced anaphylactic symptoms, including headache, abdominal pain, and breathing difficulties, 3 minutes after starting the infusion. She was further diagnosed with non-ST-elevation myocardial infarction (112607).\nless\nMusculoskeletal\nIntravenous (IV) iron may trigger hypophosphatemia in some patients, and cases of osteomalacia related to hypophosphatemia subsequent to parenteral iron administration have been rarely reported (112609, 113905). In one case, a 70-year-old male with a genetic hemorrhagic disorder infused with ferric carboxymaltose developed lower limb pain with hypophosphatemia and diffuse bone demineralization in the feet (112609). In a second case, a 61-year-old male developed femoral neck insufficiency fractures following repeated ferric carboxymaltose transfusions for anemia related to vascular malformation in the bowel (112603).\nless\nOncologic\nThere is a debate regarding the association between high levels of iron stores and cancer. Data are conflicting and inconclusive (1098, 1099, 1100, 1102). Epidemiological studies suggest that increased body iron stores may increase the risk of cancer or general mortality (56703).\n\nOccupational exposure to iron may be carcinogenic (56691). Oral exposure to iron may also be carcinogenic. Pooled analyses of population studies suggest that increasing the intake of heme iron increases the risk of colorectal cancer. For example, increasing heme iron intake by 1 mg/day is associated with an 11% increase in risk (56699, 91185).\nless\nPulmonary/Respiratory\nOrally, iron has been associated with rare reports of iron pill aspiration. This occurs when all or part of the pill is aspirated into the lungs. Once in the lungs, it can cause a chemical burn of the bronchial mucosa. Dozens of cases of iron pill aspiration have been reported in individuals ranging in age from 22 months to 92 years. Patients presented with cough, dyspnea, wheezing, and hemoptysis. The hemoptysis led to death in 2 patients due to hemorrhage. Long-term complication of fibrosis and bronchial stenosis was reported in a few of the cases. In one case, a 48-year-old female accidentally aspirated a ferrous sulfate tablet and presented to the emergency department with cough, blood-stained sputum, chest pain, dyspnea, and acute distress. Bronchoscopy was performed, parts of the pill were retrieved, and chemical burns and necrotic tissue were observed in the bronchus intermedius mucosa and throughout the middle and lower lobes. Debridement with bronchoalveolar lavage was performed. The patient was transferred to the intensive care unit, placed on mechanical ventilation for 2 days, treated with corticosteroids, and discharged on the fifth day of hospitalization. Four weeks post-discharge the patient had significantly improved but still had some reduction in lung capacity.\nless\nOther\nIntravenously, sodium ferric gluconate complex (SFGC) caused drug intolerance reactions in 0.4% of hemodialysis patients including 2 patients with pruritus and one patient each with anaphylactoid reaction, hypotension, chills, back pain, dyspnea/chest pain, facial flushing, rash and cutaneous symptoms of porphyria (56527).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nEFFECTIVE\nAnemia of chronic disease. Oral and intravenous (IV) iron in combination with erythropoiesis-stimulating agents (ESAs) are effective for treating anemia of chronic disease.\nIron supplementation with ESAs is effective for treating anemia associated with chronic kidney disease (CKD) or chemotherapy. During therapy with ESAs, iron levels should be monitored and supplementation provided as needed to ensure that the response is not limited by lack of iron for erythropoiesis (1087, 1091, 20110, 20111, 110192). Research shows that IV iron appears to be more effective than oral supplements for this purpose (20112, 20113). In patients with CKD, IV iron at total doses from 2232 mg over 6 months to 1020 mg over one week increases hemoglobin levels more than oral doses of 4-6 mg/kg daily or 325 mg daily for up to 6 months (20112).\n\nSome research has evaluated the effect of IV or oral iron in patients not treated with ESAs. In patients with cancer or CKD, oral iron supplements have been shown to improve iron status (110184, 110192). However, overall benefits of iron alone remain unclear in treated or untreated patients with cancer and more research is needed to rule out an increase in mortality and to determine any effect on blood transfusion requirements (110192).\n\nPreliminary clinical research shows that children aged 6 months to 10 years with HIV and anemia who take elemental iron 3 mg/kg daily along with a multivitamin for 3 months have a 41% lower chance of having persistent anemia at 3 months when compared with multivitamins alone (95432).\nless\nIron deficiency anemia. Oral and intravenous (IV) iron are effective for treating or preventing iron deficiency anemia. The benefits of iron supplementation in people with iron deficiency without anemia are unclear.\nOral iron supplements, mainly as ferrous sulfate, are effective for treating and preventing iron deficiency anemia in adults, children, and infants (1089, 7135, 17495, 17496, 17497, 103806, 20114, 20115, 91183, 96621)(104680, 104681, 112601). Other forms are also effective, including sodium iron ethylenediaminetetra-acetate (NaFeEDTA), iron(III)-hydroxide polymaltose complex (IPC), iron protein succinylate, iron bisglycinate, and lactoferrin with iron (20117, 20118, 110189). Treatment with iron supplements should increase hemoglobin levels by 1 gram/dL every 2-3 weeks. However, even after hemoglobin has normalized, it may take up to 4 months for iron stores to be replenished (17497).\n\nHistorically, treatment of iron deficiency anemia with oral iron supplements has typically consisted of a daily dosing regimen, often taken in divided doses to reduce adverse effects. In more recent years, however, intermittent iron supplementation (1-3 doses/week) has become preferred for some patients, particularly those with mild anemia, due to better absorption and a possible reduction in side effects compared to daily dosing. One small clinical study shows that taking ferrous sulfate 60 mg on alternate days in single doses improves iron absorption when compared to once daily dosing (96630). Another small clinical study in females with iron-deficiency anemia shows that fractional iron absorption is 40% to 50% higher with alternate-day dosing compared with daily dosing. Furthermore, total iron absorption was shown to be similar for alternate day dosing of elemental iron 200 mg compared with daily dosing of 100 mg, but the incidence of gastrointestinal adverse effects may be lower for the alternate day dosing regimen (101514). A meta-analysis of 25 clinical trials, including 10,996 menstruating females with or without pre-existing iron deficiency and/or anemia, shows that intermittent iron reduces the risk of anemia and increases hemoglobin and serum ferritin when compared with placebo or no intervention. This meta-analysis did not identify differences in the risk of anemia, hemoglobin, or serum ferritin between intermittent and daily iron supplementation. However, it did show that females receiving intermittent dosing had a 59% reduction in the risk for adverse effects. The validity of these findings is limited by significant heterogeneity in the enrolled populations and selected dosing strategies, including frequency of intermittent dosing, total weekly dose, and duration of follow-up. In addition, the subgroup analyses performed by baseline anemia, hemoglobin, and serum ferritin, as well as duration of follow-up, showed differing overall conclusions when comparing intermittent and daily iron supplementation. While intermittent dosing appears to be beneficial when compared with daily dosing for some patients with iron deficiency anemia, intermittent dosing may be less effective than daily iron supplementation in some patients (103806). For patients with severe anemia, twice daily dosing may be preferred to alternate day dosing due to faster response. A small clinical study in patients with iron deficiency anemia shows that taking ferrous sulfate 200 mg twice daily is more effective at increasing hemoglobin levels by 3 weeks when compared with ferrous sulfate 400 mg taken on alternate days in single doses (102864).\n\nIntermittent iron supplementation has also been investigated in children. A meta-analysis of clinical research in children and adolescents with or without pre-existing iron deficiency and/or anemia shows that taking iron supplements 1-2 times weekly is similarly effective as 3-7 times weekly for decreasing iron deficiency and iron deficiency anemia. However, ferritin and hemoglobin levels increased to a greater extent with 3-7 times weekly supplementation (112601).\n\nBlood transfusion may be required for some patients with severe iron deficiency anemia who have symptoms such as dyspnea and fatigue (17497). Intravenous iron should be considered in patients who cannot tolerate oral iron or in patients with chronic bleeding or intestinal malabsorption (17497).\n\nGuidance from the American Gastroenterological Association and the British Society of Gastroenterology recommends treatment with iron while awaiting investigations to rule out gastrointestinal issues in adults in the absence of an alternative explanation. Ferrous sulfate, fumarate, or gluconate daily are recommended. If adverse effects occur, intake can be reduced to once every other day, or alternative oral or parenteral sources of iron can be used. Parenteral sources should be used if oral sources are contraindicated or ineffective. Treatment should be monitored and continued after hemoglobin levels have normalized (110193, 115890).\n\nIron supplementation may also be beneficial in patients with iron deficiency without anemia, which can cause fatigue and reduced well-being, although guidelines are lacking. A meta-analysis of randomized controlled trials in adults with iron deficiency but not anemia shows that supplemental iron improves iron stores and hemoglobin levels. In addition, iron moderately reduces self-reported fatigue, but not physical capacity, when compared with placebo. Oral ferrous sulfate was used in most studies included in the analysis; however, IV or intramuscular iron were also used (104684).\n\nIntravenous iron has also been evaluated for the prevention of postoperative anemia. A meta-analysis of several, moderate-quality clinical studies in adults undergoing cardiac surgery, including patients with or without anemia, shows that various types of IV iron (e.g. ferric carboxymaltose, iron sucrose) reduce the risk of red blood cell transfusions by approximately 23%, and improve hemoglobin and iron levels by postoperative day 4, when compared with placebo and oral iron therapy (115898). The validity of these results is limited by heterogeneous methods across clinical studies including patient population, iron formulation, and use of erythropoietin.\nless\nPregnancy-related iron deficiency. Oral and intravenous (IV) iron are effective for managing pregnancy-related iron deficiency.\nClinical research shows that taking iron orally at an average daily dose of 15-225 mg of elemental iron increases maternal hemoglobin levels by up to 1 gram/dL when compared with placebo and reduces the risk of maternal anemia by 50% to 100% (20122, 20123, 20124, 110180, 110188, 115895). Some clinicians may recommend alternating days of iron administration to reduce gastrointestinal adverse effects. A pooled analysis shows that taking iron supplements, with or without folic acid, on alternating days during pregnancy maintains adequate iron intake and reduces gastrointestinal adverse effects when compared with taking iron daily (96625). Another meta-analysis shows that daily supplementation of iron with folic acid increases hemoglobin levels by 0.24 g/dL when compared with intermittent supplementation, given as 1, 2, or 3 doses weekly. However, clinical significance of this slight increase is unlikely, and no difference in rates of anemia are noted between dosing strategies (115896).\n\nVarious forms of oral iron seem to be equally effective for raising hemoglobin levels (110185, 110188, 115895). However, in patients with anemia during pregnancy, meta-analyses of several, moderate-quality clinical studies show that IV iron (e.g. iron sucrose) is more effective than oral iron (e.g. ferrous sulfate) for improving hemoglobin levels and reducing the risk for anemia (110185, 115897).\nless\nPOSSIBLY EFFECTIVE\nBreath-holding attacks. Oral iron seems to be effective for reducing the frequency of breath-holding attacks in children with iron deficiency.\nThe incidence of breath-holding attacks is increased in children with iron deficiency or iron deficiency anemia. Most research shows that oral supplementation with ferrous sulfate 3-6 mg/kg daily for 4-16 weeks reduces the frequency of breath-holding attacks in children aged 1-72 months (20128, 104682, 104683). The best evidence comes from a meta-analysis of one randomized controlled trial and 11 observational single arm studies (104682). In this analysis, approximately 84% of children experienced at least a 50% decreased frequency of breath-holding attacks (104682). Some preliminary clinical research also shows that administering intramuscular iron reduces the frequency of breath-holding attacks and increases remission in children with iron deficiency anemia (20128).\nless\nCognitive function. Oral iron seems to be effective for improving cognitive function in children and adolescents with iron deficiency.\nTaking iron orally seems to improve cognitive function in iron-deficient children and adolescents (20121, 112600). For example, ferrous sulfate 650 mg twice daily for 8 weeks improved verbal learning and memory in non-anemic iron-deficient adolescent females (1095). Ferrous sulfate 50 mg twice weekly for 16 weeks appeared to improve attention measures in adolescent females with possible anemia (91186). Iron also appears to reverse developmental and learning deficits caused by iron-deficiency in anemic infants (1104).\n\nSome clinical research is focused on children and adolescents from low- and middle-income countries. In children aged 5-19 years with or without iron-deficiency anemia, a meta-analysis of clinical research shows that iron supplementation for 3-8 months dose-dependently improves measured intelligence by a modest amount. However, there was no effect on other measures of cognition, including attention or memory (110181). Another meta-analysis of clinical research in school age children shows that taking iron for 2-12 months modestly improves intelligence, attention, and memory, but not educational achievement, when compared with placebo or no intervention. However, sub-analyses show that any benefits are limited to children with anemia (112600). Most studies included in the analyses evaluated daily iron supplementation, with a few studies assessing iron taken 4-6 times weekly (110181, 112600). In contrast, a large clinical trial in schoolchildren in Ethiopia shows that taking iron supplements, providing 42 mg of elemental iron, once weekly for 11 months does not improve working memory, nonverbal intelligence, planning, or problem-solving, and may even worsen one measure of attention and concentration when compared with placebo (113904). These discrepant findings may be related to differences in frequency of dosing (daily vs. weekly) and baseline demographics; only 20% and 4% of children in this study had iron deficiency and iron deficiency anemia, respectively.\nless\nHeart failure. Intravenous (IV) iron seems to be effective for improving certain outcomes in patients with heart failure and iron deficiency. It is unclear if oral iron is effective.\nIron deficiency is common in patients with heart failure (17499, 112597, 112598, 112599). A number of large clinical trials and meta-analyses of clinical research in patients with heart failure show that administering IV iron, as ferric carboxymaltose, iron dextran, iron isomaltoside, or iron sucrose, for at least 12 weeks modestly improves quality of life, increases exercise capacity, and reduces hospitalizations when compared with placebo or standard care. However, there was no effect on all-cause mortality or cardiovascular mortality (17498, 91179, 110176, 110187, 112597, 112598, 112599, 113900, 113901). Based on these results, guidelines from the American Heart Association and European Society of Cardiology support the use of IV iron in patients with heart failure with reduced ejection fraction and iron deficiency to improve symptoms and quality of life. Additionally, IV iron supplementation in these patients is associated with a reduced risk of heart failure hospitalization (115935, 115936).\n\nLimited research has investigated the effect of oral iron in this population. A small meta-analysis of clinical research shows with low certainty that taking iron orally has beneficial effects on serum ferritin and left ventricular ejection fraction (110178). Most research shows that taking oral iron does not improve hemoglobin levels, quality of life, or exercise capacity when compared with placebo (100970, 110178). However, one small clinical trial shows that taking oral iron modestly improves iron status and overall symptoms and increases the 6-minute walking distance by about 46 meters, compared with a reduction of only 14 meters in those taking placebo (110183). Some doses used in individual clinical studies have included iron polysaccharide 150 mg twice daily for 16 weeks and ferrous sulfate 200 mg three times daily for 12 weeks (100970, 110183).\nless\nRestless legs syndrome (RLS). Oral and intravenous (IV) iron seem to be beneficial for RLS. The American Academy of Neurology recommends a combination of oral ferrous sulfate and vitamin C or IV ferric carboxymaltose for patients with RLS.\nRLS is commonly associated with iron deficiency anemia. Some clinical research shows that taking iron in the form of ferrous sulfate 325 mg twice daily for 12 weeks reduces RLS symptoms comparably to pramipexole. Symptoms such as leg discomfort, need to move, and sleep disturbances improved considerably in about half of the patients taking either treatment (91181). Additional clinical research shows that taking ferrous sulfate 325 mg twice daily along with vitamin C 100 mg twice daily for 12 weeks reduces symptoms of RLS when compared with vitamin C alone in patients with RLS and low-normal serum ferritin levels (94189). Based on these results, clinical practice guidelines by the American Academy of Neurology report that taking this combination of oral ferrous sulfate and vitamin C is likely to improve symptoms in patients with RLS and low-normal serum ferritin (93587).\n\nIntravenous iron may also reduce symptoms of RLS. Clinical practice guidelines by the American Academy of Neurology report that two doses of IV ferric carboxymaltose 500 mg given 5 days apart are likely to improve symptoms and quality of life within 28 days in patients with moderate to severe RLS, regardless of serum ferritin levels. Iron sucrose, given IV, has also been evaluated in patients with RLS, but there is currently insufficient available evidence to support or refute the use of this form of iron for treating RLS (93587).\n\nAdditionally, IV and oral iron have been compared in the management of RLS. A clinical study in adults with RLS and iron deficiency anemia shows that administering IV ferumoxytol 1020 mg for 2 doses, 2-7 days apart, reduces self-reported symptom severity and frequency comparably to taking oral ferrous sulfate 650 mg daily for 6 weeks (115894). The validity of these results is limited by methodological concerns, including lack of a placebo control group and failure to obtain all follow-up data.\nless\nPOSSIBLY INEFFECTIVE\nAthletic performance. Oral iron does not seem to improve athletic performance.\nA meta-analysis of clinical research in adults of childbearing age shows that iron supplementation improves some exercise performance measures, such as maximal oxygen uptake capacity, but not others, such as time until exhaustion and energy consumption, when compared with control (91184). Another meta-analysis of clinical research in patients with iron deficiency without anemia shows that iron supplementation improves subjective measures of fatigue, but does not improve exercise time to exhaustion or other measures of physical capacity (104684). A small clinical study in healthy children shows that taking iron supplements or consuming food providing iron 30-200 mg daily for 1-2 months improves running performance when compared with placebo. This was demonstrated by reductions of heart rate of 6.6 to 8 beats per minute during the running exercise. One preliminary study included in this analysis also showed that iron supplementation improved treadmill endurance time (20140).\nless\nChild growth. Oral iron does not seem to be beneficial for child growth.\nMeta-analyses of mainly preliminary clinical research show that oral iron supplementation, at doses averaging 2-80 mg or 1-10 mg/kg elemental iron daily for up to 52 weeks, does not increase growth rate in children (20131, 20132, 20133, 95434).\nless\nPreterm labor. Oral iron does not seem to prevent preterm labor and may actually increase the risk in malaria-endemic regions.\nA meta-analysis of results from five clinical studies shows that maternal intake of iron as ferrous sulfate 20-60 mg daily for 14-26 weeks starting in the second trimester of pregnancy does not affect the length of gestation or increase birthweight of the infant (95434). In females from a malaria-endemic area who have never been pregnant before, another clinical study shows that taking ferrous gluconate 60 mg and folic acid 2.8 mg weekly, starting before conception and continuing to the first antenatal visit, may more than double the risk of preterm birth, defined as a delivery under 37 weeks gestation, when compared with folic acid alone (100969). Some research suggests that the adverse outcome in this latter study may be explained by a rise in hepcidin levels in pregnant patients with malaria. Hepcidin is a hormone that regulates iron absorption and distribution, and malaria can upregulate hepcidin. High levels of hepcidin can decrease iron absorption, stimulate inflammatory processes, and cause progesterone withdrawal, leading to preterm labor (102863).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nACE inhibitor-induced cough. It is unclear if oral iron is beneficial in patients with this condition.\nA small clinical trial shows that taking ferrous sulfate 256 mg daily reduces or eliminates cough induced by ACE inhibitors such as captopril (Capoten), enalapril (Vasotec), lisinopril (Prinivil, Zestril), and others, when compared with placebo (7307).\nless\nAndrogenic alopecia. Oral iron has only been evaluated in combination with other ingredients, its effect when used alone is unclear.\nA moderate-sized clinical study in adults with androgenic alopecia or telogen effluvium shows that taking one tablet daily of a specific product (GFM Oral, Cantabria Labs), providing an unknown dose of iron in combination with selenium, taurine, cysteine, methionine, and hydrolyzed collagen, along with conventional therapy, consisting primarily of finasteride or minoxidil, for 12 weeks improves hair loss when compared with conventional therapy alone (111636). It is unclear if this effect is due to iron, other ingredients, or the combination.\nless\nAttention deficit-hyperactivity disorder (ADHD). It is unclear if oral iron is beneficial in children with ADHD.\nA meta-analysis of three small, lower quality clinical studies in children and adolescents with ADHD and iron deficiency shows that taking ferrous fumarate 200-400 mg, dependent upon body weight, or ferrous sulfate 80 mg daily for 3 months does not improve hyperactivity and inattention when compared with placebo. However, the results of individual clinical studies are inconsistent (115893). The validity of these results is limited by high heterogeneity across clinical studies, including patient baseline characteristics, use of investigator-, parent-, and teacher-rated ADHD scales, and concomitant use of ADHD medication therapy (e.g. stimulants).\nless\nChild development. It is unclear if oral iron is beneficial for improving development in non-anemic children.\nSome observational research has found that iron deficiency in infancy is associated with poor verbal performance and social skills in childhood (102862). It is unknown whether iron supplementation can ameliorate these developmental issues. In non-anemic infants and children, clinical research shows that iron does not improve cognitive performance; the evidence for the benefits of iron on psychomotor development is conflicting (20129, 20130, 91315, 96616, 96626, 115891).\nless\nEsophageal cancer. It is unclear if oral iron is beneficial for esophageal cancer prevention.\nPopulation research has found that taking iron supplements is associated with a 32% lower risk of esophageal adenocarcinoma when compared to never taking iron supplements. However, use of iron supplements is not associated with a lower risk of esophageal squamous cell carcinoma (95435).\nless\nFatigue. It is unclear if oral iron is beneficial in patients with fatigue due to iron deficiency without anemia.\nA meta-analysis of mainly preliminary clinical research in adults with iron deficiency without anemia shows that iron reduces self-reported fatigue moderately more than placebo (104684). A specific ferrous sulfate supplement (Tardyferon; Pierre Fabre MÃ©dicament) providing 80 mg of elemental iron daily for 4-12 weeks was used in two studies included in this analysis (11406, 91188).\nless\nInflammatory bowel disease (IBD). In patients with active IBD, intravenous iron may be more beneficial than oral iron due to impaired absorption. However, it may also increase the risk of infection in these patients.\nSince the absorption of oral iron may be impaired in patients with active symptoms of IBD, guidelines from the British Society of Gastroenterology suggest that treatment with parenteral iron may be needed in patients with IBD who have moderate to severe iron-deficiency anemia (110193). However, a meta-analysis of clinical research in this population shows that administering IV iron, usually as iron sucrose or ferric carboxymaltose, increases the risk of infection by 73% when compared with oral iron or no iron (110186).\nless\nPostoperative recovery. It is unclear if intravenous (IV) iron is beneficial for recovery following cardiac surgery.\nA meta-analysis of low- to moderate-quality clinical research in patients with preoperative iron-deficiency anemia shows that treatment with IV iron before cardiac surgery does not improve the rate of transfusions or the length of stay in the intensive care unit or hospital when compared with control groups, including placebo, oral iron, or no treatment. Also, a meta-analysis of clinical research shows that IV iron does not reduce postoperative mortality rates (110182).\nless\nPostpartum depression. Although there has been interest in using iron for postpartum depression, there is insufficient reliable information about the clinical effects of iron for this condition.\nPrematurity. Enteral iron seems to be beneficial for some measures of development in preterm infants.\nA meta-analysis of clinical research in preterm or low birthweight infants fed human milk shows that enteral iron supplementation increases linear growth and reduces the risk of anemia when compared with control groups receiving no iron supplementation. However, there was no effect on serum ferritin, weight, head circumference, cognitive development, risk of infection, or risk of necrotising enterocolitis (110177). Additional clinical research in infants born at 24-28 weeks' gestation shows that a higher average enteral iron dose by 60 days of age is positively associated with cognitive performance at 2 years of corrected age. However, this association was not present for iron doses received at 90 days of age (110190).\nless\nMore evidence is needed to rate iron for these uses.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: For adults, the recommended dietary allowance (RDA) for iron is 8 mg/day for males ages 19 and older, and females ages 51 and older. For females 19 to 50 years, the RDA is 18 mg/day. During pregnancy, the RDA is 27 mg/day. During lactation, the RDA is 10 mg/day for ages 14 to 18 years, and 9 mg/day for ages 19 to 50 (7135).\n\nPatients should not exceed the tolerable upper intake level of 45 mg iron daily unless advised by a healthcare provider. See Effectiveness section for condition-specific information.\n\nDietary or supplemental calcium may decrease the absorption of dietary or supplemental iron. However, in people with adequate stores of these minerals, this does not appear to have a clinically significant effect on long-term iron status (8875).\n\nAdvise patients that iron should be taken on an empty stomach if possible. Taking iron supplements with food can decrease iron absorption by 40% to 75% (17500, 110193). This is likely due to binding of iron in the gut by calcium, polyphenols, tannins, and other dietary constituents (8875, 8887, 9570, 9571, 9573, 17497, 17500). If iron must be taken with food to mitigate gastrointestinal side effects, advise patients to avoid taking iron at the same time as dairy, coffee, tea, or cereals (7135, 17497, 17500).\nIntravenous/Intramuscular:Research is limited; typical dosing is unavailable.\nChildren\nOral:\nGeneral: The adequate intake (AI) of iron for infants 6 months of age and less is 0.27 mg/day (7135). For older infants and children, the recommended dietary allowances (RDAs) for iron are: 7-12 months, 11 mg/day; 1-3 years, 7 mg/day; 4-8 years, 10 mg/day; 9-13 years, 8 mg/day; males 14-18 years, 11 mg/day; females 14-18 years, 15 mg/day.\n\nFor preventing iron deficiency in children, the American Academy of Pediatrics guidelines recommend iron supplements for some groups. For breast-fed infants, elemental iron 1 mg/kg/day is recommended from ages 4-6 months. Infants from 6-12 months should get 11 mg/day from food or supplements. For pre-term infants, 2 mg/kg/day for the first year is recommended. This should be continued until the baby is switched to formula or otherwise getting enough iron from food sources. Formula-fed children get enough iron from infant formula. Toddlers aged 1-3 years usually get enough iron from foods; however, a supplement can be added as needed (17495, 17496). Plain iron drops (Fer-In-Sol, Fer-Gen-Sol, etc) are usually preferred for children (17495).\n\nPatients should not exceed the tolerable upper intake level of 40 mg iron daily for children aged 0-13 years and of 45 mg iron daily for children aged 14-18 years unless advised by a healthcare provider. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nThere are several formulations and salt forms of iron which contain different amounts of elemental iron:\n\n1 gram of ferrous gluconate = 120 mg elemental iron (12% iron)\n\n1 gram of ferrous sulfate = 200 mg elemental iron (20% iron)\n\n1 gram of ferrous fumarate = 330 mg elemental iron (33% iron)\n\n\nEfficacy and tolerability are similar for these different forms when used in equal doses of elemental iron. Manufacturers of some formulations such as polysaccharide-iron complex products (Niferex-150, etc) claim to be better tolerated than other formulations. However, there is no reliable evidence to support this claim. Enteric coated or controlled release iron formulations might reduce nausea for some patients; however, these products also have lower absorption rates (17500). Heme-iron polypeptide products (Proferrin ES, etc) are derived from the hemoglobin of animals and have better absorption compared to inorganic iron salts (17500). Carbonyl iron (Feosol with Carbonyl Iron, Iron Chews, etc) contains microparticles of 100% purified elemental iron. It is slowly absorbed which allows for controlled release over 1-2 days. It is not more effective than other forms, but is less toxic in cases of accidental ingestion (17500).\n\nOther forms include sodium iron ethylenediaminetetra-acetate (NaFeEDTA), iron(III)-hydroxide polymaltose complex (IPC), and iron proteinsuccinylate (20117, 20118).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nBICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (Biktarvy)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIron might decrease levels of bictegravir/emtricitabine/tenofovir alafenamide by reducing its absorption when taken in a fasting state.\nAdvise patients that bictegravir/emtricitabine/tenofovir alafenamide and iron can be taken together if taken with food. However, if taken on an empty stomach, bictegravir/emtricitabine/tenofovir alafenamide should not be taken with, or 2 hours after, iron containing products (116930).\nless\nBISPHOSPHONATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIron reduces the absorption of bisphosphonates.\nAdvise patients that doses of bisphosphonates should be separated by at least two hours from doses of all other medications, including supplements such as iron. Divalent cations, including iron, can decrease absorption of bisphosphonates by forming insoluble complexes in the gastrointestinal tract (15).\nless\nCHLORAMPHENICOL\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMODERATE\nOccurrence\nUNLIKELY\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking chloramphenicol with iron might reduce the response to iron therapy in iron deficiency anemia.\nChloramphenicol interferes with erythrocyte maturation (15, 3046). However, since chloramphenicol isn't usually taken for prolonged periods, this isn't likely to be clinically significant.\nless\nDENOSUMAB (Prolia, others)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nAdministration of intravenous iron within one month of denosumab administration might increase the risk of severe hypophosphatemia and hypocalcemia.\nA case of severe hypocalcemia (albumin corrected calcium 6.88 mg/dL, ionized calcium 3.68 mg/dL) and hypophosphatemia (<0.5 mg/dL) with respiratory acidosis, QT interval prolongation, and nonsustained ventricular tachycardia was reported in a 76-year-old male who had received an iron polymaltose infusion within 2 weeks of a subcutaneous injection of denosumab. Serum parathyroid hormone was also elevated (348 pg/mL). Subsequent iron infusions with iron polymaltose and ferric carboxymaltose were followed by transient hypophosphatemia, but without hypocalcemia. Additionally, a literature review describes 6 additional cases of hypophosphatemia and hypocalcemia in patients 52-92 years of age who had been administered intravenous iron as either ferric carboxymaltose or iron polymaltose and subcutaneous denosumab within 1-4 weeks of each other (113905).\nless\nDOLUTEGRAVIR (Tivicay)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nIron might decrease dolutegravir levels by reducing its absorption.\nAdvise patients to take dolutegravir at least 2 hours before or 6 hours after taking iron. Pharmacokinetic research shows that iron can decrease the absorption of dolutegravir from the gastrointestinal tract through chelation (93578). When taken under fasting conditions, a single dose of ferrous fumarate 324 mg orally along with dolutegravir 50 mg reduces overall exposure to dolutegravir by 54% (94190).\nless\nINTEGRASE INHIBITORS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking iron along with integrase inhibitors might decrease the levels and clinical effects of these drugs.\nIron is a divalent cation. There is concern that iron may decrease the absorption of integrase inhibitors from the gastrointestinal tract through chelation (93578). One pharmacokinetic study shows that iron can decrease blood levels of the specific integrase inhibitor dolutegravir through chelation (94190). Also, other pharmacokinetic research shows that other divalent cations such as calcium can decrease the absorption and levels of some integrase inhibitors through chelation (93578, 93579).\nless\nLEVODOPA\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nIron might decrease levodopa levels by reducing its absorption.\nAdvise patients to separate doses of levodopa and iron as much as possible. There is some evidence in healthy people that iron forms chelates with levodopa, reducing the amount of levodopa absorbed by around 50% (9567). The clinical significance of this hasn't been determined.\nless\nLEVOTHYROXINE (Synthroid, others)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nIron might decrease levothyroxine levels by reducing its absorption.\nAdvise patients to separate levothyroxine and iron doses by at least 2 hours. Iron can decrease the absorption and efficacy of levothyroxine by forming insoluble complexes in the gastrointestinal tract (9568).\nless\nMETHYLDOPA (Aldomet)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nIron might decrease methyldopa levels by reducing its absorption.\nAdvise patients to separate methyldopa and iron doses by at least 2 hours. Iron can decrease the absorption of methyldopa from the gastrointestinal tract through chelation, resulting in increases in blood pressure (7900, 20151).\nless\nMYCOPHENOLATE MOFETIL (CellCept)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nUNLIKELY\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, iron might decrease mycophenolate mofetil levels by reducing its absorption.\nAdvise patients to take iron 4-6 hours before, or 2 hours after, mycophenolate mofetil. It has been suggested that a decrease of absorption is possible, probably by forming nonabsorbable chelates. However, mycophenolate pharmacokinetics are not affected by iron supplementation in available clinical research (3046, 20152, 20153, 20154, 20155).\nless\nPENICILLAMINE (Cuprimine, Depen)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIron might decrease penicillamine levels by reducing its absorption.\nAdvise patients to separate penicillamine and iron doses by at least 2 hours. Oral iron supplements can reduce absorption of penicillamine by 30% to 70%, probably due to chelate formation. In people with Wilson's disease, this interaction has led to reduced efficacy of penicillamine (3046, 3072, 20156).\nless\nQUINOLONE ANTIBIOTICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIron might decrease levels of quinolone antibiotics by reducing their absorption.\nAdvise patients to separate quinolone antibiotics and iron doses by at least 2 hours. Iron decreases the absorption of quinolones due to formation of insoluble complexes in the gastrointestinal tract (15, 3072).\nless\nTETRACYCLINE ANTIBIOTICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIron might decrease levels of tetracycline antibiotics by reducing their absorption.\nAdvise patients to take iron at least 2 hours before or 4 hours after tetracycline antibiotics. Concomitant use can decrease absorption of tetracycline antibiotics from the gastrointestinal tract by 50% to 90% (15).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nACACIA\nTheoretically, taking iron together with acacia might lead to decreased absorption of iron or acacia.\nAcacia forms an insoluble gel with ferric iron (16). However, a significant interaction has not been shown in humans.\nless\nBETA-CAROTENE\nTaking iron with beta-carotene might enhance dietary non-heme iron absorption and in people with anemia and Vitamin A deficiency.\nVitamin A appears to be involved in mobilizing iron from tissue stores for delivery to immature red blood cells in the bone marrow. Improvements in hemoglobin levels can occur in people with anemia and low serum retinol levels when they are given vitamin A supplements (9586). Vitamin A may also be involved in the differentiation and proliferation of blood stem cells in the bone marrow, and in the synthesis of erythropoietin (9518). Preliminary evidence also suggests that vitamin A and beta-carotene may enhance non-heme iron absorption from iron-fortified wheat and corn flour, and rice. It's suggested that these vitamins bind to iron in the gut, improving its solubility and preventing binding by dietary polyphenols and phytate, which reduce iron absorption (9569). It's unlikely that vitamin A supplements would have significant effects on iron status in people without vitamin A deficiency.\nless\nCALCIUM\nCalcium can decrease iron absorption.\nCalcium inhibits the absorption of dietary heme- and non-heme iron (7135, 7308, 9573). However, in people with adequate iron stores, this doesn't appear to be clinically significant (1848, 1849, 1850, 7135, 7308). Advise people at risk for iron deficiency to take calcium supplements at bedtime, instead of with meals, to avoid inhibiting dietary iron absorption (7308). Calcium supplements can also inhibit absorption of iron supplements. However, the effect is variable and depends on the salt form used, presence or absence of food, and the type of food (9586). Clinical research in young females who are fasting suggests that calcium citrate decreases iron absorption from a ferrous sulfate supplement more than other calcium salts, such as chloride, gluconate, carbonate, lactate, sulfate, or phosphate (99425). The clinical significance is unclear, but advise patients to take calcium and iron supplements at different times of the day if possible.\nless\nCASEIN PROTEIN\nCasein protein, but not hydrolyzed casein protein (casein peptides), seems to decrease iron absorption.\nClinical research shows that consuming casein protein 30 grams leads to a 45% reduction in iron absorption when compared with consuming egg-white derived protein. However, this interaction does not appear to occur with hydrolyzed casein protein (casein peptides) (91634).\nless\nLACTOBACILLUS\nTheoretically, taking iron with lactobacillus might increase the absorption of iron.\nSome clinical research shows that a fruit drink containing iron and 1 billion colony forming units of Lactobacillus plantarum 299v increases the absorption of iron by about 9% when compared with a control fruit drink (96617). The clinical significance of this effect is unclear.\nless\nSOY\nSoy protein seems to decrease iron absorption.\nSoy protein reduces absorption of dietary non-heme (plant-derived) iron, probably due to binding of iron by phytate and calcium present in soy (5053, 9573). Fermented soy products seem to inhibit iron absorption less than non-fermented products (9586). The clinical significance of these effects hasn't been determined.\nless\nVITAMIN A\nTaking iron with vitamin A might enhance dietary non-heme iron absorption in people with anemia and Vitamin A deficiency.\nVitamin A appears to be involved in mobilizing iron from tissue stores for delivery to immature red blood cells in the bone marrow. Improvements in hemoglobin levels can occur in people with anemia and low serum retinol levels when they are given vitamin A supplements (9586, 20124, 20147). Vitamin A may also be involved in the differentiation and proliferation of blood stem cells in the bone marrow, and in the synthesis of erythropoietin (9518). Preliminary evidence also suggests that vitamin A and beta-carotene may enhance non-heme iron absorption from iron-fortified wheat and corn flour, and rice. It's suggested that these vitamins bind to iron in the gut, improving its solubility and preventing binding by dietary polyphenols and phytate, which reduce iron absorption (9569, 20149). It's unlikely that vitamin A supplements would have significant effects on iron status in people without vitamin A deficiency.\nless\nVITAMIN C\nWhen ingested at the same time, supplemental or dietary vitamin C improves absorption of dietary non-heme iron. Its effect on iron supplements is unclear.\nDietary vitamin C promotes the absorption of non-heme iron (iron not bound to the heme group of blood or muscle proteins) by promoting its conversion to the ferrous state (9518, 9571, 9586). The amount of vitamin C in the diet is a factor in dietary iron absorption and iron status (9570, 9572). Vitamin C can counteract the effects of substances which inhibit iron absorption such as dietary phytates, polyphenols, and tannins possibly by chemically reducing iron and preventing the formation of less soluble ferric compounds (9518, 9573, 9586). It is unclear if taking vitamin C improves the absorption of supplemental non-heme iron and may depend on the specific form of the supplement. Clinical research shows that taking vitamin C with a ferrous succinate supplement does not seem to improve iron status more rapidly than taking the iron supplement without vitamin C (104680). Additionally, a meta-analysis of clinical research in patients with iron deficiency anemia shows that taking iron with vitamin C does not improve hemoglobin or serum ferritin levels when compared with iron alone (112477). Taking a vitamin C supplement to improve absorption of dietary or supplemental iron probably isn't necessary for most people, especially if their diet contains plenty of vitamin C (9571). Also, some clinical research shows that taking copper in combination with iron and ascorbic acid negates the absorption enhancing effects of vitamin C (96624).\nless\nYERBA MATE\nTheoretically, concomitant use of iron and yerba mate may reduce the effectiveness of iron supplementation.\nPreliminary clinical research in patients with hereditary hemochromatosis shows that drinking yerba mate tea with iron-containing meals attenuates increases in serum iron levels. Some researchers have suggested that polyphenolic constituents of yerba mate, such as chlorogenic acid, bind to gastrointestinal iron and reduce oral iron absorption (107230).\nless\nZINC\nIron and zinc can interfere with each other's absorption when taken on an empty stomach.\nWhen high supplemental doses of zinc are taken on an empty stomach there is a measurable reduction in iron absorption, and high supplemental doses of non-heme iron taken on an empty stomach can reduce zinc absorption, especially when dietary mineral intake is low (8856, 9579, 9580, 9581, 9582, 9583, 9584). This is probably because the carriers for iron and zinc in the gut become saturated at high doses, and the ions then compete for non-specific carriers. If one of the ions is present in excess, absorption of the other will be decreased (9580). When food is present, the ions become complexed with food components and don't compete for absorption (9579). Therefore, there isn't a significant interaction between dietary iron and zinc, or between supplemental iron and zinc, when taken with food (8866, 9579, 9581). Advise patients to take these supplements with food.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nACHLORHYDRIA\nDecreased stomach acidity may impair iron absorption (7135).\nless\nDIABETES\nTheoretically, a high dietary intake of iron increases the risk of heart disease in females with type 2 diabetes. Females with type 2 diabetes who have the highest intake of heme iron from dietary sources such as red meat have a 50% greater risk of coronary heart disease when compared with those with the lowest intake. This risk also appears to be higher in patients with type 2 diabetes who are postmenopausal as opposed to premenopausal (15174). Other studies have linked high iron body stores to increased risk of heart disease in people who do not have diabetes (1492, 9542, 9544, 9545, 15205, 15206), but the majority of studies have found no association (1097, 1099, 9543, 9547, 9548, 9549, 9550). Some researchers speculate that patients with diabetes might be more prone to adverse effects of iron. The metabolic abnormalities that occur in people with diabetes, such as dyslipidemia, might increase the adverse cardiovascular effects of iron (9545, 15174, 15175).\nless\nHEMODIALYSIS\nSupplemental iron absorption is decreased in people requiring chronic hemodialysis (1088, 1090).\nless\nHEMOGLOBIN DISEASES\nIron overload is likely to occur in people with hemoglobinopathies or other refractory anemias erroneously diagnosed as iron deficiency anemia (15).\nless\nHEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)\nIron supplementation is associated with an increased risk of nosebleed in patients with HTT (96629); use with caution.\nless\nPHYSICAL TRAINING\nSupplemental iron absorption appears to be decreased in young females participating in physical training, as measured by serum ferritin levels (96627).\nless\nPREMATURE INFANTS\nCorrect vitamin E deficiency before administering supplemental iron to premature infants (15). Use of oral iron preparations in premature infants with low serum vitamin E levels may cause hemolysis and hemolytic anemia (15).\nless\nTRAUMATIC BRAIN INJURY\nIntravenous iron may increase the risk of cerebral edema in patients with traumatic brain injury. In a case report, a 46-year-old female hospitalized with a traumatic brain injury was given intravenous iron sucrose for anemia. She developed worsening edema with a decline in neurological status (112602).\nless",
            "Interactions with Lab Tests": "GUAIAC TEST\nIron supplements may cause a false-positive reading for occult fecal blood. However, the benzidine test for occult fecal blood is not likely to be affected (15).\nless",
            "Nutrient Depletions": "EXPAND ALL\n|\nCOLLAPSE ALL\nAMINOSALICYLIC ACID\nDepletion Rating\nMODERATE\nMonitor for depletion; a supplement is needed in some patients.\nAminosalicylic acid reduces iron absorption and might decrease iron levels.\nAminosalicylic acid sometimes causes a malabsorption syndrome, resulting in weight loss, iron depletion, and excessive fat in the stools (steatorrhea) (9574). Advise patients to consult their physician if these symptoms occur. For information on foods that are rich in iron, see our chart.\nless\nANTACIDS\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nAntacids might modestly reduce iron absorption.\nGastric acid is important for absorption of dietary, non-heme iron (4539). Antacids may therefore reduce iron absorption by increasing gastric pH and reducing iron solubility (3072). This isn't likely to be clinically significant in most people with adequate dietary iron intake. However, antacids can reduce absorption of iron from supplements by 30% to 40%, and reduced efficacy has occurred occasionally (3046). Advise patients who need iron supplements to avoid antacids or separate the doses as much as possible.\nless\nCHOLESTYRAMINE (Questran)\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nCholestyramine might modestly reduce iron absorption and reduce iron levels.\nCholestyramine and colestipol may bind iron in the gut, reducing its absorption (9566). Clinically significant iron deficiency induced by these drugs hasn't been reported, and supplements aren't likely to be needed. If patients are taking iron supplements for other causes of deficiency, recommend they separate the iron and cholestyramine or colestipol doses by at least four hours.\nless\nH2-BLOCKERS\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nH2-blockers might modestly reduce iron absorption.\nGastric acid is important for the absorption of iron, particularly dietary non-heme iron (4539). Dose-dependent reductions in dietary iron absorption have been noted with cimetidine, ranging from 28% to 65% with single doses of 300-900 mg (8876). However, long-term treatment, up to 18 years, with H2-blockers isn't associated with iron depletion or anemia in people with normal iron stores (4483, 4539, 9578). Advise people to maintain adequate dietary iron intake. Supplements aren't necessary unless people have other factors contributing to iron deficiency. For information on foods that are rich in iron, see our chart.\nless\nPANCREATIC ENZYMES\nDepletion Rating\nMODERATE\nMonitor for depletion; a supplement is needed in some patients.\nPancreatic enzymes reduce iron absorption and might decrease iron levels.\nThere is some evidence that pancreatic enzyme supplements can reduce iron absorption, possibly by binding iron or altering pH (9575, 9585). It's unlikely that this will be clinically significant, except in people with cystic fibrosis who need pancreatic enzyme supplements for prolonged periods, and have other factors contributing to iron deficiency (9575). Advise these patients to have their iron status checked regularly. For information on foods that are rich in iron, see our chart.\nless\nPENICILLAMINE (Cuprimine, Depen)\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nPenicillamine might modestly reduce iron absorption and reduce iron levels.\nPenicillamine chelates iron in the gastrointestinal tract and decreases absorption. If iron supplements are used, separate from penicillamine by at least 2 hours (9630).\nless\nPROTON PUMP INHIBITORS (PPIs)\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nProton pump inhibitors might modestly reduce iron absorption.\nGastric acid is important for the absorption of iron, particularly dietary non-heme iron (4539). However, long-term treatment, up to 12.5 years, with proton pump inhibitors isn't associated with iron depletion or anemia in people with normal iron stores (4483, 8850, 9578). Advise people to maintain adequate dietary iron intake. Supplements aren't necessary unless people have other factors contributing to iron deficiency. For information on foods that are rich in iron, see our chart.\nless\nQUINOLONE ANTIBIOTICS\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nWhen taken together, iron and quinolone antibiotics can bind together, reducing absorption. When taken separately, this effect is unlikely to be clinically significant.\nQuinolones form complexes with iron in the GI tract, which could reduce absorption of both the quinolone and iron if taken at the same time (2682). Significant effects on iron levels are unlikely when quinolones are taken at least two hours before, or four to six hours after, iron supplements or iron-containing foods.\nless\nTETRACYCLINE ANTIBIOTICS\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nWhen taken together, iron and tetracycline antibiotics can bind together, reducing absorption. When taken separately, this effect is unlikely to be clinically significant.\nTetracyclines form complexes with iron in the GI tract, reducing absorption of both the tetracycline and iron if taken at the same time (4412, 4549, 4550). Significant effects on iron levels are unlikely when tetracyclines are taken at least two hours before or after iron supplements or iron-containing foods.\nless",
            "Overdose": "Presentation\nAcute overdosage, 60 mg/kg and more, can cause vomiting and diarrhea, followed by cardiovascular, liver, or metabolic toxicity, and death (7135, 20097, 56582, 112604, 115888). Long-term use of high doses of iron can cause hemosiderosis that clinically resembles hemochromatosis (15).\n\nIron overdose during pregnancy in individuals with peak iron levels over 400 mcg/dL have been associated with organ failure, spontaneous abortion, preterm delivery, and maternal death (20109).\n\nIron supplementation appears to be associated with greater adverse events in children. For example, in a clinical trial of 24,076 children, there was a 12% increase in risk of hospitalization due to severe illness in children taking iron (50163).\nTreatment\nManagement of acute iron poisoning includes intravenous fluids and antiemetics. Intravenous deferoxamine use depends on the severity of symptoms and/or serum levels of iron 4-6 hours after ingestion (112604).",
            "Pharmacokinetics": "Absorption\nThe rate of iron absorption from food and supplements is variable. Heme iron is absorbed at a rate of 23% compared to 2% to 20% for non-heme iron. Non-heme iron is found in all foods containing iron. However, iron from plant sources is only in the non-heme form. Ascorbic acid and ferri-reductase in the duodenum aid in the absorption of dietary non-heme iron. Iron bioavailability from a vegetarian diet is estimated to be 5% to 10%. Meats and fish seem to enhance the absorption of non-heme iron (7135). Supplemental iron reduces non-heme iron absorption from food (56493).\n\nBoiling, stir-frying, or hot air drying appears to enhance the bioavailability of iron contained in some vegetables including asparagus, broccoli, cabbage, cauliflower, and corn; however, cold storage of cooked vegetables might greatly reduce the increases in iron bioavailability gained from cooking (5044). Overall, dietary iron absorption is only 10% to 15%. However, this varies significantly depending on the person and the iron demand of the body (403).\n\nVegetarians and people who engage in intense physical exercise, particularly female athletes, may have increased iron requirements (7135). Blood loss and rapid growth also increase gastrointestinal absorption (1101). Iron is stored as ferritin or hemosiderin (7135).\n\nCertain iron formulations are better absorbed than others. For example when ferrous fumarate is given as microencapsulated sprinkles in a maize-based porridge, it appears to be absorbed better (56592). Iron from purified soybean ferritin and also from recombinant human lactoferrin appears to be absorbed as well as ferrous sulfate (56622, 56625). Iron bisglycinate seems to increase iron status more than iron polymaltose or lactoferrin (110189). The frequency of iron administration also seems to impact absorption. A small clinical study shows that taking ferrous sulfate 60 mg on alternate days in single doses appears to improve iron absorption when compared with taking 60 mg daily. However, dividing a daily dose of ferrous sulfate 120 mg twice daily does not improve absorption when compared with taking 120 mg once daily (96630).\nDistribution\nMost of the iron in the human body is incorporated into hemoglobin. The remaining iron is stored in the bone marrow, liver, spleen, or muscle (myoglobin) as ferritin or hemosiderin (7135).\nMetabolism\nIron moves in the body by binding reversibly to the transport protein, transferrin. Two atoms of iron bind to one transferrin and then bind to the transferrin receptor complex. Iron that is transferred into cells can be incorporated into hemoglobin and myoglobin, stored as ferritin, or used to regulate cellular iron metabolism (7135).\nExcretion\nBody iron is highly conserved. In the absence of bleeding (including menstruation) or pregnancy, the body loses only a small quantity of iron each day, mostly through the feces (7135).",
            "Mechanism of Action": "General\nIron is a trace mineral found in two ionic forms in the body. It exists in a reduced state as ferrous iron and in an oxidized state as ferric iron. Most of the iron in the body is found in the hemoglobin of red blood cells and in the myoglobin of muscle cells where it is required for oxygen and carbon dioxide transport (1093).\n\nIron also functions in the electron transport chain as an electron carrier in cytochromes. It is also found in the functional groups of most enzymes in the Krebs cycle (945). Iron is an essential cofactor in the synthesis of neurotransmitters such as dopamine, norepinephrine, and serotonin.\n\nMeats, such as red meat, poultry, and fish provide iron in heme and non-heme forms. Meats contain about 40% heme iron and 60% non-heme iron. Heme iron is absorbed at a rate of 23% compared to 2% to 20% for non-heme iron. Iron from plant sources is only in the non-heme form. Ascorbic acid and ferri-reductase in the duodenum aid in the absorption of non-heme iron. Iron bioavailability from a vegetarian diet is estimated to be 5% to 10%. Meats and fish seem to enhance the absorption of non-heme iron (7135).\n\nThe absorption of iron supplements may be increased by intermittent administration (1-3 doses/week) compared with daily administration. Intermittent administration is thought to align better with intestinal cell turnover, increasing absorption efficiency via increased exposure to new cells. This dosing strategy may also decrease oxidative stress and reduce adverse effects (103806).\n\nIron deficiency anemia in early life seems to negatively affect behavioral and neural development (1093, 9962). Signs and symptoms of deficiency include microcytic and hypochromic anemia, lethargy, cognitive impairment, developmental delay, amenorrhea, hair loss, enlarged liver, and others (7135). Iron deficiency in pregnancy has been associated with adverse pregnancy outcomes and increased perinatal maternal mortality (7135).\nNeurological effects\nThere is interest in using iron to treat attention deficit-hyperactivity disorder (ADHD). Research suggests that children with ADHD are more likely to be iron deficient. The level of iron deficiency seems to be positively correlated with the severity of ADHD symptoms. ADHD symptoms are related to dopamine dysfunction where iron seems to plays a role. Iron affects dopamine synthesis and appears to play a role in dopamine receptors density (10700).\nRespiratory effects\nThe cough induced by angiotensin converting enzyme (ACE) inhibitors may be linked to accumulation of nitric oxide. Since iron seems to reduce nitric oxide production, this effect might be clinically useful in the suppression of cough induced by ACE inhibitors (7307)."
        }
    },
    "Irvingia gabonensis": {
        "sections": {
            "Overview": "Located throughout farms and tropical forests of central and western Africa, Irvingia gabonensis trees are typically identified by their 10-40-meter height, flared base, densely dark green foliage, elliptical leaves, yellow-white flower clusters, and spherical fruit (61594, 61659, 61660). The fruit is similar to mango and is often referred to as African mango. It is greenish yellow in color with a fibrous pulp surrounding a large hard stone. The seeds of the fruit can be eaten raw or roasted. The kernels yield a food additive used in western and central Africa. The liquid from the kernels is often used in soups and can be used as a suspending and emulsifying agent. The USDA Agricultural Research Service has listed the fruit as edible and the kernels as a source of edible fats (92825).",
            "Safety": "POSSIBLY SAFE when Irvingia gabonensis seed extract is used orally and appropriately, short-term. Irvingia gabonensis crude seed extract has been used safely in doses of up to 1.05 grams three times daily for up to 12 weeks (17069, 104524, 104525). A standardized seed extract (IGOB131) has been used safely in doses up to 150 mg twice daily for up to 12 weeks (17070, 112220).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, Irvingia gabonensis is generally well tolerated.\nMost Common Adverse Effects\nOrally: Flatulence, headache, insomnia, nausea.\nGastrointestinal\nFlatulence has been reported following 10 weeks of supplementation with Irvingia gabonensis alone (17070) or in combination with Cissus quadrangularis (16457). Similar events were observed in controls. Mild nausea has also been reported following the administration of Irvingia gabonensis 0.3-4 grams daily for up to 12 weeks; however, some of these symptoms were alleviated by the addition of milk to the test preparation (61589, 112220).\nless\nHepatic\nOne case of acute hepatitis secondary to Irvingia gabonensis has been reported. A 45-year old male with a ten-day history of Irvingia gabonensis supplementation, at a dose of 350 mg of seed extract twice daily for body fat reduction, was admitted with jaundice, abdominal discomfort, and new onset malaise. His complaints began four days after starting Irvingia gabonensis supplementation. Prior to supplementation, all outpatient laboratory parameters were normal. At the time of admission, liver function tests were as follows: ALT 902 U/L, AST 708 U/L, alkaline phosphatase 198 U/L, gamma-glutamyl transferase 998 U/L, total bilirubin 9.1 mg/dL, direct bilirubin 6.1 mg/dL, and serum albumin 4.2 grams/dL. Hemoglobin was 15.3 grams/dL, white blood cell count 9.2 x 103 /mm3, platelets 240 x 103/mm3, prothrombin time 16.1 seconds, and ferritin level 115 ng/mL. Urinalysis revealed 2+ bilirubin and urobilinogens. Tests for viral hepatitis, autoimmune hepatitis, hemochromatosis, alpha-1-antitypsin deficiency, and Wilson's disease were negative. Ultrasonography showed a bright liver parenchyma consistent with steatosis, 15 cm in vertical size with regular edges. A spleen 13 cm in vertical size was also seen. Acute hepatitis secondary to Irvingia gabonensis was the diagnosis. When the Irvingia gabonensis capsules were discontinued, an immediate improvement was seen. Liver enzymes and other laboratory tests were normal 3 weeks after the admission (92824).\nless\nNeurologic/CNS\nHeadache and insomnia have been reported in patients taking Irvingia gabonensis alone or in conjunction with Cissus quadrangularis for periods of 10 weeks (16457, 17070). Similar events were observed in control groups.\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nDiabetes. It is unclear if oral Irvingia gabonensis is beneficial in patients with diabetes.\nPreliminary clinical research shows that taking 4 grams of ground Irvingia gabonensis seed fiber orally, dissolved in 100 mL water, daily for one month can reduce fasting blood glucose, total cholesterol, and triglycerides, and can increase high-density lipoprotein (HDL) cholesterol, when compared with baseline in patients with type 2 diabetes (61589). The validity of these findings is limited by the lack of a comparator group.\nless\nHypercholesterolemia. It is unclear if oral Irvingia gabonensis is beneficial in patients with hypercholesterolemia.\nPreliminary clinical research shows that taking Irvingia gabonensis crude seed extract 150 mg to 3.15 grams orally daily for 4-10 weeks lowers total and low-density lipoprotein (LDL) cholesterol and raises high-density lipoprotein (HDL) cholesterol in overweight adults who have normal or mildly elevated cholesterol levels when compared with placebo (17069, 17070, 104524). A meta-analysis of 5 small clinical studies in obese or overweight adults shows that taking Irvingia gabonensis 0.3-3.15 grams orally daily for 4-10 weeks reduces LDL by an average of 24% and increases HDL by an average of 10% when compared with placebo. The average change in triglycerides was inconclusive. However, the small size, poor quality, and heterogeneity of the included studies limits the validity of these findings (104524).\nless\nMetabolic syndrome. It is unclear if oral Irvingia gabonensis is beneficial in patients with metabolic syndrome.\nA preliminary clinical study in adults with metabolic syndrome shows that taking Irvingia gabonensis seed extract 150 mg orally twice daily for 90 days reduces triglycerides by 25%, waist circumference by 3%, and blood glucose upon oral glucose tolerance testing by 14%, but does not significantly affect low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, body weight, or body mass index, when compared with baseline. The validity of this study is limited by a very small sample size and the lack of a comparator group (104525).\nless\nObesity. Small clinical studies suggest that Irvingia gabonensis may modestly improves weight loss in overweight adults.\nOne preliminary clinical study shows that taking a crude seed extract 1.05 grams orally three times daily, combined with a low-fat, low-calorie diet, reduces weight by about 4 kg after 4 weeks, compared to no weight reduction in those taking placebo (17069). Another preliminary clinical study shows that taking a standardized seed extract (IGOB131) 150 mg twice daily orally for 10 weeks reduces weight by 12.8 kg, compared with 0.7 kg in those taking placebo. However, in this study, overweight patients taking Irvingia gabonensis consumed an average of 2767 kcal/day, compared to 3156 kcal/day in the placebo group (17070). Similar results also occurred in a study using a combination of standardized Irvingia gabonensis seed extract (IGOB131) and Cissus quadrangularis, for 10 weeks (16457). A meta-analysis of these and 2 additional trials in obese or overweight adults shows that taking Irvingia gabonensis 0.3-3.15 grams orally daily for 4-10 weeks reduces body weight by an average of 9%, body fat by 4%, and waist circumference by 7% when compared with placebo. However, the small size, poor quality, and heterogeneity of the included studies limits the validity of these findings (104524). In addition, some research shows conflicting results. Preliminary clinical research in overweight and obese individuals shows that taking a standardized seed extract (IGOB131) 300 mg orally daily for 12 weeks does not reduce body weight, body mass index, or fat mass when compared with placebo (112220). However, the study may have been inadequately powered to detect a difference between groups. The reasons for these discrepant findings are unclear but may be explained by differences in doses and patient populations studied or by changes in overall caloric intake, rather than the study drug.\nless\nMore evidence is needed to rate Irvingia gabonensis for these uses.",
            "Dosing & Administration": "Adult\nOral:\nIrvingia gabonensis seed extract has been in total daily doses of 0.3-4 grams, divided twice to three times daily for up to 12 weeks. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Irvingia gabonensis.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, taking Irvingia gabonensis with antidiabetes drugs might increase the risk of hypoglycemia in some patients.\nHuman research shows that Irvingia gabonensis decreases blood sugar in diabetic patients being treated with antidiabetes agents (61589, 61591). Monitor blood glucose levels closely. Dose adjustments might be necessary.\nless\nTESTOSTERONE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, taking Irvingia gabonensis with testosterone products drugs might cause additive effects in some patients.\nAnimal research suggests that Irvingia gabonensis increases testosterone levels (61613). The mechanism of action is unclear. Until more is known, advise patients taking testosterone to avoid using or use Irvingia gabonensis cautiously.\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, taking Irvingia gabonensis with other herbs and supplements with hypoglycemic potential might increase the risk of hypoglycemia in some patients.\nHuman research shows that Irvingia gabonensis decreases blood sugar in diabetic patients being treated with antidiabetes agents (61589, 61591). See other products with hypoglycemic potential here.\nless",
            "Interactions with Conditions": "PERIOPERATIVE\nTheoretically, Irvingia gabonensis might interfere with blood glucose control during and after surgical procedures. Human research shows that Irvingia gabonensis decreases blood sugar in diabetic patients being treated with antidiabetes agents (61589, 61591). Tell patients to discontinue Irvingia gabonensis at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nThere is insufficient reliable information available about the presentation of overdose with Irvingia gabonensis.\nTreatment\nLaboratory research shows that Irvingia gabonensis seeds contain small amounts of cyanide and gossypol (61614). Theoretically, an overdose with Irvingia gabonensis may present similar to overdose with these constituents. However, the effectiveness of administering cyanide or other antidotes to patients with Irvingia gabonensis overdose has not been evaluated.",
            "Pharmacokinetics": "Absorption\nThe digestibility of Irvingia gabonensis seeds has been estimated to range between 94% and 98% (61657). Regarding the digestibility of specific seed components, Irvingia gabonensis has demonstrated a protein digestibility of 0.5% and 0.8% for dehulled and hulled seeds, respectively (61626).",
            "Mechanism of Action": "General\nIrvingia gabonensis seeds are the most common part of the plant used for medicinal purposes. The seeds contain a variety of constituents, including saccharides (glucose, arabinose, rhamnose), carbohydrates (starch), protein, fat, amino acids, vitamin A, vitamin C, minerals, heavy metals, polyphenols, flavonoids, carotenoids, plant sterols, tannins, saponins, anthraquinones, alkaloids, aldehydes, aglycones, esters, glycosides, cardiac glycosides, fatty acids (myristic acid, stearic acid, lauric acid), free acids (acetic acid, butyric acid, hexanoic acid, ethyl 3-hydroxybutyrate), monoterpene alcohols, norisoprenoids, terpenoids, steroids, enzymes, ash, gum, pectin, phytate, fiber, and volatile essential oils (17074, 61582, 61583, 61585, 61586, 61588, 61601, 61602, 61603, 61606), (61607, 61609, 61610, 61613, 61614, 61616, 61617, 61618, 61619, 61620), (61621, 61622, 61623, 61624, 61625, 61626, 61627, 61628, 61629, 61630), (61631, 61632, 61633, 61634, 61635, 61636, 61637, 61638, 61639, 61640), (61641, 61642, 61643, 61644, 61645, 61646, 61647, 61650, 61651, 61652, 61653, 61654).\nAnalgesic effects\nAnimal research suggests that a water extract of Irvingia gabonensis has analgesic effects against heat-induced pain similar to morphine, while an ethanol extract has analgesic effects against non-heat-induced pain, similar to that of metamizole sodium (17075). The mechanisms of Irvingia gabonensis' analgesic effects are unclear.\nAntibacterial effects\nIn vitro research shows that methanol extracts of Irvingia gabonensis and some of its polyphenoic and triterpene derivatives inhibit the growth of various lines of both Gram-positive and Gram-negative bacteria, such as Neisseria gonorrhoeae and Pseudomonas aeruginosa (17074, 61602, 61586). Three compounds isolated shown to have activity against several Gram-positive and Gram negative bacteria, were identified as 3,3',4'-tri-O-methylellagic acid, 3,4-di-O-methylellagic acid, and a diterpenic acid known as hardwickiic acid (17074). Compared to standard amoxicillin antibiotics, Irvingia gabonensis has demonstrated significant inhibitory activity against Staphylococcus aureus bacteria, possibly due in part to its abundance of constituent alkaloids (61601). In another in vitro study, Irvingia gabonensis was shown to exert a comparable antibacterial effect to that of the standard antibiotic gentamicin (61586).\nAntifungal effects\nIn vitro research shows that methanol extracts of Irvingia gabonensis and some of its polyphenoic and triterpene derivatives inhibit the growth of various strains of fungi, including Candida (17074) and Aspergillus flavus (61600). Three of compounds isolated that have been shown to have activity against Candida yeast species, were identified as 3,3',4'-tri-O-methylellagic acid, 3,4-di-O-methylellagic acid, and a diterpenic acid known as hardwickiic acid (17074). The antifungal effects of Irvingia gabonensis have been shown to be comparable to that of tioconazole and better than that of nystatin, both of which are standard antifungal medications (61586, 61600).\nAntiobesity effects\nIn vitro and in vivo research shows that IGOB131, a marketed Irvingia gabonensis seed extract, inhibits adipogensis by stimulating the expression of adiponectin and downregulatng the expression of both PPAR-gamma and leptin (17072, 92824, 92825). Similarly, various studies involving overweight or obese human subjects have shown that Irvingia gabonensis improves multiple parameters related to obesity, including body weight, body fat, waist and hip circumference, adiponectin activity, and leptin sensitivity (17070, 17069, 16457). It may also modulate glycerol-3-phosphate dehydrogenase (92825).\nAntioxidant effects\nSome laboratory research suggests that Irvingia gabonensis has antioxidant effects (13455, 61603, 61604). The abundance of constituent polyphenols has been implicated as playing a role in the antioxidant capacity of Irvingia gabonensis (61603).\nGastrointestinal effects\nAnimal research suggests that a methanol extract of Irvingia gabonensis reduces gastrointestinal motility, protects against castor oil-induced diarrhea, and dose-dependently inhibits gastric ulceration to a seemingly greater extent than cimetidine, a standard gastric ulcer medication, by means of increased intragastric mucus secretion and decreased gastrtic acid secretion (61584, 61605). The high-soluble fiber content of the seeds acts as a bulk-forming laxative and also delays gastric emptying (16457, 17069).\nHormonal effects\nSome animal research shows that an aqueous extract of Irvingia gabonensis exerts a similar testosterone-increasing effect to that of proviron, a standard steroid (61613).\nHypocholesterolemic effects\nBoth human and animal research suggests that extracts of Irvingia gabonensis may reduce total cholesterol, low-density lipoprotein (LDL)-cholesterol, and triglycerides and increase high-density lipoprotein (HDL)-cholesterol (17069, 17070, 61588, 61589, 61591, 61607, 61612, 61615, 61616). The cholesterol-lowering effects of Irvingia gabonensis seeds might be due to their fiber content. The fiber can bind bile acids in the gut, preventing their reabsorption and causing conversion of more cholesterol to bile acids (16457, 17069). The oil extracted from Irvingia gabonensis seeds contains vitamin A, beta-carotene, and phytosterols, which might also contribute to cholesterol-lowering effects (17071).\nHypoglycemic effects\nIn vitro, animal, and clinical research all suggest that Irvingia gabonensis has hypoglycemic effects (17069, 17070, 61589, 61591, 61593, 61597, 61598, 61599, 61611). These effects may be explained by inhibition of maltase, sucrase, alpha-amylase, pyruvate kinase, lactate dehydrogenase enzyme activity and induction of glucose-6-phosphatase activity (61593, 61597, 61598, 61611) and increased glycogen synthesis due to the compensatory increase of hepatic glycolytic enzyme activity (61593). Irvingia gabonensis was shown to be a weak inhibitor of alpha-amylase activity but a potent inhibitor of both maltase and sucrase (61597). The high-soluble fiber content of the seeds acts as a bulk-forming laxative and delays gastric emptying. This might help improve blood glucose control in diabetes (16457, 17069).\nInsecticidal effects\nIn grain, Irvingia gabonensis has been shown to inhibit the activity of insect pests and provide significant protection against pest infestation (61608). Conversely, a diethyl ether extract of Irvingia gabonensis has been shown to be a potent attractant to older, but not younger, Oryzaephilus mercator beetles, irrespective of diurnal cycle (61656)."
        }
    },
    "Isatis": {
        "sections": {
            "Overview": "IIsatis, a biennial plant with small yellow flowers, grows in northern and central China. The leaves and roots of this plant are used in traditional Chinese medicine (12643, 12644). Isatis has also been traditionally used as a source of indigo dye (12644).",
            "Safety": "POSSIBLY SAFE when used topically and appropriately, short-term. A specific product containing indigo naturalis, an isatis leaf extract, in olive oil (Lindioil), applied topically in doses of 0.05-0.1 mL to the skin around the fingernails twice daily, has been used with apparent safety for 24 weeks (88276, 108089).\nThere is insufficient reliable information available about the safety of isatis when used orally.\nPREGNANCY AND LACTATION: Insufficient reliable information is available; avoid using.",
            "Adverse Effects": "General\nOrally and topically, no adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nPsoriasis. Clinical research shows that topical isatis leaf extract may reduce the severity of nail psoriasis.\nA small clinical study in patients with fingernail psoriasis shows that using a specific product containing indigo naturalis, an isatis leaf extract, in olive oil (Lindioil), 0.05-0.1 mL topically to nail folds and to skin beneath the edge of the nail twice daily for 24 weeks, improves fingernail psoriasis severity by 50% to 80% when compared with treatment with a solution containing calcipotriol (Daivonex scalp solution) 50 mcg/mL (88276). Another small clinical study in this population shows that applying 0.05 mL of this same product to the fingernails twice daily for 12 weeks improves fingernail psoriasis severity by 50% to 59%, compared with 16% to 23% in those using the olive oil vehicle as a control (108089).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAging skin. It is unclear if topical isatis can improve the appearance of aging skin.\nA small clinical study in healthy females aged 37-59 years shows that twice daily facial application of a cream containing isatis leaf extract for 8 weeks improves the visual appearance of wrinkles and roughness scores when compared with baseline (108088). It is unclear if the improvement from baseline differed between those receiving the isatis leaf extract cream and those receiving a placebo cream.\nless\nDiarrhea. Although there is interest in using oral isatis for diarrhea, there is insufficient reliable information about the clinical effects of isatis for this condition.\nHepatitis. Although there is interest in using oral isatis for hepatitis, there is insufficient reliable information about the clinical effects of isatis for this condition.\nProstate cancer. Although there is interest in using oral isatis for the treatment of prostate cancer, there is insufficient reliable information about the clinical effects of isatis for this purpose.\nRespiratory tract infections. Although there is interest in using oral isatis for respiratory tract infections, there is insufficient reliable information about the clinical effects of isatis for this purpose.\nUlcerative colitis. Although there is interest in using oral isatis for ulcerative colitis, there is insufficient reliable information about the clinical effects of isatis for this condition.\nMore evidence is needed to rate isatis for these uses.",
            "Dosing & Administration": "Adult\nTopical:\nA specific product (Lindioil) containing indigo naturalis, an isatis leaf extract, has been applied to the skin around the fingernails as 0.05-0.1 mL twice daily for 24 weeks.\nStandardization & Formulation\nA specific product containing indigo naturalis, an isatis leaf extract, in olive oil (Lindioil), has been used in clinical research. The indigo naturalis was standardized to contain indirubin 200 mcg/mL (88276).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "ASPIRIN ALLERGY\nIsatis contains unknown quantities of salicylate (12643). Theoretically, the salicylate constituents in isatis could trigger an allergic reaction in people with aspirin allergy or aspirin-related asthma.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with isatis.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of isatis.",
            "Mechanism of Action": "General\nThe applicable parts of isatis are the leaf and root (12643). Indigo naturalis, which contains indirubin, is an extract of isatis leaf (88276). Constituents of isatis include isatan A (indoxyl-3-O-(6'-O-malonyl-beta-D-ribohexo-3-ulopyranoside), isatan B (indoxyl-3-O-beta-D-ribohexo-3-ulopyranoside), and indican, levels of which increase after drying of the leaf (12646). Isatis root contains isaindigotone, salicylic acid, CPQ [3-(2-carboxyphenol)-4(3 H )-quinazolinone], syringic acid, benzoic acid, and 2-aminobenzoic acid (12643). Isatis leaf contains tryptanthrin (12641, 12646, 12647).\nAnti-cancer effects\nIn vitro, indirubin, a component of indigo naturalis, an isatis leaf extract, and its derivatives appear to have an antiproliferative effect on leukemia and other cancer cells (12642).\nAnti-inflammatory effects\nIn animal research isatis extract inhibited paw inflammation and fever (12644). Isatis extracts seem to inhibit the release of histamine and serotonin from mast cells. Isatis extracts also seem to inhibit cyclooxygenase-2 (COX-2), but not COX-1 or 5-lipoxygenase, which are mediators of inflammatory activity (12641). Tryptanthrin, an isatis leaf constituent that is produced during the drying process, inhibits both cyclooxygenase-2 (COX-2) and 5-lipoxygenase (12641, 12646, 12647). Indirubin, a constituent of isatis root, might inhibit airway inflammation produced by the influenza virus, according to preliminary research (12640). Another isatis root constituent, isaindigotone, seems to be a superoxide scavenger and inhibit 5-lipoxygenase and leukotriene B4 production, which might also contribute to an isatis anti-inflammatory effect (12645)."
        }
    },
    "Isopropylnorsynephrine": {
        "sections": {
            "Overview": "Isopropylnorsynephrine is an investigational beta-agonist that has not been approved for use in humans. However, it has been found in some commercial dietary supplements (104185, 104949, 107919). It is a chemical derivative of synephrine and octopamine, which are constituents of bitter orange (104949).",
            "Safety": "POSSIBLY UNSAFE when used orally or parenterally. Isopropylnorsynephrine has been associated with vomiting, hypertension, blurred vision, palpitations, and respiratory distress. When used in combination with stimulants or intensive exercise, isopropylnorsynephrine has been associated with adverse cardiovascular events such as stroke and cardiac arrest (21079, 104949).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally. Isopropylnorsynephrine has been associated with vomiting, hypertension, blurred vision, palpitations, and respiratory distress. When used in combination with stimulants or intensive exercise, isopropylnorsynephrine has been associated with adverse cardiovascular events such as stroke and cardiac arrest (21079, 104949). Avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally and parenterally, isopropylnorsynephrine is generally regarded as unsafe.\nSerious Adverse Effects (Rare)\nOrally: Hypertension, palpitations, respiratory distress, and vomiting. Stroke and cardiac arrest have been reported when used with other stimulants or intensive exercise.\nCardiovascular\nOrally, isopropylnorsynephrine has been associated with hypertension and palpitations. When used in combination with stimulants or intensive exercise, isopropylnorsynephrine has been associated with adverse cardiovascular events such as stroke and cardiac arrest (21079, 104949).\nless\nGastrointestinal\nOrally, isopropylnorsynephrine has been associated with vomiting (21079, 104949).\nless\nOcular/Otic\nOrally, isopropylnorsynephrine has been associated with blurred vision (21079, 104949).\nless\nPulmonary/Respiratory\nOrally, isopropylnorsynephrine has been associated with respiratory distress (21079, 104949).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAthletic performance. Although there is interest in using oral isopropylnorsynephrine for athletic performance, there is insufficient reliable information about the clinical effects of isopropylnorsynephrine for this purpose.\nExercise-induced muscle damage. Although there is interest in using oral isopropylnorsynephrine for muscle recovery after exercise, there is insufficient reliable information about the clinical effects of isopropylnorsynephrine for this purpose.\nObesity. Although there is interest in using oral isopropylnorsynephrine for weight loss, there is insufficient reliable information about the clinical effects of isopropylnorsynephrine for this purpose.\nMore evidence is needed to rate isopropylnorsynephrine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nIsopropylnorsynephrine is a synthetic amine that does not occur naturally. While it is not permitted for use in dietary supplements, it has been detected in bitter orange products and other combination weight loss or sports supplements (104185, 104949, 107919).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, isopropylnorsynephrine might decrease the effects of antihypertensive drugs.\nIn vitro research shows that isopropylnorsynephrine is a highly selective, direct-acting beta-adrenergic receptor agonist with positive chronotropic effects (107918), and hypertension has been reported in patients taking combination products containing isopropylnorsynephrine and other stimulants (21079).\nless\nSTIMULANT DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking isopropylnorsynephrine with stimulant drugs might have additive effects and increase the risk of adverse cardiovascular effects.\nIsopropylnorsynephrine is an investigational beta-agonist and a derivative of synephrine and octopamine, which are stimulant constituents of bitter orange (104949). In vitro research shows that isopropylnorsynephrine is a highly selective, direct-acting beta-adrenergic receptor agonist with positive chronotropic effects (107918). Theoretically, isopropylnorsynephrine may also have stimulant effects.\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH STIMULANT PROPERTIES\nIsopropylnorsynephrine might have stimulant effects.\nTheoretically, combining isopropylnorsynephrine with other supplements with stimulant properties might increase the risk of adverse cardiovascular effects. In vitro research shows that isopropylnorsynephrine is a highly selective, direct-acting beta-adrenergic receptor agonist with positive chronotropic effects (107918). See other products with stimulant activity here and here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nHYPERTENSION\nTheoretically, isopropylnorsynephrine might elevate blood pressure in patients with hypertension. Avoid use. In vitro research shows that isopropylnorsynephrine is a highly selective, direct-acting beta-adrenergic receptor agonist with positive chronotropic effects (107918), and hypertension has been reported in patients taking combination products containing isopropylnorsynephrine and other stimulants (21079).\nless\nPERIOPERATIVE\nIsopropylnorsynephrine has positive chronotropic and hypertensive effects (21079, 107918), which might interfere with heart rate and blood pressure control if used perioperatively. Tell patients to discontinue isopropylnorsynephrine at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with isopropylnorsynephrine.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of isopropylnorsynephrine.",
            "Mechanism of Action": "General\nIsopropylnorsynephrine is an investigational beta-agonist and a derivative of synephrine and octopamine, which are stimulant constituents of bitter orange (104949).\nBeta-adrenergic effects\nIn vitro research shows that isopropylnorsynephrine is a highly selective, direct-acting beta-adrenergic receptor agonist (107918). While an agonist at these receptors, it appears to be around 200-440-fold less potent than isoproterenol (107918), and 500-fold less potent than clenbuterol (107919).\nWeight loss effects\nIn vitro research shows that isopropylnorsynephrine stimulates lipolysis in human adipocytes, possibly through activation of beta-adrenergic receptors. Isopropylnorsynephrine's lipolytic effects appear to be greater than synephrine and octopamine (100081)."
        }
    },
    "Ivy Gourd": {
        "sections": {
            "Overview": "Ivy gourd is an aggressive, climbing, perennial vine that is a member of the Cucurbitaceae or \"cucurbit\" family. The plant has been used in traditional Sri Lankan medicine for centuries (12693, 56883, 110430). The fruit and leaves of the plant are also used as a vegetable in India and other Asian countries (12694).",
            "Safety": "POSSIBLY SAFE when ivy gourd leaf is used orally and appropriately daily for up to 6 weeks (12693, 17752). The long-term safety of ivy gourd is unknown.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, ivy gourd leaf seems to be well-tolerated. It may cause mild nausea, headache, and drowsiness (17752).\nGastrointestinal\nOrally, ivy gourd leaf may cause mild nausea (17752).\nless\nNeurologic/CNS\nOrally, ivy gourd leaf may cause mild headache and drowsiness (17752).\nless",
            "Effectiveness": "Diabetes. Preliminary clinical research shows that taking ivy gourd leaves 20 grams with breakfast significantly improves glucose control after receiving a meal containing 75 grams of glucose (17752). Other preliminary clinical research shows that taking ivy gourd orally twice daily for 6 weeks improves glucose tolerance compared to baseline in patients with diabetes (12693). Also, clinical research in patients with type 2 diabetes suggests that taking ivy gourd extract 500 mg or 1 gram daily for 90 days decreases fasting and non-fasting blood glucose, glycated hemoglobin (HbA1C), and insulin levels when compared with placebo. It also decreases the homeostatic model assessment for insulin resistance (HOMA-IR) (56889, 110430).\nThere is insufficient reliable information available about the effectiveness of ivy gourd for its other uses.\nless",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of ivy gourd.",
            "Interactions with Drugs": "ANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nA (High-quality randomized controlled trial (RCT))\nIvy gourd may lower blood glucose levels (12693, 56884, 56889) and might have additive effects when used with antidiabetes drugs. This might increase the risk of hypoglycemia in some patients. Monitor blood glucose levels closely.",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nIvy gourd may lower blood glucose levels (12693, 56884, 56889) and might have additive effects when used with other herbs and supplements that also lower glucose levels. This might increase the risk of hypoglycemia in some patients. See other hypoglycemic agents here.",
            "Interactions with Conditions": "PERIOPERATIVE\nIvy gourd might affect blood glucose levels (12693, 56884, 56889). Theoretically, ivy gourd might interfere with blood glucose control during and after surgical procedures. Tell patients to discontinue ivy gourd at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with ivy gourd.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of ivy gourd.",
            "Mechanism of Action": "General\nThe applicable parts of ivy gourd are the roots, leaves, and fruit. Ivy gourd fruit contains pectin. The leaves contain triterpene, flavonoid, secoiridoid, and phenolic acid constituents (12249, 12694, 12696, 12698, 102045). Constituents of aqueous leaf extracts of ivy gourd include cucurbitacins B and D, cephalandrol, cephalandrin A and B, taxaterone, tinsoporin, ferulic acid, methyl caffeate, ligstroside, trans-p-coumaric acid, and kaempferol-3-O-Î²-D-glucoside (110430).\nAntimicrobial effects\nIn vitro research shows that ivy gourd extract has activity against Bacillus subtilis, Bacillus cereus, Candida albicans, Escherichia coli, and Staphylococcus aureus, with the greatest inhibitory effect on Bacillus cereus (102045).\nHypoglycemic effects\nAnimal studies and clinical research show that all parts of ivy gourd may decrease blood sugar levels (12693, 12694, 56884, 56889). Preliminary research suggests that the fruit constituent pectin has hypoglycemic activity (12249, 12694, 12696). Ivy gourd leaf extracts depress gluconeogenesis by inhibiting enzymes such as glucose-6-phosphatase (12697). Triterpene constituents of ivy gourd leaf have antidiabetic activity and may also improve metabolic function (12698). Other preliminary research suggests ivy gourd leaf extract might stimulate insulin production and have antioxidant effects (12699).\nHypolipidemic effects\nTriterpene constituents of ivy gourd leaf may lower cholesterol and improve metabolic function (12698). In adults with newly-diagnosed type 2 diabetes, taking ivy gourd aqueous leaf extract, 500 mg once daily for 3 months, lowers triglyceride and very low-density lipoprotein cholesterol levels by a small amount when compared with baseline, but does not affect other lipids (110430).\nWound healing effects\nAnimal research shows that application of a hydrogel containing a methanolic extract of ivy gourd to wounds infected by Bacillus cereus inhibits bacterial growth and improves wound healing when compared with a placebo hydrogel. The antibacterial activity and healing effects of the ivy gourd topical extract were close to that of fusidic acid, a topical antibiotic used for bacterial skin infections. The wound healing effects of ivy gourd are thought to be related to the antimicrobial, anti-inflammatory, antioxidant, and skin rejuvenating activity of various constituents (102045)."
        }
    }
}